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Abstract 
 
The quinoline derivative clioquinol (CQ) was widely used as a topical disinfectant for skin 
conditions and as an oral antibiotic against diarrhoea. However, in 1970 the oral formulation 
was taken off the market in many countries after it was linked to about 10 000 cases of subacute 
myelo-optic neuropathy (SMON) in Japan. SMON was characterised by optic neuritis and 
axonopathy of the spinal cord. Although a clear mechanistic connection is still disputed, a clear 
reduction in SMON cases was witnessed following drug withdrawal from the market. 
Furthermore, the common pathological features of SMON-associated neurotoxicity have been 
successfully recapitulated in CQ-treated animals, which support a direct connection. Several 
hypotheses have tried to explain CQ-dependent toxicity such as CQ-induced DNA damage and 
oxidative stress. However, none of these studies has attempted to explain the restriction of CQ-
induced neurotoxicity to the Japanese population. Despite this toxicity, CQ and its structural 
analogues are currently under investigation as a disease modifying treatment for the 
neurodegenerative disorders such as Alzheimer’s and Huntington’s Disease, with some 
encouraging preclinical and clinical results. In light of the re-emergence of CQ and its structural 
analogues, it is crucial to understand the underlying mechanism of CQ-induced toxicity beyond 
the scope of SMON to prevent any potential CQ-associated risks to future patients. 
 
From a previous research project that screened marketed drugs and drug-like compounds 
against their potential to cause mitochondrial dysfunction in vitro, CQ and 8-HQ were 
identified as hits (unpublished). The mitochondrial liability of these compounds (0.5-10) µM 
was subsequently confirmed in RGC5 cells by measuring galactose-hypersensitive ATP levels, 
lipid peroxidation and cellular viability. However, the confirmation of CQ-induced 
mitochondrial toxicity in another cell line, HepG2, failed. Prior unrelated observations (N. 
 xxvii 
 
Gueven, unpublished) showed that these cell lines differ in the response to oxidants, which is 
associated with different cellular levels of the antioxidant enzyme NADPH Quinone 
Oxidoreductase 1 (NQO1). NQO1-dependent CQ associated-mitochondrial-dysfunction was 
confirmed in isogenic cell lines that differ only in the expression levels of NQO1. NQO1 
expression was inversely correlated to CQ-induced mitochondrial-dysfunction. While cells 
with low NQO1 were highly sensitive to CQ-induced mitochondrial-dysfunction, recombinant 
NQO1 expression in these cells provided protection against CQ-toxicity. CQ-induced 
reduction of cellular ATP levels, increased lipid peroxidation and elevated cell death could be 
attenuated by concomitant treatment with different antioxidants, implicating oxidative stress 
as the core mechanism of CQ-induced toxicity. Furthermore, biochemical studies also revealed 
that CQ and 8-HQ directly inhibited NQO1 enzyme activity at a concentration range of 10-100 
µM. 
 
In order to translate the in-vitro findings of NQO1-dependent CQ toxicity into an in-vivo 
situation, zebrafish were selected as a suitable animal model. Zebrafish are characterised by 
variable NQO1 expression in the retina during different stages of their life. While larval 
zebrafish are reported to lack retinal NQO1 expression, the protein is highly expressed in the 
adult zebrafish retina. The observed general CQ-induced toxicity in zebrafish was strain-
dependent. Petshop (PET) strain zebrafish larvae were less sensitive compared to a commonly 
used laboratory strain (AB). The maximum tolerated concentration of CQ that did not lead to 
systemic toxicity was 10 µM in PET and 3 µM in AB. To demonstrate retinal CQ effects in 
this model, visual CQ toxicity in PET zebrafish larvae was determined by measuring eye 
velocity as a function of different stimulus velocities. Comparable to the human situation, CQ 
inhibited visual function in a dose-dependent manner between 3-10 µM, which is surprisingly 
consistent with the concentration range that caused mitochondrial-dysfunction in-vitro. In 
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contrast to larval responses, even the highest CQ concentration (10 µM) did not affect visual 
function in the adult zebrafish. This is in line with the in-vitro results where high NQO1-
expressing HepG2 cells were resistant to CQ-induced mitochondrial-dysfunction. NQO1-
dependent protection against CQ-induced visual impairment was confirmed by the presence of 
NQO1 enzyme activity in the adult zebrafish retina. Consistent with this, pharmacological 
inactivation of NQO1 resulted in CQ-induced oxidative stress in the retina and acute systemic 
toxicity in the adult fish. 
 
Overall, these results highlight the importance of NQO1 expression in mitigating CQ toxicity 
both in-vitro and in-vivo and that CQ induces mitochondrial-dysfunction through the 
generation of oxidative stress. Strikingly, nearly 50 years after the drug was retracted from the 
market, this connection between NQO1 and CQ-toxicity might explain the geographic 
restriction of SMON cases. It is important to note that a much higher prevalence of the 
inactivating C609T NQO1 polymorphism has been reported for the Japanese population 
compared to the European population. Based on the results of this study, this population group 
should, therefore, be highly susceptible to the toxicity of CQ. The results of the present study 
could for the first time explain the geographic restriction of CQ-induced neurotoxicity to Japan. 
Currently, this hypothesis is tested by assessing the presence of the C609T NQO1 
polymorphism in Japanese SMON survivors. Furthermore, if CQ or its derivatives are to be 
employed for the treatment of neurodegenerative diseases, it appears imperative that NQO1 
status of the patients should be ascertained before the start of the treatment. Therefore, in 
addition to potentially solving a long-standing medical mystery, this project offers a significant 
benefit towards personalised medicine to minimise drug treatment-associated risk to a specific 
group of patients.  
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Chapter 1:  General Introduction 
1.1 Mitochondria 
 
Mitochondria, also known as the powerhouses of cells, generate the majority of the energy 
needed for cellular life. Mitochondria are dynamic intracellular organelles that exist as a 
reticulum and constantly undergo biogenesis and degradation to maintain the overall health of 
the mitochondrial pool within each cell. The number of mitochondria per cell varies from 
hundreds to thousand depending on the metabolic demand of the specific cell. Since the brain 
and the visual system have very high energy demands, they are highly populated with 
mitochondria [1]. The structure of mitochondria consists of an outer and inner membrane 
(Figure 1) [2]. The permeability of the outer mitochondrial membrane is regulated by a family 
of channel-forming proteins, known as porins or voltage-dependent anion channels (VDAC), 
which are permeable to uncharged low molecular weight molecules up to 10 kDa [3]. The inner 
membrane is relatively impermeable compared to the outer membrane. The space between the 
outer and the inner membrane of mitochondria is called the inter-membrane space [2]. Bounded 
by the inner membrane is the matrix, which contains the enzymes that make up the 
Tricarboxylic Citric Acid (TCA) cycle, enzymes for beta-oxidation of fatty acids, 
mitochondrial DNA (mtDNA), RNA, and mitochondrial ribosomes [2]. The mitochondrial 
genome consists of thousands of copies of maternally inherited mtDNA as well as 
approximately 1500 genes that are coded in the nuclear DNA (nDNA) [4].  Mitochondrial DNA 
encodes 37 genes, 13 of which code for proteins essential for the process of mitochondrial 
oxidative phosphorylation (OXPHOS), 22 genes that code for mitochondrial transfer RNAs 
(mt-tRNAs) and 2 that encode mitochondrial ribosomal RNAs (mt-rRNAs), which are essential 
for the synthesis of OXPHOS proteins [4]. All proteins that are responsible for other aspects 
of mitochondrial function, such as mitochondrial biogenesis, are encoded by nuclear genes [4]. 
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 Apart from energy production, mitochondria are also responsible for other essential cellular 
functions such as fatty acid synthesis, maintenance of calcium homeostasis, biosynthesis of 
haem and iron sulphur proteins, production and regulation of reactive oxygen species (ROS), 
as well as regulation of cell death through the activation of the mitochondrial permeability 
transition pore (mt PTP) [4,5]. 
 
Figure 1: Schematic representation of mitochondrial structure.  
Mitochondria are organelles consisting of an outer and an inner membrane. The space between the 
outer and the inner membrane is called the intermembrane space. The permeability of the outer 
membrane is regulated by voltage gated anion channels (VDAC). Embedded on the matrix side of 
the inner membrane are components of the oxidative phosphorylation (OXPHOS) complexes. The 
matrix mainly contains the enzymes of the Tricarboxylic-Citric Acid cycle (TCA), enzymes for β-
oxidation as well as mtDNA and mitochondrial ribosomes. 
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1.1.1 Mitochondria and Energy Metabolism 
 
Mitochondria produce energy by oxidizing glucose, amino acids and fatty acids present in food, 
to generate chemical energy mainly in the form of adenosine triphosphate (ATP). This energy 
is stored in the covalent phosphate bond of ATP and is released upon hydrolysis of this bond 
to generate ADP as a reaction product (a lower energy molecule). Cellular energy production 
occurs via different metabolic pathways. Glycolysis occurs in the cytoplasm, oxidative 
phosphorylation (OXPHOS) occurs exclusively in the mitochondrial inner membrane in the 
presence of oxygen while the tricarboxylic-cyclic acid (TCA) cycle takes place in the 
mitochondrial matrix [6].  
 
Figure 2: Cellular energy metabolism. 
Glucose is metabolised to pyruvate via glycolysis in the cytoplasm. Pyruvate is then completely 
oxidised in the mitochondrial TCA cycle to provide energy equivalents for oxidative 
phosphorylation. In total, this process generates 36 molecules of ATP per molecule of glucose. When 
oxygen is limiting, cells divert the glycolysis-generated pyruvate towards the production of lactic 
acid (anaerobic glycolysis), a highly inefficient process that generates only a net of 2 molecules of 
ATP per molecule of glucose. 
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Glycolysis is a multistep metabolic pathway that consists of ten enzymes, which metabolize 
glucose to pyruvate. This process starts by the addition of two phosphate groups to the glucose 
molecule at the expense of two ATP molecules and in turn generates two molecules of pyruvate 
and four molecules of ATP. Hence glycolysis in total provides a net of two ATP molecules and 
two molecules of the reduced form of the electron donor nicotinamide adenine dinucleotide 
(NADH). The pyruvate molecules either enter the mitochondrial TCA cycle or are converted 
to lactate in the presence of the enzyme lactate dehydrogenase. Both pathways generate NAD+ 
that is continuously required to maintain the process of glycolysis (Figure 2). During anaerobic 
glycolysis, mitochondria are non-functional with regards to oxidative phosphorylation due to 
the lack of oxygen as terminal electron acceptor. Under these conditions, pyruvate is converted 
to lactate with a net production of two ATP and 2 NAD+ molecules (Figure 2) [7]. In contrast, 
under conditions of adequate oxygen supply, pyruvate is entirely metabolized in the 
mitochondria.  
 
In the mitochondrial matrix, pyruvate is decarboxylated by the pyruvate dehydrogenase 
complex yielding one molecule of CO2, NADH and acetyl-coenzymeA (acetyl-CoA). Acetyl-
CoA then enters the TCA cycle to generate one molecule of ATP, one molecule of the reduced 
form of the electron carrier flavin adenine dinucleotide (FADH2) and three molecules of NADH 
per acetyl-CoA. The NADH and FADH2 molecules act as electron carriers by transferring 
electrons derived from glycolysis and TCA cycle into OXPHOS to provide maximal ATP 
production.  
 
OXPHOS involves series of reduction/oxidation (redox) reactions that ultimately leads to the 
production of ATP through phosphorylation of ADP. OXPHOS is comprised of the electron 
transport chain (ETC; complexes I to IV) and the ATP synthase (complex V). The ETC consists 
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of four different large multi-protein complexes embedded in the inner mitochondrial 
membrane: Complex I (NADH: Ubiquinone oxidoreductase), complex II (succinate 
ubiquinone oxidoreductase), complex III (cytochrome bc1 complex) and complex IV 
(cytochrome c oxidase). During each ETC cycle, these complexes accept electrons from 10 
NADH and 2 FADH2 generated during glycolysis, mitochondrial conversion of pyruvate to 
acetyl-coA and TCA cycle. Complex I accepts electrons from NADH while complex II accepts 
electrons from FADH2. These high-energy electrons then pass through series of redox centres 
including FMN, iron-sulphur centres (Fe-S) within the complexes and finally are used to reduce 
the mobile electron carrier ubiquinone by a 2 electron conversion to ubiquinol. Complex III 
then accepts electrons from reduced ubiquinone (ubiquinol) and reduces another electron 
carrier, cytochrome c, which transports the electrons to complex IV. Complex IV ultimately 
transfers the electrons to the final electron acceptor oxygen to produce water (Figure 3). The 
energy released during this electron transport is used to pump protons across the inner 
mitochondrial membrane from the matrix into the inter-membrane space by complexes I, III 
and IV. This creates an increased pH in the inter-membrane space and a highly negative 
membrane potential, ΔΨm (>−240mV) across the inner mitochondrial membrane. This 
electrochemical proton gradient is used by the ATP synthase (complex V) to drive 
mitochondrial ATP production by phosphorylation of ADP to ATP when protons are allowed 
to re-enter the matrix [8]. For each molecule of glucose, a total of 32 molecules of ATP are 
produced by this mechanism, 2 additional ATP are derived from glycolysis and 2 ATP originate 
directly from the TCA cycle. This is a total yield of 36 ATP produced via aerobic respiration. 
Therefore, functional mitochondria increase the efficiency of the energy production by 34 ATP 
or 17-fold in comparison to glycolysis alone. 
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Figure 3: Mitochondrial OXPHOS. 
Mitochondrial OXPHOS consists of the electron transport chain (ETC; complexes I-IV) and the F0-
F1 ATPase (complex V). OXPHOS is located on the matrix-side of the inner mitochondrial 
membrane. The electron carriers NADH2, FADH2 derived from the TCA donate electrons to 
complexes I and II respectively thus activating the ETC which leads to a proton gradient across the 
inner mitochondrial membrane and the generation of ATP via complex V. The generated ATP is then 
translocated to cytosol with the help of ANT. ANT: Adenine Nucleotide Transporter; ATP: 
Adenosine triphosphate; ADP: Adenosine diphosphate; pi: inorganic phosphate; NADH: 
Nicotinamide Adenine Dinucleotide; FADH: Flavin Adenine Dinucleotide; FMN: Flavin Mono 
Nucleotide; CoQ: Coenzyme ubiquinone; Cytc: Cytochrome C. 
 
 
It is now thought that the complexes I, III and IV within the inner mitochondrial membrane 
occur as a supercomplex known as the respirasome, which is in stark contrast to the classically 
depicted model of complexes floating individually in the inner membrane [9]. A 3D 
reconstruction of this supercomplex suggests that the ubiquinone and cytochrome c binding 
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sites in this supercomplex are facing each other. This structural organization of the 
supercomplex is thought to promote the higher efficiency of electron transfer and also increase 
the stability of the complexes. It has been reported that the supercomplex, containing 
complexes I, III and IV, is more stable and displays higher activity compared to a supercomplex 
without complex IV [10]. Although the overall structure of the respirasome has yet to be 
elucidated in detail, the identification of novel components of this complex, such as the novel 
mitochondrial complex I (CI) assembly factor, C17orf89 [11], has already provided new 
insights into the role of mitochondria under physiological as well as pathological conditions.  
[11]. The suppression of C17orf89 markedly reduced CI activity and lack of which has been 
associated in an unresolved cases of isolated CI deficiency [11]. 
   
1.1.2 Mitochondria and Reactive Oxygen Species 
1.1.2.1 Reactive Oxygen Species (ROS) 
 
Besides their role in producing cellular energy, mitochondria are also one of the main sources 
of reactive oxygen species (ROS). ROS encompasses oxygen free radicals such as superoxide 
anion (O2.-), hydroxyl anion (OH·) and non-radical oxidants such as hydrogen peroxide (H2O2) 
and singlet oxygen (1O2) [12]. ROS are known to have both beneficial and detrimental effects 
on cellular function depending on their concentration [13]. At low concentration, ROS can 
regulate cellular functions through redox-dependent signalling and redox-dependent 
transcription factors [14]. However, at high concentrations ROS can damage cellular processes 
as a consequence of their detrimental effects on biomolecules such as protein, lipids and DNA. 
Therefore, a balance between ROS production and removal is essential for normal cellular 
functions. Any imbalance in production and removal of ROS results in oxidative stress and is 
likely to result in pathological conditions. Mitochondria are a known source of ROS production 
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and at the same time, these organelles themselves are highly susceptible to the effect of 
oxidative stress imposed by ROS [15]. 
 
1.1.2.2 Mitochondria as a Major Source of Intracellular ROS 
 
The majority of ROS are generated locally within the mitochondrial ETC [13,15]. Partial 
reduction of molecular oxygen either by electrons that leak predominantly from complexes I 
and III of the ETC during cellular respiration or by enzymatic reduction (xanthine/xanthine 
oxidase, uncoupled nitric oxide synthase, cytochrome p450 isoform and NADPH-dependent 
oxidase) lead to the formation of superoxide anions (O2·-) [15,16]. Recent studies have 
demonstrated that besides complexes I and III complex II also contributes to ROS production 
[17]. It is estimated that approximately 2-4 % of the oxygen consumed during OXPHOS is 
converted to ROS (107 ROS molecules/mitochondrion/day) [18]. ROS the main source of 
oxidative stress and are invariably linked to many pathological conditions such as 
neurodegeneration and aging [19].  
 
Since mitochondria are major sources of ROS (80-90 % of cellular ROS) cells have developed 
powerful antioxidative strategies, which protect against ROS-induced macromolecular damage 
[20]. These detoxification systems predominantly involve antioxidant defence systems 
containing non-enzymatic molecules such as GSH (glutathione) and thioredoxins (Trx), alpha-
tocopherol, as well as enzymatic systems such as superoxide dismutases (SODs), catalase (cat), 
coenzyme Q (CoQ), and cytochrome c (cyt C) [15,21]. The GSH system consists of the 
glutathione reductase (GSR) and glutathione peroxidase 1 (GPx1) while the Trx system 
includes Trx reductase 2 (TrxR2), Trx2 and peroxiredoxin 3 (Prx3). These antioxidative 
systems respond to the cellular stressors by interacting with the pool of cellular redox couples 
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including NADPH/NADP+, NADH/NAD+, GSH [reduced glutathione]/GSSG [oxidised 
glutathione], Trx(SH)2 [reduced Trx]/ Trx(SS) [oxidised Trx] [22] (Figure 4). For any 
antioxidative strategy to be successful it is important to precisely understand the source and 
nature of generated ROS. Superoxide generated by complex I for example is released into the 
mitochondrial matrix whereas superoxide generated from Complex III is released to inter-
membrane space [23]. Consequently, superoxides that are released into the matrix are 
detoxified by MnSOD to H2O2 while those that are released into the inner-membrane space are 
dismutated to H2O2 by Cu/Zn SOD [23]. Subsequently, H2O2 is reduced to water by catalase, 
peroxiredoxins (Prx) and glutathione peroxidase 1 (GPx1) [23]. Peroxiredoxins reduce H2O2 
by employing mitochondrial Trx whereas GPx1 employs mitochondrial GSH [23].   
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Figure 4: Mitochondrial ROS and antioxidative defence systems. 
Superoxide generated by the mitochondrial ETC gets dismutated to hydrogen peroxide via Cu/Zn 
SOD or MnSOD. Hydrogen peroxide is further detoxified to water by either GPx, which utilizes 
reducing equivalents of NADPH via GSH. During this process, GSH gets oxidised to GSSG, which 
is then converted back to GSH by NADPH-dependent GSR. In the thioredoxin pathway, hydrogen 
peroxide is detoxified to water via utilizing Prx3 which is then reduced by Trx, the oxidation of 
which is then reduced by TrxR2. ETC: Electron transport chain; MnSOD: Manganese superoxide 
dismutase; Cu/ZnSOD: Copper/Zinc superoxide dismutase; GSH: Glutathione; GSSG: 
Glutathione disulphide; GPx: Glutathione peroxidase; Prx3: peroxiredoxin 3; Trx: Thioredoxin; 
TrxR2: Thioredoxin reductase 2. 
 
Given the fact that mitochondria are essential for many cellular functions, it is not surprising 
that mitochondrial dysfunction leads to diverse pathologies in a multitude of human diseases. 
These include neurodegenerative diseases [24], cardiac dysfunction [25], kidney failure [26], 
liver dysfunction [27], cancer [28] and diabetes [29]. There is also significant evidence that 
mitochondrial dysfunction is implicated in the pathogenesis of many disorders associated with 
impaired vision [15]. Not only do nearly all mitochondrial diseases show some form of visual 
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impairment [30], mitochondrial dysfunction has also been reported for the majority of 
ophthalmological disorders [31].  
 
1.1.3 Mitochondria and the Eye  
1.1.3.1 Molecular Pathology of Mitochondrial Dysfunction 
 
Mitochondrial dysfunction can occur as a result of many physiological events including 
inherited mitochondrial mutations, age related cumulative mitochondrial DNA (mtDNA) 
damage, oxidative damage, calcium dysregulation and perturbation in mitochondrial dynamics. 
Mitochondrial dysfunction in turn can result in defective ATP synthesis, defects in 
mitochondrial biogenesis, elevated levels of oxidative stress and cell death. [32-34]. However, 
it has to be noted that these pathological events hardly ever occur in isolation and frequently 
affect each other [34-36]. 
 
1.1.3.2 Susceptibility of Visual Function by Mitochondrial Dysfunction 
 
The visual information from the eye is transmitted to the brain via the axons of retinal ganglion 
cells (RGC). The visual inputs from these axons are first received in the lateral geniculate 
nucleus and then in the superior colliculus, from where it is relayed to the higher visual 
processing centres in the brain. As mention earlier these cells are extremely vulnerable to 
mitochondrial dysfunction. It has been hypothesized that RGC, which are some of the most 
metabolically active neuronal cells in the body, possess a unique structural feature, which 
predisposes them to toxicity caused by mitochondrial dysfunction [37]. Intriguingly, RGC 
axons are only partially myelinated (Figure 5). While RGC axons in the optic nerve are 
myelinated, the retinal, pre-laminar parts of these axons lack myelination [37]. These non-
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myelinated areas within the retina require much higher levels of energy to sustain efficient 
signal transmission, and as a consequence, contain significantly higher numbers of 
mitochondria [38]. On the other hand, mitochondrial numbers decrease significantly in the 
myelinated, post-laminar optic nerve, where mitochondria are predominantly located around 
the nodes of Ranvier [38]. This unique absence of myelination of the intraocular part of the 
axons, together with the significantly increased energy demand in this area could be responsible 
for the selective vulnerability of RGC to impaired energy supply. 
 
Figure 5: Graphical representation of the structure of retinal ganglion cells (RGC). 
RGC are partially myelinated. Axons in the retinal nerve fibre layer (RNFL), anterior to the lamina 
cribrosa is unmyelinated and shows high concentrations of mitochondria, while axons posterior to 
the lamina cribrosa are myelinated and contain much lower numbers of mitochondria that are 
located around the nodes of Ranvier. 
 
1.1.3.3 Hereditary Mitochondrial Diseases (MDs) 
 
MDs are a heterogeneous group of disorders caused by mutations in either nuclear or 
mitochondrial genes that code for mitochondrial proteins. These disorders typically involve a 
variety of tissues from the brain to muscles [39] and the diagnosis of mitochondrial diseases is 
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difficult since a direct correlation between the specific mutation and the clinical phenotype is 
not always present [40]. Specific mutations can be responsible for symptoms specific to a 
particular disorder but can also produce symptoms associated with other conditions. However, 
most consistently associated with nearly all MDs are ophthalmological manifestations such as 
optic atrophy, retinal degeneration, visual field loss, ptosis, and ophthalmoplegia. Leber’s 
hereditary optic neuropathy (LHON) and Autosomal dominant optic atrophy (ADOA) are the 
most common hereditary optic neuropathies and serve as a model to understand the role of 
mitochondrial dysfunction in the molecular pathogenesis of other optic neuropathies. 
 
1.1.3.3.1 Leber’s Hereditary Optic Neuropathy (LHON) 
 
One of the best-described examples of visual defects directly caused by mitochondrial 
dysfunction is LHON, which is one of the most common mitochondrial disorders with an 
incidence of 1:30 000 to 1:50 000 [41]. It is maternally inherited and manifests with acute or 
subacute loss of vision usually in one eye, followed by loss of visual acuity in the second eye 
within 6-8 weeks, although simultaneous involvement of both eyes has been described in few 
cases [42]. Visual acuity in patients can worsen over a period of one month dropping to less 
than 20/200 (legal blindness). During the early course of the disease, colour vision is frequently 
affected [41,43]. LHON is mostly seen in young adults between 15-35 years of age with a 
predilection to males (80-90% pedigree), but a few cases of LHON have been reported in 
children and geriatrics [41]. Although at least 18 different mtDNA point mutations in complex 
I genes are known to be associated with LHON, over >95% of all cases occur as a result of one 
of the three pathogenic “primary LHON mutations” in mitochondrial DNA (11778G>A, 
3460G>A or 14484T>C) [41]. Despite LHON being one of the best-studied MDs, there are 
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still many unanswered questions relating to its incomplete penetrance, gender bias and most 
importantly why the visual system is predominantly affected [44]. 
 
Almost all LHON cases are homoplasmic, meaning all mtDNA copies harbor mutations and 
only a few (10-15 %) cases are heteroplasmic containing both wild type and mutated mtDNA, 
which leads to phenotypic variability among the pedigrees [41]. In addition, genetic 
mitochondrial haplotypes also play key roles in determining the degree of severity in patients 
[45]. Higher risk of visual failure was associated with the 11778G>A or 1448T>C mutations 
in patients carrying haplogroup J whereas the identical mutation (11778G>A) in haplogroup K 
significantly reduced the risk of visual loss [45]. Vision loss is observed in around 50 % of 
male carriers and only 10 % of female carriers. The gender predilection seen among 
symptomatic 11778G>A LHON carriers may possibly be associated with a neuroprotective 
role of oestrogen in female carriers of LHON [46].  
 
Although in most LHON cases vision loss is permanent, spontaneous visual recovery was 
reported in some patients, even several years after visual deterioration [47]. The probability for 
recovery of vision is different for the three LHON mutations, with the highest recovery rates 
(50 % or more) associated with the 14484T>C mutation. On the other hand, the 11778 G>A 
and 3460G>A mutations are associated with only low to intermediate recovery rates (4-20 %) 
[41,47,48]. The presence of visual recovery in LHON patients, even several years after the 
onset of the disease, strongly suggest that loss of visual acuity is not immediately associated 
with cell loss but rather represents cellular dysfunction that prevents the signal being 
transmitted from the retina to the brain [49]. Only in the later stages of the disease will cell loss 
make visual recovery impossible. Therefore, the time period between the cellular dysfunction 
General Introduction 
15 
 
and the cell death can be regarded as a window of opportunity where in principle it could be 
possible to restore vision loss [49]. 
 
It is interesting to note that the pathology of LHON is predominantly restricted to the visual 
system, although all somatic cells harbour the same mitochondrial DNA mutation. 
Histochemical studies in LHON have shown selective loss of RGCs and thinning of the retinal 
nerve fibre layer (RNFL) in the chronic stage of the disease [42,50].   
 
1.1.3.3.2 Autosomal Dominant Optic Atrophy (ADOA) 
 
A second mitochondrial optic neuropathy with similar clinical symptoms compared to LHON 
but with a slower disease progression is ADOA. Similar to LHON, this disease is characterized 
by insidious bilateral loss of central vision with a marked decrease in colour perception and 
relative preservation of pupillary reflex and optic pallor [51]. Vision loss in ADOA commonly 
starts during childhood at the age of 6-10 and adolescence and equally affects both males and 
females [3]. As the disease progresses, visual acuities in the patients deteriorate from 20/80 to 
20/120 [30]. However, unlike LHON, spontaneous visual recovery was not reported in ADOA 
[51]. Although ADOA and LHON differ in terms of disease onset and progression, both 
diseases are characterised by decreased RNFL thickness, RGC dysfunction with preferential 
loss of small neurons in a papillomacular bundle, axonal degeneration, swelling and 
demyelination in the optic nerve [52-54]. 
 
Although ADOA can result from mutations in four nuclear genes OPA1, OPA3,  OPA4 and 
OPA5, the majority of ADAO cases (60 % - 70 %) are associated with mutations in OPA1 
[55,56]. OPA1 is highly expressed in brain and retina [57], resides in the inner mitochondrial 
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membrane and is implicated in different functions including mitochondrial fusion, cristae 
structure, mitochondrial membrane maintenance and OXPHOS [55-57]. Therefore the 
pathological hallmarks of OPA1 mutations are mitochondrial network fragmentation and 
disorganised cristae [3]. OPA1 also sequesters cytochrome c, a pro-apoptotic factor in the 
mitochondria, and thus inhibits its release into the cytoplasm and consequently apoptotic cell 
death [58]. Dysfunctional OPA1 in ADOA patients was also shown to negatively affect 
mitochondrial ATP synthesis and respiration in skeletal muscles similar to LHON [59,60]. 
Despite the systemic presence of OPA1 mutations, optic atrophy is the most dominant clinical 
symptoms documented in ADOA. Interestingly reduced OPA1 expression was also reported in 
LHON [61]. This suggests that ADOA and LHON might share their pathology by converging 
on to the same biochemical pathway. 
 
1.1.3.3.3 Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like 
Episodes (MELAS) 
 
In contrast to LHON and ADOA, some mitochondrial optic neuropathies may occur as more 
complex disorders with multiple pathologies as a result of mtDNA mutations. MELAS is a 
maternally inherited mitochondrial disease and is characterised by variable phenotypes 
including stroke like episodes, seizures, dementia and lactic acidosis [41]. Additional 
symptoms of MELAS include migraine, depression and cardiac conduction defects [41]. 
Consistent with a causal relationship of mitochondrial and visual function, MELAS is also 
associated with a loss of visual acuity [41,48]. The ophthalmological features of MELAS 
patients are bilateral ptosis, chronic external ophthalmoplegia, choroidal atrophy degeneration 
of outer segment of photoreceptors, hyperpigmentation in the macular region as a result of 
retinal pigment epithelium (RPE) hyperplasia, as well as RPE atrophy in the macular area, as 
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well as iris stroma atrophy and optic atrophy [62,63]. For MELAS, the age of onset is generally 
before 15 years of age [64]. Although MELAS has been linked to a number of heteroplasmic 
point mutations in mt-DNA coding for complex I subunits including 3380 G>A in MT-ND1 
and m.13513 G>A in MT-ND5 [65,66], nearly 80% of MELAS cases result from an A3243G 
mutation in the MTTL1 gene encoding the mitochondrial tRNA (Leu(UUR)) [64]. Since 
mitochondrial complex I is dysfunctional in both LHON and MELAS, it is not surprising that 
cases of LHON/MELAS overlap syndrome have been reported associated with the 
heteroplasmic m.3376G>A mutation in MTND1 [67]. Although the pathogenesis of MELAS 
is still not fully understood, it was proposed that the mtRNA mutation causes decreased 
expression of mitochondrial respiratory chain complexes, leading to bioenergetic failure [41].  
 
1.1.3.3.4 Myoclonic Epilepsy and Ragged Red Fibres (MERRF) 
 
MERRF is another multiple system mitochondrial disorder with common ocular involvement. 
Almost all MERRF patients are affected by a mutation in mtDNA (m.8344T>C in the MT-TK 
gene) encoding tRNA Lys [48]. The age of onset is generally between 5-15 years. Comparable 
to the situation in MELAS, MERRF patients present with variable clinical phenotypes 
including myoclonus seizures, cerebellar ataxia, myopathy, dementia bilateral deafness and 
peripheral neuropathy. The most prominent ocular pathologies include progressive bilateral 
vision loss, retinal dystrophy, pigmentary retinopathy and macular pattern dystrophy [39,68]. 
Dysfunction of mitochondrial complex I or IV or occasionally both have been reported in 
MERRF [69]. The similarity of MERRF to other mitochondrial disorders is highlighted by the 
recent description of patients with two mutations in mitochondrial tRNA genes (m. 8356 T>C 
and m.3243A>G) that are responsible for the MERRF/MELAS overlap syndrome [70]. Overall 
the similarity of these disorders was described by a retrospective study where patients with 
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known mitochondrial diseases MERRF, MELAS and LHON showed a common ocular 
phenotype of retinal dystrophy [68]. 
 
Based on the evidence described above it appears that no matter how mitochondrial dysfunction 
arises, either by mtDNA or nDNA mutations, the most consistent clinical symptom is that of 
vision impairment. 
 
1.1.3.4 Neurodegenerative Diseases, Mitochondria and Vision  
 
Neurodegenerative diseases are a heterogeneous group of disorders characterised by loss of 
selected neuronal systems, with aging as a major risk factor. Since neurons are heavily 
dependent on a constant energy supply, it is increasingly recognized that mitochondrial 
dysfunction acquired during aging as a result of accumulated mtDNA mutations likely 
contributes to subsequent neurodegenerative pathologies such as Parkinson’s disease, 
Alzheimer’s disease [71]. 
 
1.1.3.4.1 Parkinson’s disease (PD) 
 
A multisystem disorder associated with mitochondrial dysfunction with a wide variety of motor 
and non-motor symptoms is PD. This disease is the second most common neurodegenerative 
disease that affected 4.3 million people in 2005 and is projected to increase to 9 million by 
2030 [72]. This dramatic increase in the incidence of PD could likely be a cause of age-related 
mitochondrial dysfunction in an aging population [73]. PD is associated with resting tremor, 
bradykinesia and rigidity. About 90-95 % cases of PD are sporadic while for only 5-10 % a 
genetic origin has been identified. PD is caused by loss of dopaminergic neurons responsible 
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for motor, cognitive and limbic function in the substantia niagra and is characterized by the 
presence of Lewy bodies (cytoplasmic inclusions containing α-synuclein protein) [71]. 
Oxidative stress as a result of mitochondrial dysfunction has been implicated in the 
pathogenesis of PD [74]. Initially, mitochondrial complex I defects were demonstrated in the 
substantia niagra of PD patients [75]. Later, reduced activities of complexes IV, V have also 
been reported in platelets and lymphocytes of patients suggesting that mitochondrial 
dysfunction is not only restricted to the substantial niagra [71] but comparable to classic MD’s 
detectable in all tissues. Consistent with these observations, complex I inhibitors such as 
rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) have been used to 
generate pre-clinical models of PD [75]. Chronic exposure of rats to rotenone produces a 
phenotype strikingly similar to PD, such as loss of dopaminergic neurons, the appearance of 
Lewy bodies, microglial activation, and the presence of biomarkers of oxidative damage [76]. 
Furthermore, mutations in genes such as α-synuclein, parkin, PINK1, and DJ-1 have been 
implicated in the hereditary forms of PD. Defects in these genes lead to oxidative stress, 
mitochondrial dysfunction and ultimately cell death [77]. In line with the mitochondrial 
dysfunction in PD, it is therefore not surprising that this disease also affects the visual system 
[54,78]. Decrease in visual acuity, contrast sensitivity, impaired colour vision, nystagmus are 
some of the features seen in PD patients [78]. Furthermore, a significant reduction in RNFL 
thickness has also been documented in PD patients compared to their aged-matched control 
[79].  
 
1.1.3.4.2 Alzheimer’s disease (AD) 
 
The most common neurodegenerative disease and the most common cause of dementia 
affecting more than 26.6 million patients globally is AD [80]. AD is characterized by a slow 
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progressive loss of cognitive function, and a gradual decline in memory and intellectual 
function [81]. The hallmark of AD is the extracellular deposition of the amyloid beta (Aβ) 
protein and the appearance of intracellular neurofibrillary tangles composed of 
hyperphosphorylated tau proteins [81]. Many studies have highlighted mitochondrial defects 
in the disease progression of AD [81]. Evidence of mitochondrial Aβ deposition within the 
visual cortex of AD patients and in the brain of AD animal models supports the notion of 
mitochondrial involvement in AD [81]. It has been suggested that Aβ enters the mitochondria 
via a translocase in the outer membrane and subsequently accumulates in mitochondrial cristae 
[82]. Thus, accumulated Aβ then causes an imbalance of mitochondrial fusion and fission, 
which results in mitochondrial fragmentation [83]. Mitochondrial dysfunction is proposed to 
occur as an early event during development and progression of sporadic AD and includes 
abnormalities in mtDNA, OXPHOS enzymes, mitochondrial gene expression, mitochondrial 
dynamics and mitochondrial trafficking [71,81]. 
 
Consistent with a connection between mitochondrial and visual function, changes to the visual 
system such as reduced visual acuity, contrast sensitivity and colour vision defects have also 
been reported in the early stages of AD patients [84] as well as in animal models of AD [85]. 
Furthermore, AD patients show pathological changes to the retina and optic nerve and in fact 
these changes can be regarded as the surrogate markers of the pathological changes in the 
central nervous system of AD patients [86]. These changes include decreased RGC numbers, 
reduced macular pigment, optic disc cupping, retinal microvascular abnormalities and a 
significant reduction in macular RNFL thickness [84,87].  
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1.1.3.4.3 Multiple Sclerosis (MS) 
 
MS is an inflammatory neurodegenerative disease of a central nervous system characterized by 
demyelination and progressive axonal degeneration [88]. Although MS is typically depicted as 
a single disease entity, it has to be noted that it encompasses several distinct clinical phenotypes 
such as relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), relapsing 
progressive MS (RPMS) and primary progressive MS (PPMS). Intriguingly, these different 
forms of the disease are reportedly associated with different levels of mitochondrial 
impairment, with PPMS reported to have the highest mitochondrial dysfunction. Although it is 
still unclear what events contribute to the pathogenesis of the disease, accumulating evidence 
suggest that calcium dysregulation, mitochondrial electron transport chain (ETC) defects, 
excess free radical production and mitochondrial permeability transition pore opening are 
responsible for predisposing to MS [88]. MS is often associated with acute onset of vision loss 
followed by a reduction in contrast sensitivity, loss of colour vision usually in one eye and is 
associated with pain during eye movements [3]. The loss in visual acuity is not permanent and 
generally recovers within 2-4 weeks [3]. In 15-20 % of patients, optic neuritis is the first clinical 
manifestation of MS and 50 % of MS patients develop optic neuritis as the disease progresses 
[3]. Recently, significant thinning of macular RNFL, reduction of retinal thickness and RGC 
loss have been reported in MS patients and reduced RNFL thickness, RGC loss, and brain 
atrophy correlate well with the staging of MS [3,89]. These results suggest that similar to the 
situation in AD, retinal neurodegeneration can be considered as a surrogate marker of brain 
atrophy in MS. Interestingly, some MS patients also carry LHON mutations [90]. The resulting 
LHON-MS overlap syndrome (also known as Harding disease) differs from LHON by its 
predominance to females; longer time to affect the fellow eye (nearly two years); mostly with 
more than two visual events [91]. Although Harding disease differs from MS by a higher visual 
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involvement, lack of painful eye movement; and rare visual recovery [91], both diseases share 
dysfunctional mitochondrial ETC and defective ATP synthesis [41,88]. However, in contrast 
to LHON, mitochondrial defects in MS are usually thought to be secondary to the process of 
acute inflammation [92]. 
 
Mitochondrial dysfunction has been universally implicated in the neurodegenerative diseases 
described above and importantly their visual phenotypes closely resemble those associated with 
hereditary mitochondrial diseases. 
 
1.1.3.5 Major Ocular Diseases and Mitochondria 
 
Based on the visual impairment in diseases that are characterized by mitochondrial dysfunction 
and the hypothesis that mitochondrial dysfunction is responsible for vision loss, it is not 
surprising that most ocular diseases also show mitochondrial dysfunction. 
 
1.1.3.5.1 Diabetic Retinopathy (DR) 
 
DR is one of the major causes of blindness worldwide [93] and is characterised by the abnormal 
growth of blood vessels in order to supply oxygenated blood to a hypoxic retina. DR patients 
experience sudden painless loss of visual acuity in one or both eyes that eventually leads to 
complete blindness [94]. Contrast sensitivity and colour vision can be significantly impaired in 
diabetic patients before the disease progresses to DR, which is why these ocular features are 
predictive of DR [95]. Neuronal degeneration along with vascular abnormalities has been 
reported in the pathogenesis of diabetic retinopathy [96]. In fact, neuronal changes in the retina 
precede the vascular changes in DR [97]. This statement is supported by a recent cross-
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sectional study that compared retinal layers among patients without diabetes, patients with type 
2 diabetes without diabetic retinopathy and patients with diabetes but with mild diabetic 
retinopathy [97]. In this study, the mean ganglion cell layer and retinal nerve fibre layer were 
thinner in diabetes without retinopathy when compared to healthy individuals [97]. There was 
a significant reduction in average retinal thickness in mild diabetic retinopathy compared to 
control and diabetes with no diabetic retinopathy. Moreover, in DR the reduction of RNFL 
thickness due to a loss of RGC [98] is more prominent in the superior quadrant, which worsens 
with the severity of disease and with progressing age [99,100]. Since this loss of RGC is 
painless, it is likely due to an apoptotic pathway as evidenced by increased expression and 
activation of apoptosis-related proteins [101,102]. 
 
Central to the pathology of DR, hyperglycaemia-induced mitochondrial ROS production 
activates four synergistic biochemical pathways that are likely causative for the loss of RGC 
in DR [103,104]. These pathways are initiated by increased mitochondrial ROS production, 
which inhibits glyceraldehyde 3-phoshate dehydrogenase (GAPDH). This inhibition of 
glycolysis results in increased accumulation of glycolytic metabolites and diverts the glycolysis 
pathway to activate polyol, hexokinase, PKC and advanced glycation end products (AGE) 
pathways (Figure 6). Activation of the polyol pathway causes osmotic damage of retinal cells 
through the accumulation of sorbitol. More importantly, it also reduces cellular NADPH levels, 
which in turn directly impairs the regeneration of the endogenous antioxidant GSH, a 
mechanism that further increases oxidative stress levels [103,104]. 
 
In addition, simultaneous activation of the hexokinase and PKC pathways activate transcription 
factors responsible for vascular complications including blood flow abnormalities, retinal 
capillary occlusion, stimulation of neovascularization, by upregulating vascular endothelial 
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growth factor (VEGF), a key element of retinal neovascularization. At the same time, PKC 
activation indirectly leads to the formation of AGEs from the non-enzymatic reaction of 
intracellular dicarbonyls with intra and extracellular amino groups of proteins. AGEs 
accumulate in the retinal microvasculature and activate the RAGE receptor, a process that 
further increases ROS levels and activates pro-inflammatory transcriptional factors such as NF-
κB as well as apoptosis of the retinal cell.  
 
Based on the activation of these pathways, it is not surprising that elevated levels of 
mitochondrial superoxide have also been detected in retinal cells of diabetic animal models 
[105]. Consistent with a central role of mitochondrial ROS in the activation of those pathways, 
inhibition of mitochondrial superoxide production prevented hyperglycaemia-induced 
activation of PKC, AGEs accumulation, sorbitol formation and NFkB activation in bovine 
aortic endothelial cells [106]. Furthermore, in support of a causative role of mitochondrial ROS 
in DR, overexpression of mitochondrial manganese superoxide dismutase (MnSOD) SOD2 
protected murine and bovine retina against diabetes-induced oxidative stress and cell death 
[107,108]. These results strongly implicate mitochondrial dysfunction in the pathogenesis of 
DR. 
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Figure 6: Mitochondrial pathology of diabetic retinopathy. 
Hyperglycaemia-induced mitochondrial dysfunction and subsequent generation of excess ROS 
inhibits glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which diverts the glycolytic 
pathway to the hexokinase (HK), polyol, protein kinase C (PKC), and advanced glycosylation end 
products (AGE) pathways. These pathways are also activated by hyperglycaemia and 
hyperglycaemia-induced autoxidation of glucose can activate the AGE pathway. These processes 
further increase ROS production, retinal ganglion cell (RGC) death and finally lead to loss of visual 
acuity. 
 
1.1.3.5.2 Glaucoma  
 
Glaucoma is a second leading cause of blindness worldwide [109]. The most common form of 
glaucoma is primary open-angle glaucoma (POAG), which affects nearly 70 million people 
worldwide [110]. POAG comprises normal tension glaucoma (NTG), in which intra-ocular 
pressure (IOP) is normal and high-tension glaucoma (HTG), in which increased IOP is a main 
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pathological feature [111]. Similar to LHON, glaucoma is associated with central but also 
peripheral vision loss, decreased contrast sensitivity and colour vision, which eventually 
progresses to blindness [112]. The major known risk factors for glaucoma include elevated 
intraocular pressure (IOP), age, and family history [113]. Elevated IOP is caused by reduced 
outflow of aqueous humor through the trabecular meshwork (TM), a connective tissue lining 
the iridocorneal angle of the anterior chamber of the eye [114]. The histological hallmarks of 
glaucoma include progressive loss of RGC and RNFL thinning [115]. Similar to LHON and 
ADOA the defect of RNFL thinning in glaucoma is more pronounced in the inferior and infero-
temporal quadrants and is followed by the superior quadrants [115]. Moreover, decreased 
expression of OPA1 in patients with POAG indicates that the molecular pathology of these 
diseases could be very similar to LHON and ADOA [116,117]. Indeed, there is evidence that 
mitochondrial dysfunction-mediated oxidative stress may play a significant role in glaucoma 
by inducing trabecular meshwork (TM) damage and RGC loss by direct or indirect mechanisms 
(Figure 7) [118]. The damage to TM cells prevents the regulated drainage of aqueous humor 
from the eye, which results in elevated IOP and obstructed blood flow to the optic nerve head 
(ONH) resulting in ischaemic conditions. This ischemia further compromises mitochondrial 
energy production in the RGC [118,119]. This combined pathology renders RGC more 
vulnerable to light and certain astrocyte- and microglia-derived chemicals such as glutamate, 
prostaglandins and nitric oxide [119]. Moreover, in a mouse model of glaucoma oxidative 
stress was directly correlated to the development of elevated IOP [120]. It can be hypothesized 
that the origin of mitochondrial oxidative stress in TM cells in POAG patients is likely 
associated with a defect in mitochondrial oxidative phosphorylation [121]. This idea is 
supported by the higher than expected frequency of OPA1 polymorphisms in POAG and 
especially in NTG patients [116,122]. Given the consequences of OPA1 deficiency on 
mitochondrial function in ADOA, it can be hypothesized that in POAG patients a defect in 
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mitochondrial respiration might also be present. Intriguingly, the presence of complex I 
dysfunction was recently described in lymphocytes obtained from POAG patients that resulted 
in decreased rates of complex I-driven ATP synthesis, decreased respiration and reduced cell 
growth, which suggest a mitochondrial defect in all cells of POAG patients [123]. The close 
similarities of POAG with hereditary mitochondrial diseases in terms of molecular pathology, 
visual defects, optic disc pallor, peripapillary atrophy and elevated IOP provide an explanation 
why POAG, LHON and ADOA can be easily misdiagnosed [51,124]. 
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Figure 7: Mitochondrial pathology of glaucoma. 
Mitochondrial dysfunction-mediated excess production of reactive oxygen species (ROS) damages 
trabecular meshwork cells causing aqueous humor flow obstruction as a consequence increases 
intraocular pressure (IOP). Subsequently, elevated IOP obstructs blood flow to optic nerve head 
(ONH) leading to ischaemic condition and ultimately to RGC death and development of glaucoma.  
 
1.1.3.5.3 Age Related Macular Degeneration (AMD) 
 
AMD is a neurodegenerative disease that affects individuals over 65 years of age and is also 
among the leading causes of blindness worldwide [125]. AMD is characterized by a loss of 
central vision as a consequence of retinal pigment epithelium (RPE) atrophy/hypertrophy and 
choroidal neovascularization. These predisposing factors become more pronounced as the 
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disease progresses and ultimately lead to complete loss of visual acuity. The underlying 
biochemical pathways leading to AMD are still not clear. However, like in DR, many 
experimental studies have pointed towards oxidative stress as a key factor (Figure 8) [126]. 
 
 
Figure 8: Mitochondrial pathology of age-related macular degeneration. 
Mitochondrial DNA damage, accumulated as a result of normal aging, leads to mitochondrial 
dysfunction, which in turn generates excess ROS. Elevated levels of ROS impair retinal pigment 
epithelium (RPE) function, a process that indirectly damages photoreceptors and that leads to the 
development of age-related macular degeneration. 
 
RPE cells continuously engulf, recycle and nourish the photoreceptor outer layer in order to 
maintain healthy photoreceptors. Therefore, the RPE has a high metabolic rate and as a result 
mitochondrial density in this region is particularly high [125]. Although a significant decrease 
in mitochondrial density in the RPE with increasing age was documented in the elderly, in 
AMD patients these age-related changes are even more pronounced [127]. Furthermore, with 
increasing age, decreased mitochondrial respiration, increased oxidative damage of mtDNA 
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and a decreased capacity to repair oxidative damage in the RPE is linked to AMD [128]. In 
support of a central role of mitochondrial ROS in AMD, knockdown of mitochondrial 
superoxide dismutase (MnSOD) in the murine RPE recapitulates the AMD phenotype such as 
RPE dysfunction, damage to photoreceptors and choroidal damage [129]. Comparable to the 
situation in LHON and ADOA, spectral-domain optical coherence tomography (SD-OCT) 
examination of AMD patients showed a decrease in RGC numbers despite no significant 
difference in RNFL thickness compared to healthy individuals [130]. RPE atrophy and 
pigmentary retinopathy, hallmarks of AMD, are reported for the majority cases of 
mitochondrial encephalopathies such as MELAS and MERRF that have mutations in mtDNA 
(3243A>G and 8344T>C) suggesting that mtDNA defect could also be associated with RPE 
abnormalities in AMD [63]. Supporting evidence that mtDNA mutations could be the 
underlying cause of AMD comes from a recent study that compared the localization of mtDNA 
damage in the diseased retina among human retinal samples obtained from different stages of 
AMD [131]. This study showed that mtDNA damage was specific to the RPE region in the 
retina. MtDNA of both the macular and peripheral RPE were equally damaged and the 
mutations localized to regions of the mtDNA that influence overall mitochondrial function. 
These observations led the authors to speculate that mitochondria of the RPE could be a 
therapeutic target to treat AMD.  
 
Given that the major ocular diseases not only share very similar visual phenotypes with 
hereditary mitochondrial diseases and the growing evidence that mitochondrial dysfunction 
predisposes to ocular disease, most ocular diseases could, in fact, be regarded as mitochondrial 
diseases.  
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1.1.4 Drug-induced Mitochondrial Optic Neuropathy 
 
The tight connection between vision and mitochondrial function is also illustrated at the 
pharmacological level. A number of widely used drugs are reported to induce mitochondrial 
dysfunction (Table 1). As a consequence, many drugs have been withdrawn from the market 
and in fact, about 80 % of drugs that received black box warnings by the FDA are known to 
cause mitochondrial toxicity [132]. These drugs cause mitochondrial defects through different 
mechanisms including impairing the function of ETC enzymes, generating ROS (particularly 
from complexes I and III) and depleting levels of the endogenous anti-oxidant, glutathione. 
These drugs represent a large range of drug classes that include antibiotics, anti-arrhythmics, 
anti-tuberculosis, anti-depressants, analgesics and anti-inflammatory drugs [133]. Drug-
induced mitochondrial toxicity has been implicated in organ toxicity such as hepatotoxicity, 
cardiotoxicity and toxic optic neuropathy (TON) [134]. The clinical features of TON include 
insidious onset, slow progressive and painless bilateral central vision loss, normal, oedematous 
or hyperaemic optic disc at an early stage, which may progress to temporal optic disc pallor at 
the later stages [134]. Patients may also present with colour vision loss [134]. OCT 
examinations in patients with TON show a marked reduction in RNFL, predominantly due to 
loss of small-caliber axons within the papillomacular bundle [135-137], consistent with the 
mitochondrial optic neuropathy seen in LHON and ADOA. Thus, mitochondrial impairment is 
central to the pathology of drug-induced optic neuropathy and RGCs are the main target in 
toxic optic neuropathy cases. 
 
At the same time, there is evidence that drug-induced mitochondrial optic neuropathies could 
also be the consequence of a pre-existing genetic mitochondrial dysfunction such as LHON 
and ADOA that are activated by drug use. Severe vision loss, defects in colour vision and 
General Introduction 
32 
 
bilateral optic nerve pallor have been observed in a LHON patient after initiation of 
antiretroviral drugs belonging to the class of nucleoside reverse transcriptase inhibitors that 
have a clear mitochondrial liability [138,139]. Antituberculosis drugs, such as ethambutol and 
antibiotics, such as erythromycin have also been reported to activate LHON and induce vision 
loss in individuals with asymptomatic LHON or ADOA [140-143].  
 
Table 1: Drugs associated with mitochondrial dysfunction and optic neuropathy 
 
 
 
                  
  CI CII CIII CIV CV β- OX mtDNA 
replication 
ANT Monograph 
Listed 
Ref 
Amiodarone X X X X X X     X [144-146] 
Amitriptyline X X   X         -- [147,148] 
Aspirin X       X X     -- [148,149] 
Chloramphenicol                                         X   X [150] 
Chlorpromazine X               -- [144,148,151] 
Cocaine X               -- [152] 
Desipramine X     X         -- [147,148] 
Dexamethasone       X         -- [148,153] 
Didanosine             X X X [148,154] 
Ethambutol X     X         X [145,150] 
Fluphenazine X               -- [148,151] 
Gentamycin             X   --  [148,155] 
Hexachlorophene          X       -- [148,156] 
Hydrocortisone       X         -- [148,153] 
Imipramine X X   X         -- [147,148] 
Indomethacin X       X X     -- [148,149] 
Isoniazid   X             X [148,157] 
Linezolid X     X         X [158] 
Naproxen X       X X     X [148,149] 
Piroxicam X       X X     -- [148,149] 
Prednisolone         X       -- [148,153] 
Streptomycin             X   -- [148,150,155] 
Sulindac X       X X     -- [149] 
Tamoxifen X   X           X [144,159] 
Thioridazine       X               X [148,160] 
Tobramycin             X   --  [148,155] 
Triamcilone         X       -- [148,153] 
*Clioquinol         X [161] 
*CQ-Zn chelate has shown to cause mitochondrial dysfunction by decreasing mitochondrial membrane potential. 
 
 
Effect on Mitochondria Drugs 
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1.2 Clioquinol and Vision  
1.2.1 Clioquinol in Neurotoxicity 
 
Clioquinol (CQ), a quinoline derivative, has been widely used (1950 to 1969) as a topical 
disinfectant and anti-microbial agent that was mainly used against diarrhoea. However, in 1970 
its oral form was withdrawn from the market after it was linked to about 10,000 Japanese cases 
of subacute myelo-optic neuropathy (SMON), a neurodegenerative disease characterised by 
sensory and motor disturbances in the lower limbs and visual impairment [162]. The autopsy 
of SMON patients revealed symmetrical and continuous degeneration of nerve fibres of a distal 
dominant portion of the long tracts in the spinal cord and demyelination of the retrobulbular 
optic nerves [162]. Severe lesions were detected in the distal end of the optic tract around the 
lateral geniculate body. The proximal optic nerve was less severely affected and the inner 
ganglion cells of the retina were the least severely affected [162] (Figure 9). Other associated 
clinical symptoms observed in SMON patients include abdominal pain, diarrhoea usually 
occurring before the onset of neurological symptoms, [162]. The majority of symptoms were 
reversible but permanent disability was reported in approximately 10 % of the SMON patients 
[163]. Intriguingly, there were only a few cases (220) of SMON outside Japan although this 
drug was used in different parts of the world at the same time and this geographical restriction 
has never been explained [164,165]. Soon after its ban, health records of SMON patients were 
examined. The health records survey conducted between 1964 and 1969 showed that of 47 
SMON cases, 81 % of the patients were receiving CQ at a dose of 300 mg to 3.5 g/day before 
the onset of symptoms [166]. Similarly, in a review of health records of 263 patients that used 
CQ for their digestive ailments compared to 706 patients that did not use CQ, neurological 
complaints were exclusively recorded in patients taking CQ [167]. A subsequent investigation 
revealed that among patients on CQ treatment neurological symptoms were more prevalent if 
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CQ treatment persisted for more than 14 days (35 % of 110 patients), while in 153 patients 
receiving CQ for less than 13 days neurological symptoms were recorded in only 2.6 % [167].  
 
To confirm the association of CQ in SMON, toxicological studies were carried out in humans. 
In 1973, healthy volunteers were administered oral CQ at doses of up to 1.5 g for 7 days 
followed by 750 mg for an additional 7 days [168], but no adverse effects were reported. 
Likewise, no neurological adverse effects were reported when up to 1.5 g CQ was given to 
prevent diarrhoea or cholera [169,170]. At present, this suggests that CQ-neurotoxicity requires 
continuous exposure for more than 14 days. Due to the overlapping phenotype (lesion in the 
posterior and lateral columns of the spinal cord) of early SMON and vitamin B12 deficiency 
CQ associated neurotoxicity has also been linked to vitamin B12 deficiency, [171]. Moreover, 
reduction in serum and cerebrospinal fluid levels of vitamin B12 has been demonstrated in 
mice injected with CQ for 20 days [172]. However, in SMON patients normal vitamin B12 
levels in serum or CSF were observed [173].  In fact, SMON patients were largely unresponsive 
to vitamin B12 supplementation and neurological symptoms continue to exist in these patients 
through 32 years of follow-up [163,174]. The connection between CQ and SMON was 
confirmed after 20 months of intensive investigations that were conducted by the Japanese 
SMON research group. This was largely based on the evidence that the majority of SMON 
patients had been taking CQ before the onset of the symptoms and that after the drug was 
withdrawn from the market the incidence of SMON reduced [175]. Furthermore, the common 
pathological features of SMON, including abdominal symptoms preceding to neurotoxicity 
have been successfully recapitulated in animals (dogs, cats and monkeys) after CQ 
administration [175-177]. 
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Figure 9: Comparison on severity of different damage sites between SMON and LHON. 
RGC and RNFL are mainly affected in LHON whereas they are the least affected in SMON. Severe 
lesions were detected in the distal end of the optic tract around the lateral geniculate body in SMON. 
RGC: Retinal Ganglion Cells; RNFL: Retinal Nerve Fibre Layer; ON: Optic Nerve; OT: Optic Tract; 
LGB: Lateral Geniculate Body. 
  
CQ is a lipophilic metal chelator of zinc (Zn), copper (Cu) and iron (Fe) and exerts its anti-
parasitic effect by acting as an ionophore [178]. It has been suggested that the chelating and 
ionophore activities of CQ contribute to its neurotoxicity in-vitro [161].  This is supported by 
green hairy tongue and green urine, markers of iron chelates of CQ, that have been observed 
in SMON patients [177]. In cultured neural cells from chicken embryos, CQ-ferric chelate 
increased iron uptake into cells leading to increased lipid peroxidation and subsequent neuronal 
cell degeneration [179]. Similarly, CQ-zinc chelate (25:50 µM) has been shown to reduce 
mitochondrial membrane potential in human melanoma cells, which subsequently led to 
cellular toxicity [161]. This pro-oxidant effect of CQ was also observed in murine cortical 
cultures where exposure to CQ (1-3 µM) for 24 h caused 40 % neuronal death and enhanced 
lipid peroxidation [180]. Co-administration of metal ions such as Fe and Cu with CQ further 
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enhanced its neurotoxicity and caused 100 % neuronal death [180].  Consistent with these 
findings, a reduction in cellular viability was observed in human prostate cancer cells only 
when CQ was combined with zinc [181]. CQ (at and above 10 µM) induced neurotoxicity 
through an inhibition of superoxide dismutase 1 (SOD1) in human neuroblastoma cells [182]. 
CQ is believed to inhibit SOD1 by chelating Cu and Zn ions, which are essential for the activity 
of SOD1. CQ is also reported to inhibit the 20S proteasome by Cu-dependent and independent 
mechanisms and as a consequence leads to increased intracellular levels of misfolded proteins, 
which subsequently result in cell death [183]. A metal-independent mechanism of CQ 
neurotoxicity directly at the level of DNA was also suggested. CQ decreased cellular 
proliferation of neuroblastoma cells at concentrations of 10 µM or more [184]. Furthermore, 
CQ (50 µM) induced neurotoxicity by the induction of DNA double-strand breaks and the 
subsequent activation of the ATM/p53 signalling cascade [184]. In neuronal PC12 cells, CQ 
dose-dependently inhibited nerve growth factor (NGF)-induced Trk autophosphorylation and 
neurite outgrowth, which is essential for neuronal growth and differentiation [185]. Consistent 
with this inhibition, CQ also inhibited NGF-induced mitogen-activated protein kinase (MAPK) 
phosphorylation, which is downstream of NGF-induced signalling [185]. CQ treatment of 
PC12 cells also reduced histone acetylation, a process essential for transcriptional activation of 
genes that are responsible for cell proliferation [186]. Consistent with this activity, HDAC 
inhibitor treatment upregulated histone acetylation, decreased CQ-induced neurite retraction, 
neuronal death and finally restored Trk autophosphorylation [186].  
 
Despite the numerous mechanisms that have been put forward to explain CQ-induced 
neurotoxicity, none of these have explained the restriction of CQ-induced neurotoxicity to the 
Japanese population. Surprisingly, despite its reported neurotoxicity, CQ is currently 
investigated as a disease modifying treatment for some neurodegenerative diseases such as 
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Alzheimer’s disease (AD) and Huntington’s disease (HD) with some promising preclinical and 
clinical outcomes.[187-189].   
 
1.2.2 Clioquinol in Neuroprotection 
1.2.2.1 Clioquinol in Alzheimer’s disease (AD) 
 
AD is a neurodegenerative disease characterised by a progressive decline in cognitive function 
and represents a major challenge to healthcare worldwide [190]. The major pathological 
hallmarks of AD include extracellular deposition of highly insoluble and proteolysis-resistant 
extracellular amyloid plaque also known as senile plaque, neurofibrillary tangles and cortical 
neuronal loss [191]. Metals such as Zn, Cu, Fe have been implicated in neocortical amyloid 
formation and deposition in AD’s brain as a result of metal-Aβ interactions [192]. A number 
of pre-clinical and clinical studies have proposed possible mechanisms where the interaction 
of metal ions with Aβ contributes to the neurotoxicity in AD. In the presence of Cu, Aβ is 
shown to inhibit mitochondrial complex IV in cultured human cells [193]. These metal ions 
are also responsible for generating reactive oxygen species that contribute to the oxidative 
stress observed in AD brains [192,194]. When Cu2+ or Fe3+ binds to Aβ, metal ions are reduced 
by Aβ to form H2O2 via a two-electron transfer to oxygen [195]. In primary cortical neurons, 
the presence of Cu2+ contributes to the formation of toxic Aβ aggregates [196]. Likewise, the 
formation of synaptotoxic Aβ oligomers in the presence of Zn2+ has been observed both in-
vitro and in-vivo [197,198]. It has to be pointed out that in the absence of metal ions, Aβ are 
degraded by matrix metalloprotease enzymes (MMP-2) [199]   However, the presence of metal 
ions render Aβ highly protease-resistant due to metal ions-induced conformational changes in 
Aβ-amyloid [199]. Therefore, the therapeutic strategies to control Aβ accumulation in AD are 
either to promote degradation of the soluble form of Aβ by proteases or to promote the 
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clearance of its insoluble form through metal chelation. It was proposed that CQ as a lipophilic 
metal chelator and an ionophore can support both of these strategies to reduce Aβ toxicity in 
AD brains [200,201]. As a lipophilic molecule, CQ and its structural analogue PBT2 (Prana 
Biotechnology) can cross the blood-brain barrier and has a high affinity for metal ions such as 
copper and zinc. CQ and its derivatives are believed to function via two mechanisms. First, 
they out-compete Aβ-amyloid for metal ions and eventually lead to the disaggregation of Aβ-
amyloid. As a second mechanism, they prevent the formation of toxic metal ions, which 
subsequently prevents the generation of oxidative stress and the formation of toxic Aβ 
aggregates [191,200,202,203]. Extracellular accumulation of metal ions implies a limited 
availability of intracellular metal ions, which ultimately leads to a pathological metal ion 
homeostasis, a condition that is reported for neurodegenerative diseases such as AD [204].  
 
In addition to metal chelation, CQ and PBT2 are believed to act as ionophores that redistribute 
metal ions intracellularly to promote neuroprotective cell signalling pathways [194]. It was 
proposed that CQ can upregulate MMPs and thus promotes Aβ degradation when used with 
metal ions such as Cu2+ and Zn2+ [201,205]. Based on these mechanisms CQ administration for 
9 weeks in a mouse model of AD (Tg2576) reduced insoluble Aβ by 49 % [200]. It is worth 
noting that administration of CQ in AD animal model has also been associated with toxicity 
[206]. CQ treatment induced lethality in young amyloid precursor protein (APP) transgenic 
mice, a model that represents only mild cognitive impairment [207]. Co-administration of CQ 
with Cu, however, abrogated the lethality by normalising cerebral Cu levels, increasing SOD1 
activity, and reducing Aβ generation {reviewed by [207]}. In a transgenic AD mice model 
(APP/PS1) as well as in control animals systemic administration of CQ at 6mg/kg/day for 5 
months induced myelinopathies in the dorsal lateral geniculate nucleus (DLG), which was 
almost devoid of amyloid plaque and is the primary site of retinal efferent projection via the 
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optic nerve [206], suggesting chronic systemic administration of CQ even at the lowest dose 
could induce neurotoxicity of the optic system. CQ-induced myelinopathies recapitulate the 
pathology of SMON, which includes demyelination in the lateral and posterior funicular of the 
spinal cord and the optic nerve [208].  
 
Following promising in-vivo studies, CQ and its structural analogue PBT2 were then moved to 
clinical trials in patients with AD. Although the drugs were shown to be safe and tolerable in 
patients over the treatment durations [188,202,209,210], few neurotoxicity cases have been 
reported (Table 2). 
 
1.2.2.2 Clioquinol in Huntington’s disease (HD) 
 
HD is an inherited neurodegenerative disease characterized by progressive and selective loss 
of neurons in the striatum causing motor function impairment, gradual decline in intellectual 
ability and personality changes. The disease is caused by an abnormally expanded CAG 
(polyglutamine; polyQ) repeat expansion in the huntingtin (htt) gene [211]. The disease starts 
to develop when the number of polyQ repeats reaches 40 or more [211]. Several lines of 
evidence indicate that ROS contributes to the pathogenesis of HD [212]. Metal ions such as 
Cu, Fe and Zn may be involved in ROS production, which eventually leads to the accumulation 
of mutant huntingtin protein [212]. Moreover, levels of Cu and Fe levels are reported to elevate 
in the striata of the human brain in HD [213]. In line with a role of metal ions in HD 
pathogenesis, treatment with a metal-chelators and ionophores including CQ and PBT2 is 
thought to reduce the accumulation of huntingtin protein aggregates and to restore metal 
homeostasis. CQ and PBT2 have shown beneficial effects in pre-clinical models of HD as well 
as in clinical trial [211,214]. CQ treatment of PC12 cells that overexpress polyglutamine-
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expanded huntingtin exon 1, down-regulated mutant huntingtin expression and inhibited cell 
death in in-vitro [214]. In transgenic Huntington’s mice and in a nematode model of HD, CQ 
and PBT2 treatment improved coordination (rotarod), decreased mutant huntingtin aggregates, 
decreased striatal atrophy and increased overall health measures such as reduced weight loss 
and extension of lifespan [211,214]. Based on these encouraging pre-clinical results, PBT2 
(100 mg, 250 mg and placebo) was evaluated in a randomised double-blind placebo–controlled 
trial in 109 early to mid-stage HD patients (USA/AUS). The study was conducted in USA and 
Australia over a period of 26 weeks and the primary endpoint measurement was safety, 
tolerability. The secondary end point was cognition, measured by the change from baseline 
after 26 weeks in the main composite Z score of 5 cognitive tests (Category Fluency Test, Trail 
Making Test Part B, Map Search, Symbol Digit Modalities Test, and Stroop Word Reading 
Test) and scores on eight individual cognitive tests (the five aforementioned plus the Trail 
Making Test Part A, Montreal Cognitive Assessment, and the Speeded Tapping Test) [215]. 
Compared to placebo, patients receiving either PBT2 100 mg or 250 mg/day did not 
significantly improve the main composite cognition Z-score while those receiving PBT2 250 
mg/day showed improvement only in one of the cognitive tests (trail making test part B) [215]. 
The European Medicines Agency (EMA) and US Food and Drug Administration (FDA) 
granted PBT2 orphan drug status. However, the FDA placed a partial clinical hold on PBT2 
after its use in dogs induced neurotoxicity [216].  
 
Collectively these data suggest that CQ and its structural analogue are still controversial drugs 
and the exact mechanism of CQ toxicity has to be understood thoroughly before CQ or its 
analogues can be used for the treatment of neurodegenerative diseases. 
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Table 2: CQ and PBT2 in clinical trial for neurodegenerative diseases 
Drug Study 
design/patient 
type/country 
Dose-patient 
number 
receiving that 
dose 
Duration 
(wks) 
End-point 
measurement 
Clinical findings Ref 
CQ Open label-AD 
Swedish 
 
20 mg/day-10 
80 mg/ day-10 
3 CSF-tau protein, 
growth 
associated 
protein, GAP43 
measured in 1/3 
weeks 
Biomarkers 
increased in 1 
week and 
decreased in 3 
weeks, 
Slight 
improvement after 
3 weeks 
[202] 
CQ Pilot Phase II, 
double blind 
placebo-
controlled, 
parallel-group/ 
Moderately-
severe AD/ 
AUS 
125 mg BD 
250 mg BD-  18 
375 mg BD 
 
Placebo-18 
0-12 
13-24 
25-36 
ADAS-cog at 4, 
12, 24, 36 wks,  
Plasma Aβ, Zn, 
Cu levels 
Drug well 
tolerated, 
Clinical benefit 
only seen in 
severely affected 
subject at 4 weeks, 
Plasma Aβ 
decreased at 20 
weeks, plasma Zn 
increased in 
treated group. 
3/16 receiving 
CQ+Vit B12 
developed 
impaired nerve 
induction. 
Two patients 
receiving CQ 
complaint about 
leg numbness and 
one had 
impairment in 
visual acuity, 
colour vision 
 
[188] 
PBT2 
(EURO) 
Phase II a 
double blind 
randomised, 
placebo-
controlled/ early 
AD 
in spinal fluid 
Sweden/AUS 
50 mg-20 
250 mg-29 
Placebo-29 
12  Safety, 
tolerability, 
Investigated 
levels of 
unaggregated 
soluble Abeta 
peptides in CSF, 
plasma, 
Cognition 
(ADAS-cog, 
MMSE, NTB) 
Drug safe and 
well tolerated, 
Patients receiving 
250 mg PBT2 
showed decreased 
in CSF Aβ while 
no effect seen in 
plasma biomarker 
as well as metal 
ions (Cu, Zn) 
levels, significant 
improvement in 
only two 
executive 
function 
component of 
NTB test 
(category fluency 
test: 2.8 words, 
p=0.041; trail 
making part B: -
[209] 
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48.0s, p=0.009) 
was reported in 
250 mg patient 
group over 
placebo treatment. 
PBT2 
(Imagine) 
 
 
 
 
 
 
 
Imagine 
extension 
Phase 
Prodormal/ Mild 
AD 
 
 
 
 
 
 
Open label study 
Extension of 
Imagine study  
250mg: 
Placebo-15 
PBT2-27 
 
 
 
 
 
 
250 mg-33 
No placebo group 
52 weeks 
 
 
 
 
 
 
 
 
52 weeks 
Safety, 
tolerability,  
PiB-PET 
standardized 
Uptake Value 
Ratio (SUVR)  
 
 
 
Safe and well 
tolerated 
No statistically 
reduction in beta-
amyloid plaques 
compared to 
placebo as  
 
 
 
 
No improvement 
in secondary 
endpoints of brain 
metabolic activity, 
cognition and 
function 
 
 
[217] 
 
 
 
 
 
 
 
 
[218] 
PBT2 Randomised, 
double blind, 
placebo-
controlled/ 
Early to mid 
stage HD/ 
USA/AUS 
100 mg -38 
250 mg -36 
Placebo-35 
26 Safety, 
tolerability, 
cognition 
(change in the 
baseline to 26 
weeks in the 
main composite 
Z score of 5 
cognitive test) 
Drug well 
tolerated, 
No significant 
improvement in 
the main 
composite 
cognition z score 
observed, trail 
making test part B 
showed 
improvement only 
in group receiving 
250 mg PBT2. 
[215] 
 
 
In order to fully understand the molecular mechanism underlying the above-mentioned 
mitochondrial optic neuropathies (MON), drug induced MON and to test new treatment 
modalities, prognostic and representative animal models are required. Pre-clinical models in 
several different animals have been described to study eye diseases including rats, mice and 
monkeys [219]. Recently, zebrafish have become a popular model to study vision and visual 
defects [220]. 
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1.3 Zebrafish and Vision 
1.3.1 Zebrafish as a Preclinical Model 
 
Over the last 20 years, zebrafish (Danio rerio) have been increasingly used as a vertebrate 
model for developmental and genetic studies [221]. There are many reasons for their 
popularity. Zebrafish are easy to maintain and breed in large numbers at relatively low cost. 
They become sexually mature after 3-4 months and each pair can generate 200-300 offspring 
on a weekly basis. The eggs fertilize and develop into transparent embryos outside the mother, 
which allows real-time observation of organogenesis occurring inside the embryo. The 
embryos are small enough (< 1 mm in diameter) to be easily distributed and maintained in 96 
well plates, which facilitates drug screening approaches using only small quantities of drug 
solution. In addition, embryos are permeable to many small molecules allowing easy 
administration of drugs [222]. Embryonic development in zebrafish is rapid and takes only a 
few days with the majority of organs such as brain, heart, liver, intestine and eye developing 
within 24 hours and becoming functional within a week. The free-swimming larvae hatch from 
around 72 hours post fertilization (hpf) and soon start foraging for food. All of these attributes 
explain the steady increase in the use of zebrafish in pharmaceutical research. A large number 
of embryos produced per clutch makes zebrafish a prominent model for higher throughput 
screening of small molecules [223], which is mandatory for preclinical drug development and 
toxicity assessment [224]. So far zebrafish have been used to model a wide variety of human 
diseases including hereditary muscle diseases [225], neurological disorders [226], tuberculosis 
[227], cancer[228], cardiovascular diseases [229], haematopoietic and infectious diseases 
[230]. In addition, zebrafish are a valuable vertebrate model for studying vision related 
disorders [231]. However, there are a few differences between the visual system of zebrafish 
and humans, which need to be taken into account. 
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1.3.2 The Visual System of Zebrafish  
1.3.2.1 Eye Structure 
  
The visual system of zebrafish is fundamentally similar to human subjects but exhibits some 
notable structural differences (Figure 10, Table 3) [231-241]. The lens in zebrafish eyes is 
spheroid and not ellipsoid as compared to the human eye and as a consequence, the zebrafish 
eye has a much lower volume of vitreous compared to the human eye (Figure 10).  
 
 
Table 3: Comparison of human and zebrafish eye 
Structure Human Zebrafish Ref 
Eye position 
Frontal eyes with highly overlapped 
binocular vision 
Lateral eyes with less 
overlapped binocular vision 
[238] 
Lens  
Ellipsoidal  
 
Completely spherical extending 
partially through iris providing 
wide-angle view. 
 
 
Retina 
(thickness) 
≈289 μm ≈ 180 μm  
[239] 
Ganglion cells Highly populated Less densely populated [234] 
Presence of 
Fovea 
Yes No 
[238] 
Vision 
 
Cone dominant and trichromatic 
vision (lacks UV sensitive colour 
vision. 
Cone dominant and 
tetrachromatic vision (contains 
UV sensitive short single cones). 
[237] 
Retinotectal 
projection 
Half of the optic fibres from each 
eye project on to the same side of 
the brain and other half crosses over 
at the optic chiasm and projects to 
the other side of the brain. 
All of the optic fibres coming 
from each eye crosses over at the 
optic chiasm and extends on to 
the opposite side of the brain. 
 
 
[238] 
Myelination 
The part of optic fibres before the 
lamina cribrosa are not myelinated 
while fibres after protruding from 
lamina cribrosa are all myelinated  
Whole optic fibres are 
myelinated. Loose, single layer 
myelin sheath is present around 
the intra-retinal axon and optic 
nerve consists of compact 
myelin. 
[232,240,241] 
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Figure 10: Comparison of the human and zebrafish eye. 
(a) Comparison of the human and zebrafish eye: Human and zebrafish eyes mainly differ in lens shape 
and space between lens and retina. (b) Comparison of human and zebrafish retinal structure:  
Schematic representation of the differences of the retinal layers between human and zebrafish retina. 
Information on human retinal thickness taken from [239] and for zebrafish derived from 
http://zfatlas.psu.edu/view.php?atlas=18&s=207; zebrafish atlas, 12 months post fertilized male 
transverse section). All quantifications are approximates only and may differ between individuals and 
areas within the retina. 
 
 
 
 
1.3.2.2 The Zebrafish Retina  
 
Since zebrafish use vision to protect themselves against predators and depend on light to search 
their food, their visual system develops rapidly [237]. The retinal structure starts to develop 
from 32 hpf and continues to develop extraordinarily fast within 5 days post fertilization (dpf) 
[231]. By then the zebrafish retina becomes functional. Unlike the mammalian eye, that 
contains a specialized area within the retina that is responsible for high acuity vision [233], this 
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so called macula is notably absent in zebrafish (Figure 10). Comparable to the human eye, the 
retinal structure of zebrafish is comprised of five distinct layers (Figure 10); three nuclear 
layers - the outer nuclear layer (ONL), the inner nuclear layer (INL) and the ganglion cell layer 
(GCL); and two plexiform layers (PL) - the inner (IPL) and outer plexiform layers (OPL) [233]. 
The ONL consists of the cell bodies of photoreceptors (rods and cones) whereas the cell bodies 
of horizontal cells, bipolar cells and amacrine cells reside within the INL [233]. The GCL 
contains the cell bodies of ganglion cells while their axons are located in the retinal nerve fibre 
layer (RNFL) before becoming bundled into the optic nerve to carry the visual information 
from the eye to the brain. Synapsis between different neurons takes place at PLs [233]. The 
synapsis between photoreceptors and bipolar cells (and horizontal cells) occurs in the OPL and 
the synapsis between bipolar and ganglion cells (and amacrine cells) occurs in the IPL [233]. 
Horizontal and amacrine cells initiate sidewise interaction in the OPL and IPL respectively 
[242]. Horizontal cells are responsible for enhancing contrast while amacrine cells, in addition 
to detecting a change in illumination, also process movement and direction of light on the retina 
[242]. In contrast to human ganglion cells where part of the axon within the retina is 
unmyelinated while other parts of the optic nerve are myelinated, the whole axon in zebrafish 
is myelinated [240,241].   
 
The photoreceptor outer segment (POS) of zebrafish consists of rods and cones, comparable to 
the human retina. Anatomically cones are arranged in a mosaic pattern that can be categorised 
into four types; short single cones (SSCs) or ultraviolet sensitive cones, long single cones 
(LSCs) or blue sensitive cones and double cones (DCs) consisting of short (green sensitive) 
and long(red sensitive) cones [235,243]. They are also classified based on the peak sensitivities 
of the photopigment present in each cone as follows; ultraviolet (UV, 360-361 nm), short (S, 
407-417 nm), medium (M, 473-480 nm) and long (L, 556-564 nm) cones [235]. Based on the 
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four cone types in zebrafish, their vision is tetrachromatic. In contrast, the human eye lacks the 
UV-sensitive cones and therefore has the only trichromatic vision [237]. Unlike cones that have 
four types of opsins as their photopigment, the rods consist of only a single type and contain 
rhodopsin as their photopigment [237]. During the development of the zebrafish retina, the 
SSCs become distinct at around 5-6 dpf while LSCs appear at around 7-8 dpf and the DCs at 
around 10-12 dpf. However, all of the visual pigments are expressed between 50-55 hpf, so the 
various cone types are presumably there at 50-55 hpf, but not recognizable. The first rod cells 
appear at 5-6 dpf [231,244]. Although small rod responses can be detected at this stage, full 
rod responses are not evident until 15-21 dpf [231,245,246]. Therefore, until 15, dpf zebrafish 
only have functional cones that are responsible for colour vision. 
 
1.3.2.3 Visual Processing 
 
Light signals entering the eye are first refracted from the cornea to the lens and then projected 
onto the retina. The signal is then collected by the photo pigment of photoreceptor layer where 
the rod and cone cells convert the light signals into electrical signals [247] that are transmitted 
via the horizontal, amacrine and bipolar cells to the RGCs [242]. RGCs give rise to the nerve 
fiber layer, which is responsible for carrying the signals from the eye, via the optic nerve to the 
optical centers in the brain. 
 
1.3.2.4 Eye Development 
 
The initial development of the eye structures in zebrafish generally resembles those of other 
vertebrates [248,249] (Figure 11). Eye morphogenesis begins with the evagination of the optic 
vesicle from the forebrain at 11 hpf as a flat structure which then extends laterally, forming an 
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optic lobe [248,250]. The anterior portion of the optic lobe remains attached to the forebrain 
through the optic stalk [250]. The optic vesicle finally gives rise to the neural retina and 
pigmented epithelium at 15 hpf. By 16 to 20 hpf, the eyecups are developed through a series 
of different stages from the optic lobe. Surface ectoderm cells underlying the eyecups thicken 
and form a lens placode at around 16 hpf. Delamination of the lens placode from the surface 
ectoderm occurs at approximately 24 hpf and then detaches fully by 26 hpf. By 30 hpf the 
corneal epithelium is formed from the surface ectoderm which overlies the lens. Further 
morphogenesis of the eyecups forms an optic fissure by 24 hpf and closes thereafter at 48 hpf, 
which signals that morphogenesis of the embryonic eye is largely terminated and that only 
retinal neurogenesis is in progress at that time [221,248,249]. At around 32 hpf, the first 
ganglionic cells differentiate [251] and soon after that their axons reach the optic tectum [233]. 
The amacrine and horizontal cells within the INL first appear at 50 hpf and by 55 hpf, rod and 
cone outer segments in the ONL are developed [249]. Rods cells and Muller glial cells are the 
last to differentiate [252]. The presynaptic photoreceptor ribbon (Figure 12) develops at about 
65 hpf [249]. Visual information is processed once the ribbon synapses of the bipolar cells 
reach maturity at 74 hpf [249], which are responsible for passing the light-induced changes in 
photoreceptor cell membrane potential down the retinal circuit [253]. This means that the 
retinal structure becomes functional at around 74 hpf [254]. At the same time, the extra-ocular 
muscles become fully functional, which is a prerequisite for tracking of moving objects by eye 
movement [255]. Consequently, visually-mediated response improves thereafter with adult-
like performance after 96 hpf, where full tracking of eye movement (optokinetic response) is 
evident. 
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Figure 11: Sequences of eye development in zebrafish. 
hpf-hours post fertilization; dpf-days post fertilization; RGCs-Retinal Ganglion cells; SSCs-short single cones; LSCs-long single cones; 
POS-photoreceptor outer segment; OKR-optokinetic response. 
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Figure 12: Synaptic ribbons. 
Photoreceptors showing presynaptic ribbons, which are responsible for signal transmission from photoreceptor layer to bipolar and 
horizontal cells. 
General Introduction 
51 
 
1.3.3 Why Zebrafish are a Good Animal Model for Ophthalmological Studies 
 
Unlike mouse models, zebrafish are relatively easy to maintain at a fraction of the cost. 
Zebrafish are prolific breeders and produce as many as 100-200 eggs on every mating, while a 
pair of mice reliably produces a maximum 6-8 offspring. This large number of eggs per clutch 
in zebrafish allows higher throughput screening for the identification of mutants and potential 
drug candidates [231].  In many respects, the zebrafish visual system mirrors the human 
situation better compared to other animal models. Contrary to mice which have a rod-
dominated vision, zebrafish have cone-dominant vision like humans [221], which is a 
prerequisite to study human disorders associated with cone degeneration such as age-related 
macular degeneration (AMD) [236]. In addition, the eyes of zebrafish develop fast from only 
12 hpf and display a functional visual system by 5 dpf. This is significantly faster compared to 
mice (around 15-20 days) [256,257] and permits study visual function already in 5 day old 
larvae. Furthermore, the significant amount of genetic information available from zebrafish 
mutants associated with defective visual development and function illustrates the power of this 
model for understanding human ophthalmological disorders. 
 
1.3.4 Measurement of Visual Behaviour 
 
Behavioural responses have been utilized as an important tool for screening genetic defects of 
the visual system as well as to study the development of the visual system in zebrafish. Several 
well described behavioural responses with unique advantages and limitations have been used 
so far (Table 4).  
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1.3.4.1 Optokinetic Response (OKR) 
 
The OKR is based on the eye movement reflex in response to a moving stimulus to help 
stabilize the image on the retina to maintain visual acuity and is evidence of a fully functional 
visual system in zebrafish [258,259]. The OKR is tracking eye movements which consist of 
smooth pursuits (slow phase) and fast resetting saccades in the opposite direction [238]. OKR 
begins at around 74 hpf when only 5 % of the zebrafish larvae respond to the visual stimulus 
which then increases steadily to 100 % by 80 hpf [248,254]. The OKR improves in terms of 
time spent in tracking the stimulus and velocity of tracking eye movement by 96 hpf  
[254,255,260]. For this method, zebrafish larvae are immobilized to restrain the body while 
maintaining the ability for eye movement and are then exposed to a visual stimulus that usually 
consists of alternate black and white stripes that move around the larvae [237,238,261,262]. 
The larvae respond to this stimulus by moving their eyes in the direction of the moving stripes 
[237]. Experimental visual stimuli, such as spatial frequency, contrast and angular velocity can 
be altered in this setting to gain a deeper understanding of a potential defect [262]. With some 
experimental adaptations, such as a constant supply of oxygen-rich water while body 
movement is restrained, this method can be applied to adult fish as well [263]. This assay is 
rapid and responses of larvae or adult fish can be processed within only a few minutes [258]. 
OKR was used to identify and characterize many zebrafish mutants that are associated with 
vision system defects (Table 4) such as bumper mutant (defect in lens development), noir, 
dropje, lakritz mutants (defect in retinal structure), belladonna mutant (RGCs axon misrouting) 
and grumpy and sleepy mutants (optic nerve disorder) [261]. Other examples of visual function 
defects are the brass mutant with a phenotype similar to glaucoma [264]. In addition, OKR was 
also useful in isolating a colour-blind mutant by changing the colour of visual stimulus [265]. 
In summary, the OKR appears to result in more robust, reliable and quantifiable behavioural 
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data compared to other methods described below, especially after automated commercial 
systems have become available [260,265]. 
 
1.3.4.2 Optomotor Response (OMR)  
 
The OMR tests the visual behaviour of zebrafish by their tendency to swim towards moving 
black and white stripes [266]. Since numerous fish with possible visual function defects can be 
tested at once, this OMR assay enables higher throughput analysis compared to the OKR. 
However, it has to be noted that compared to the OKR there is a significantly higher risk to 
miss mutants when using OMR [266]. The set-up of OMR is similar as that of OKR except 
that the embryos or adult fish are not constrained and are able to swim towards the perceived 
black white stripes [267]. This type of behavioural response shown by zebrafish is one of the 
innate behaviours known as taxis where fish orient themselves in the direction of the stimulus 
[268]. This behaviour is important to maintain their orientation in water [268]. In the assay, the 
wild type fish swim towards the perceived motion and gather at one end of a chamber while 
zebrafish with visual defects swim in random patterns [267]. OMR is suitable to test the visual 
acuity of both larvae and adult zebrafish and has been used to isolate at least 17 mutants from 
411 previously identified loci in zebrafish that affect visual function so far [231,254,261,267]. 
Furthermore, the development of visual behaviour in zebrafish under different light conditions 
(ON and OFF)[267] and the effects of ethanol exposure on embryonic eye development 
[267,269] have also been studied using OMR.   
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1.3.4.3 The Startle Response (SR) 
 
The SR in zebrafish is based on a form of body movement within 2 seconds in response to a 
sudden exposure to a low-intensity light (~60 μW/m2) or an acoustic signal and is also useful 
to determine the development and maturation of the visual system in zebrafish [254,270]. The 
SR is typically first seen at 68 hpf where 17 % of the fish show startle responses, which then 
steadily increase to 100 % at 79 hpf at a time when the POS appear abundantly together with a 
functional retina and fully developed synaptic ribbon [254]. This assay has been successfully 
used to assess visual development in zebrafish embryos as well as used to detect defects of 
visual development in response to exposure to toxins such as methylmercury [271]. Recently a 
modification of startle response has been introduced called visual motor response (VMR) 
which can be performed on 4 dpf zebrafish larvae to screen for visual mutants. VMR is 
developed to confirm the result of OKR. This assay examines whether the visual mutants that 
fail to detect motion under OKR can detect changes in light intensities and are not completely 
blind [272,273]. 
 
1.3.4.4 Phototactic Behaviour (PTB) 
 
The PTB is based on the tendency of zebrafish with normal vision to move towards an 
illuminated chamber [260]. The experimental setup for this assay consists of a rectangular 
acrylic box with two chambers inside separated by a sliding bar. There are two methods in 
which PTB can be assessed [260]. The first approach is based on two chambers, which are 
equally illuminated. The fish are allowed to distribute between both chambers and the number 
of larvae in each chamber are counted after a set of the time interval. Then the same procedure 
is repeated with only one chamber illuminated, while the other chamber is covered. In general, 
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larvae between 7-14 dpf are suitable for the first method. For the second method, larvae aged 
between 7 to 19 days are kept in a darkened chamber for up to 2 minutes before the partition is 
removed and the fish are free to enter the second illuminated chamber [260]. The partition is 
replaced after several minutes and the numbers of fish in both chambers are quantified. 
Typically, fish with normal vision will move towards the illuminated chamber while fish with 
vision defects will not show a preference for the illuminated chamber. For this assay, it was 
noted that fish move towards the illuminated chamber in both methods, which is evidence of 
phototactic behaviour in zebrafish [260]. However, there appears to be no significant difference 
in the number of fish moving from one chamber to another in the light and dark condition 
approach, which has to be taken into account when interpreting the results. Because of this 
limitation, the PTB is less suitable for screening zebrafish for mutants with defective vision 
[260].  
 
1.3.4.5 Escape Response (ER) 
 
Another method to assess vision in zebrafish is the ER, which is based on the natural tendency 
of zebrafish to evade an approaching predator. In a typical experimental setup, zebrafish are 
kept inside a white circular rotating drum with a single black strip that mimics a threatening 
predator [274]. In this assay, zebrafish show a tendency to keep on opposite site of the black 
stripe. The response of zebrafish either to move towards the visual cues or to move away from 
it, is determined by the size of the visual cue [275]. Zebrafish orient them towards a small 
moving visual stimulus as in the case of OMR. As the size of the visual stimulus increases, 
their behavioural response change into aversive turns and they move away from it as in the 
case of ER. This is well explained as a transition from a prey capture related orienting response 
to a predator avoidance response [275]. This test is robust and has been used before in several 
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studies to characterize mutants that affect vision [274,276], such as nba (night blindness a) and 
nbb (night blindness b), which are dominant mutants with adult retinal degeneration [274]. 
Using ER, the role of the circadian clock in modulating visual sensitivity has also been studied 
in zebrafish [277,278]. When the threshold light intensity to initiate an escape response was 
measured over a period of 24 hours under light-dark cycle, the threshold light intensity was at 
its highest prior to “lights on” early in the morning and at its lowest prior to “light off” in the 
late afternoon. Therefore, the authors concluded that zebrafish are more sensitive towards 
visual stimuli at dusk than at dawn [277]. 
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Table 4: Summary of behavioural assays used in zebrafish 
Assays Suitability Validity Advantages Disadvantages 
 
Ref 
SR  
 
 
 
 
 
 
 
VMR 
≥4dpf (embryo) Yes Suitable for analysing 
simple visual function 
such as differentiating 
light from darkness. 
Useful to study visual 
function   
development. 
 
VMR complements 
OKR and is useful for 
visual mutants 
screening. 
Not suitable for 
larvae ≥ 5 dpf as 
spontaneous 
movement is often 
difficult to 
distinguish from 
startle response. 
 
Not suitable for 
screening visual 
defect mutants. 
[254] [270] 
 
 
 
 
 
 
 
[272,273] 
OKR 5-7 dpf (embryo 
and adult) 
 
 
Yes 
Suitable for complex 
visual function test 
(visual acuity, 
contrast sensitivity, 
colour blindness). 
 
Useful for mutant 
screens. Provides 
specificity in 
screening mutants. 
Time consuming 
assay (test one fish at 
a time). 
 
Possibility of 
missing the strong 
mutants.-randomly 
selected 
[255,261,2
62,266] 
OMR >6 dpf (Embryo 
and Adult) 
Yes Fast assay for high 
throughput analysis 
of visual mutants 
(large number of fish 
can be analysed at 
once). 
Lower risk of missing 
mutants while 
screening. 
Lack of specificity 
in result (possibility 
of false result 
sometimes)-as it 
does not test each 
and every 
individual fish. 
[261,267,2
79] 
PTB >6 dpf (embryo 
and adult) 
No Suitable for simple 
light responses. 
Not suitable for 
mutants screening-
due to unreliable 
result. 
[260] 
ER >2 months 
(adult) 
Yes Simple, robust 
method. 
Provides high 
throughput analysis. 
Useful in screening 
visual mutants, visual 
sensitivities as well 
as for drug 
identification and 
toxicity studies. 
 [274] [276] 
 
1.3.5 Limitations of Visual Behaviour-based Assays 
 
It has to be pointed out that the assessment of visual function in zebrafish by the assays 
described above is entirely based on their behavioural response to the visual stimulus. As a 
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consequence, there is the potential that these assays could produce misleading results. In 
particular, it can be hypothesized that defects in tissues other than the eyes that are nevertheless 
crucial for behaviour, such as neuronal circuits that affect muscle function, have the potential 
to produce misleading results. Genetic analysis of visual behaviour in zebrafish mutants (10 
loci, 12 new alleles) did reveal defective visual behaviours (OMR, OKR) with no obvious 
morphological defect in the retina and RGC projection [266]. This study has highlighted the 
potential involvement of brain functions beyond retinotectal projection, which is not 
unexpected given our knowledge of drugs that can alter behaviour. For example, it has been 
reported that acute alcohol exposure reduces the fear responses and zebrafish become 
unresponsive towards visual cues [280]. Nevertheless, some drugs can inhibit motility thus 
ending up with a false impression on visual behaviour assays that is examined by the fish 
movement such as OMR, therefore further assessment in such condition is necessary [281]. 
Finally, defects in all processes and systems that are involved, from the processing of visual 
information to the actual observed change of visual behaviour, such as motor function, have to 
be seen as possible sites that could influence results. As such, processing of the visual signal 
in the visual cortex (in higher vertebrates) or optic tectum (in the case of zebrafish) only serves 
as a prerequisite for induced behaviour, therefore dysfunction in the visual cortex but also other 
brain areas involved in decision-making could potentially lead to unresponsiveness to the 
visual stimulation. Thus, confirmation of behavioural assay results with additional methods, 
such as detection of pathology in the retina or optic nerve or the use of electroretinography 
[274,279] will significantly increase the reliability of results. 
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1.3.6 Drug-related Ophthalmological Toxicity Assessment in Zebrafish 
 
More than 200 currently used drugs are associated with ophthalmic toxicity as a result of 
adverse drug reaction [282]. Assessment of oculotoxicity associated with drugs at the early 
stage of their development is crucial. However, this process is partly hindered due to a lack of 
predictive, convenient methods as well as the high expense associated with testing drug 
candidates in mammals [281,283]. For many years researchers have been using zebrafish 
assays for drug toxicity screening with a view to provide early drug safety assessments 
[284,285]. So far zebrafish have been used to predict drug-related cardiotoxicity, ototoxicity, 
developmental toxicity, neurotoxicity, oculotoxicity and many more [284,285]. Furthermore, 
zebrafish have demonstrated good prediction of toxicity associated with the effects of systemic 
drugs in humans [285]. More recently, a study described zebrafish as a potential animal model 
to predict drug related oculotoxicity at the preclinical stage [283]. In this study 3 dpf zebrafish 
larvae were exposed to the known oculotoxic drugs (digoxin, gentamicin, ibuprofen, minoxidil 
and quinine) for 48 h and toxicity was assessed using visual behaviour assay. These drugs 
resulted in damage to visual function in zebrafish thereby confirming the potential toxicity of 
these drugs to the human eye. 
 
In addition, many studies have been carried out to validate zebrafish assays for drug toxicity 
assessment. In one of those, 27 drugs, 19 of which with known and 8 with no record of 
oculotoxicity in human were assessed in zebrafish using OMR [281]. Of the 19 compounds, 
13 drug compounds including chlorpromazine, quinine, digoxin, AZ compound 1, 
deferoxamine, flecainide, ganciclovir, ibuprofen, minoxidil, thioridazine and vardenafil were 
found to be oculotoxic in zebrafish. This finding is supported by another similar study which 
tested 9 known drug compounds with oculotoxicity and found 7 out of 9 compounds had the 
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adverse effect on the visual function of zebrafish as well [286]. Furthermore, zebrafish have 
been used extensively as a screening tool for small molecules that modulate vertebrate 
development [287]. For example, small molecule screens have identified compounds that can 
affect vascular development in the zebrafish retina. In one study, around 2000 small molecules 
were tested in zebrafish embryos followed by monitoring changes in retinal vasculature and 
out of those, 5 compounds were identified [288], which suggests that these drugs may also 
contribute to the development of pathological changes in the retinal vasculature in human 
patients. These findings suggest that zebrafish models are successful in mirroring known 
oculotoxic characteristics of drugs in human and have the potential to predict oculotoxicity 
profiles of novel drugs. 
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Chapter 2:  In-vitro Studies  
2.1 Overview and Rationale  
 
 Mitochondria generate the majority of cellular energy in the form of adenosine triphosphate 
(ATP) by oxidative phosphorylation and they are crucial to cellular function and survival as 
well as for regulating cell death. The density of mitochondria varies among different cell types 
such that highly metabolically active cell types such as in the visual system have higher 
numbers of mitochondria. Mitochondria are responsible for retinal cell function and survival 
as they are the major source of cellular energy supply. Therefore, defects in energy metabolism 
resulting from mitochondrial dysfunction often lead to visual defects. Retinal ganglion cells 
(RGC), one of the most metabolically active cells in the body have high numbers of 
mitochondria predominantly in the pre-laminar axonal region in the retina before they enter the 
optic nerve [15]. The reason that mitochondria are particularly abundant along the 
unmyelinated axons of RGCs is to sustain the energy intensive signal transduction in the 
absence of insulating myelin sheath. Vision impairment is a common feature of most 
mitochondrial disease including Leber’s Hereditary Optic Neuropathy (LHON) and Autosomal 
Dominant Optic Atrophy (ADOA) [31]. At the same time there is evidence that ROS and 
mitochondrial dysfunction are at least contributing, if not causal of the pathogenesis of many 
ophthalmological disorders such as glaucoma, diabetic retinopathy and age related macular 
degeneration (AMD) [15]. Beside this, a number of widely used drugs have been reported to 
induce mitochondrial dysfunction and are implicated in toxic optic neuropathy [134].   
 
Since many drugs can potentially cause mitochondrial dysfunction, this research project was 
designed to identity potential mitochondrial toxins by in-vitro screening. Around 200 selected 
marketed drugs (obtained from the Royal Hobart Hospital Pharmacy) and drug-like molecules 
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were screened using an assay to identify drug-induced mitochondrial dysfunction. Drug-
induced mitochondrial dysfunction was identified by measuring cellular drug-hypersensitivity 
in galactose versus glucose-containing media (endpoint: drug-induced reduction in cellular 
ATP levels). From this screen, two compounds were identified, clioquinol (5-chloro-7-iodo-8-
hydroxyquinoline) and its parent compound 8-hydroxyquinoline. Clioquinol (CQ) was widely 
used as a topical disinfectant for skin conditions and as an oral antibiotic to treat diarrhoea. 
However, after 1970, its oral form was banned in many countries after being linked to more 
than 10,000 cases of Subacute-Myelo-Optic Neuropathy (SMON) that were restricted mainly 
to Japan [167]. Despite its toxic history, there is a renewed interest to employ CQ and its 
derivatives as a disease modifying treatment for neurodegenerative diseases such as 
Alzheimer’s and Huntington’s diseases with some promising preclinical and clinical results 
[188,200,211,215]. In light of the re-emergence of CQ and its structural analogues, it is crucial 
to understand the underlying mechanism of CQ-induced toxicity to prevent any potential CQ-
associated risks to the patients.  
 
2.2 Aim and Objectives 
 
The mechanism of CQ-induced neurotoxicity and the reason for restriction of this neurotoxicity 
to Japan are still elusive. Amidst this toxic history, CQ and its structural analogues have 
recently re-emerged as a neuroprotective agent. This is contradictory in itself and poses the 
question: how can a drug have neurotoxic as well neuroprotective effect at the same time? 
Therefore, the overall aim of this research project is to explore the molecular mechanism of 
CQ-induced neurotoxicity. 
To achieve this aim, experiments were carried out to fulfil the following objectives: 
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 To confirm in-vitro screening result of CQ- and 8-HQ-induced mitochondrial 
dysfunction. 
 To investigate if ROS is responsible for CQ-induced toxicity by measuring CQ-induced 
lipid peroxidation. 
 To investigate if oxidative stress is the mechanism of CQ toxicity by examining if CQ-
induced toxicity can be ameliorated by antioxidants. 
 
2.3 Materials and Methods 
2.3.1 Drugs and Compounds 
 
All chemicals were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia) unless 
otherwise specified. Clioquinol (CQ) and 8-hydroxyquinoline (8-HQ) were purchased from 
Ciba (Basel, Switzerland) and Ajax Chemicals Ltd (NSW, Australia) respectively. CQ and 8-
HQ were dissolved in DMSO, dicoumarol (Dic) was dissolved in 0.1 % NaOH to prepare 10 
mM stock solutions. The antioxidants; vitamin C, N-acetyl cysteine (NAC), trolox and vitamin 
E were dissolved in water or DMSO depending on their solubility in the respective vehicles to 
generate stock solution of 1 M Vitamin C, 0.5 M NAC, 10 mM trolox and 10 mM vitamin E. 
Stock solutions were stored as single-use aliquots at -20 ˚C until use. Further dilutions were 
made in the culture media to achieve the final concentration of drug and to keep final DMSO 
concentrations below 0.5 % v/v. All cell culture plastic materials were purchased from 
Corning-In Vitro Technologies (Victoria, Australia) unless otherwise specified. 
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2.3.2 Cell Culture 
 
The human hepatocellular carcinoma cell line (HepG2) was purchased from the European 
Collection of Cell Culture (EACC). Rodent neuronal RGC5 cells were provided by Associate 
Professor Ian Trounce (Centre for Eye Research Australia, CERA, Melbourne, Australia). 
Human Embryonic Kidney (HEK293) cell lines stably transfected with pCI-neo expression 
plasmid (Promega) containing the sequence for recombinant human NQO1 were provided by 
Dr. Robert Dallmann (University of Warwick, UK). All cell lines were cultured under normal 
culture conditions (37 °C, 5 % CO2 & 95 % RH) in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing low glucose (1 g/l) or in glucose free culture media supplemented with 
either 5 % or 10 % heat inactivated fetal bovine serum (FBS; Gibco, Life Technologies 
Victoria, Australia), 100 units/ml penicillin and 100 µg/ml streptomycin (Gibco, Life 
Technologies Victoria, Australia). In addition, glucose free media was supplemented with 1g/l 
d-(+)-galactose and 1mM sodium pyruvate for some experiments. RGC5 cells were maintained 
in DMEM with 5 % FBS while DMEM with 10 % FBS was used for HepG2 and HEK293 
cells. Additional selection antibiotic G418 (50 mg/ml stock solution) was used for HEK293 
cells at a 1:100 dilution in every fourth passage to maintain a stable transfected cell line. 
  
All cells were routinely cultured in T25 and occasionally in T75 flask. All cells were passaged 
every three to four days when cell density reached around 80 % confluency. The cells were 
initially washed twice with phosphate-buffered saline (PBS) without Ca2+ or Mg2+ (5 ml for 
T25, 15 ml for T75) followed by a brief wash with 1ml of 1mg/ml EDTA solution before 
incubation with 1 ml of 0.05 % Trypsin solution (0.5g/l)-EDTA(0.2g/l) (Gibco-25300-054, 
Life Technologies, Victoria, Australia) for 3-5 min until cells were detached. Detached cells 
were resuspended in culture media at a 1:9 dilution (trypsin: culture media) to inactivate trypsin 
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and then counted manually using a Neubauer chamber. Cells were subsequently diluted in the 
required culture medium to the desired cell number (2.0 *106 cells for HepG2; 2.0*105 cells 
for RGC5; 5.0*105 cells for HEK293 cells) for T-25 flasks. 
 
2.3.3 Freezing of Cells 
 
The cells grown in T75 flasks were harvested using trypsin [see section 2.3.2 for details]. To 
harvest the cells, the cell suspension was centrifuged at 500 x g for 5 min at RT using a 
swinging bucket centrifuge (CM-6MT, Elmi, skyline Ltd, Riga, Latvia). The resulting pellet 
was resuspended in 1 ml of culture media supplemented with 20 % FBS and 10 % DMSO and 
then transferred to labelled cryotubes. The cells were initially cooled down at a constant rate 
to -80 °C over a period of 24 h in an isopropanol-containing tube box and then transferred to 
liquid nitrogen for long-term storage. 
 
2.3.4 Thawing of Cells 
 
Cryopreserved cells were thawed at 37 °C and then transferred to a T75 culture flask containing 
15 ml of pre-warmed culture media. The cells were cultivated overnight and after 24 h the 
culture media was replaced by a fresh culture media to remove residual DMSO. Standard 
harvesting and subculturing was performed when the cells reached 80 % confluency. 
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2.3.5 Assays 
2.3.5.1 Colony Formation    
 
Colony formation is used as an in-vitro cell survival assay that determines the reproductive 
ability of the cells to grow from a single cell to a large colony that by definition should contain 
at least 50 cells or more [289]. The cells are generally cultivated for a period of 1-3 weeks. 
This is a suitable and very sensitive method to measure cellular viability and reproductive cell 
death in response to drug exposure. Only a fraction of cells that survive a drug treatment retain 
the capacity to grow into colonies [289].  
Cells (RGC5, HEK293 and HepG2) were seeded at 200 cells per 100 mm cell culture petri dish 
and 1000 cells per well in 6 well culture plates in culture media containing low glucose. After 
24 h, cells were treated as four replicates per condition with different concentrations of CQ 
(RGC5/HepG2: 0, 1, 2, 3, 4, 5, 10 µM; HEK293: 0, 1, 5, 6, 8, 10 µM) and 8-HQ (RGC5: 0, 1, 
2, 3, 4, 5, 10 µM) and incubated 7 days for RGC5 cells, 10 days for HEK293 and 15 days for 
HepG2 cells due to the different growth rates of these cell lines. For comparison purposes, 
HepG2 cells were incubated with the drug for 7 days only, equivalent to the treatment of RGC5 
cells. Culture media was not changed during the incubation period for the cell lines. For RGC5 
and HepG2 cells, the colonies were washed twice with PBS, fixed with 2 % paraformaldehyde 
(in PBS) for 15 min and stained with 0.1 % w/v crystal violet (Oxoid, Thebarton, SA, Australia) 
or Coomassie blue (0.25 % Coomassie Brilliant Blue R-250, 40 % methanol, 10 % acetic acid) 
for 10 min before excess dye was removed with tap water and the plates were air dried. Due to 
the low attachment of HEK293 cells, culture plates were coated with collagen but the coating 
rendered cells more resistant to the effects of the drug. In addition to promoting cell adhesion, 
collagen is also reported to promote cell survival and proliferation [290]. Therefore, washing, 
fixing and staining steps were omitted and the samples were air dried instead to prevent loss of 
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colonies. Finally, colonies of equal to or more than 50 cells/colony were scored manually under 
a light microscope (Inverted Microscope, Model INV-100, Aktivlab, SA, Australia). Colony 
formation was expressed as the percentage of the untreated control samples. Colony formation 
was performed as four replicates per experiment. These four replicates provided the average 
for each experiment. Three independent experiments were performed and one representative 
experiment was shown for all cells. For HepG2 cells, however,  only two independent 
experiments were performed. 
 
2.3.5.2 Cellular ATP Levels  
 
Cellular ATP levels were measured, based on an ATP-driven enzymatic reaction between the 
enzyme luciferase and the photon-emitting substrate luciferin, which generates a stable 
luminescent signal. This reaction takes place in two steps. 
 
                                             
 
 
Cellular ATP levels were determined as described previously [291]. The detailed procedures 
for each cell type and the different conditions are discussed below. 
 
For RGC5 and HepG2 cells ATP levels were measured after 24 h of drug treatment (chronic) 
and after up to 2 hours of drug treatment (acute) in culture media containing either glucose or 
galactose [see section 2.3.2 for detail]. For HEK293 cells only acute ATP measurements were 
performed in galactose-containing culture media. Briefly RGC5, HepG2, HEK293 cells were 
seeded at 1.5*104 cells/well, 2.0*104 cells/well and 1.5*104 cells/well in 96 well culture plates 
Oxyluciferin +AMP Luciferyl-AMP + O2 Luciferin + ATP 
Luciferase  
Enzyme bound  
Intermediate  
 High energy  
 state  
 Light                       
Step 1 Step 2 
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in their respective culture media. Due to low attachment of HEK293 cells, poly-l-lysine 
(0.01%) coated 96 well culture plates were used. After 24 h, cells were treated with CQ or 8-
HQ at 0, 0.5, 1, 5, 10 µM in glucose or galactose containing culture media for either 24 h 
(RGC5 and HepG2) or up to 2 h (RGC5, HepG2 and HEK293). After the treatment period, 
cells were briefly washed twice with 100 µl PBS and lysed with 40 µl of lysis solution (4 mM 
EDTA, 0.2 % Triton X-100) for 5 min on a shaker at RT. 10 µl of lysate was transferred to a 
white 96 well culture plate and 90 µl of ATP measurement buffer containing substrate solution 
(25 mM HEPES pH 7.25, 600 μM D-luciferin, 75 μM DTT, 6.25 mM MgCl2, 625 μM EDTA 
and 1 mg/ml BSA) and enzyme solution (25 mM HEPES pH 7.25, 10 μg/ml firefly luciferase, 
75 μM DTT, 6.25 mM MgCl2, 625 μM EDTA and 1 mg/ml BSA) at a 1:1 ratio was added to 
the lysate. Luminescence was quantified immediately using a multimode plate reader 
(Fluroskan Ascent FL Thermo Scientific, VIC, Australia). ATP levels for each individual 
experiment were averaged from five replicate  wells/sample for both the control and each drug 
concentration and the data were expressed as the percentage of control values. Due to the short 
incubation period for acute ATP measurements, no changes in cell number were observed. 
Hence standardisation of ATP levels on protein contents was carried out only for long-term 
exposure experiments, while it was omitted for the acute experiments. ATP standard diluted in 
the lysis solution (concentrations: 0-10 µM) was included in each experiment for two reasons. 
Firstly, to generate a standard curve for the quantification of the cellular ATP concentrations 
and secondly as a positive control for ATP measurement. The measurement of cellular ATP 
levels was repeated three times for all cell types and one representative experiment was shown. 
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2.3.5.3 Protein Quantification 
 
Quantification of the protein content of cell lysates was performed using the DC protein assay 
kit (Bio-Rad Laboratories PTY Ltd, Gladesville, NSW, Australia). This assay is based on the 
reaction of protein with alkaline copper tartrate (cuprous ions) yielding reactive monovalent 
cupric ions, which immediately reduce folin reagent thereby producing a reduced species 
(molybdenum/tungsten blue) that has a characteristic blue colour with a maximum absorption 
at 750 nm. The method was performed according to manufacturer’s instruction. 
 
Briefly, 10 µl of cell lysate or protein standards (BSA: 0 to 2 mg/ml) were added in triplicate 
in individual wells of a clear 96 well plate followed by the sequential addition of 25 µl of 
reagent A’ (A’ contains 20 µl of reagent S: surfactant and 1 ml of reagent A: alkaline copper 
tartrate) and 200 µl of reagent B (folin) into each well. After 15 min, at RT absorption at 750 
nm was measured using a multimode plate reader (Thermo Scientific Multiskan GO UV/Vis 
microplate spectrophotometer, SkanIt Software). Protein concentrations were calculated using 
a standard curve derived from a BSA protein standard.  
 
2.3.5.4 Cellular Lactate Levels 
 
Increased lactate production is one of the hallmarks of mitochondrial dysfunction. Extracellular 
lactate levels after CQ treatment were determined as a supportive assay to confirm drug-
induced mitochondrial dysfunction.  The assay was performed according to the protocol 
previously described with slight modification [292]. Extracellular lactate levels were 
determined by measuring oxidized form of 2, 6-dichlorophenol-indophenol (ox-DCPIP; blue). 
Lactate is converted to pyruvate in the presence of lactate dehydrogenase enzyme (LDH) thus 
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generating NADH from NAD+. Subsequently, NADH reduces phenazine methosulfate (PMS), 
which in turn reduces DCPIP to its reduced form (red-DCPIP; pink). In order to prevent 
generation of lactate from pyruvate, pyruvate is converted to glutamate by glutamate pyruvate 
transaminase (GPT). Briefly, HepG2 cells were seeded at a density of 60, 000 cells/ml/well in 
12 well culture plates in low glucose-containing cell culture media. After 24 h the media was 
replaced by challenge media (DMEM-low glucose, 3.5 g/l glucose, sodium bicarbonate 3.7 g/l, 
penicillin and streptomycin) containing different concentrations of CQ or a known 
mitochondrial inhibitor, rotenone (Rot) as a positive control. After 24 h and 48 h, 10 µl of 
supernatant was transferred to a clear 96 well culture plate and 90 µl of lactate reaction buffer 
(10 mM KH2PO4 pH 7.8, 2 mM EDTA, 1 mg/ml BSA, 0.6 mM DCPIP, 0.5 mM PMS, 0.8 mM 
NAD+, 1.5 mM glutamate, 5 U/ml glutamate-pyruvate-transaminase and 12.5 U/ml lactate 
dehydrogenase) was added. The oxidation of DCPIP was measured immediately 
spectrophotometrically at 30 ˚C at 600 nm every 2 minutes for 102 minutes. A lactate standard 
was run in parallel. Lactate levels were averaged from 9 replicate samples from 3 individual 
wells. To determine protein content, the cells were lysed in 500 µl of lysis buffer (4 mM EDTA, 
0.2% NP-40, 0.2%Tween-20) for 10 minutes in a shaker and protein content was determined 
using Bio-rad DC method [see section 2.3.5.3 for detail]. Finally, lactate levels were 
standardised to protein content. The experiment was repeated independently three times. 
 
2.3.5.5 Oxidative Stress  
2. 3.5.5.1 Lipid Peroxidation  
 
Lipid peroxidation is an indirect measure of oxidative stress as it measures ROS-induced 
membrane damage. Cellular lipid peroxidation was measured using C11-Bodipy 581/591 
(D3861 Invitrogen, Eugene, Oregon, USA). It is a lipophilic dye that enters the lipid bilayer 
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membrane due to its C11 carbon side chain. Once inside the membrane, it can be oxidized by 
oxygen radicals or lipid-peroxides that result in a shift of fluorescent emission from 590 nm 
(red) to a shorter wavelength 510 nm (green) [293]. The green (oxidized form) and red (non-
oxidized form) fluorescence of C11-Bodipy 581/591 are obtained using excitation and 
emission wavelength and the increase in the ratio of green to red fluorescence signifies an 
increase in lipid peroxidation [293]. The assay was performed using the manufacturer’s 
instruction. Briefly RGC5, HepG2 and HEK293 cells were seeded at a density of 4*104, 5*104 
and 5*104 cells/well respectively in black 96 well culture plates. Due to low attachment rates, 
poly-l-lysine (0.01%) coated black 96 well culture plates were used for HEK293 cells. After 
24 h the cells were washed once with 100 µl of PBS and were then incubated with 100 µM of 
C11-Bodipy 581/591 dye in HBSS for 30 min under normal culture conditions. The cells were 
once washed with 100 µl PBS before being treated with different concentrations of CQ (0, 0.5, 
1, 5, 10 µM) in HBSS for different time intervals (0, 30, 60, 90 and 120 min). After the 
treatment period, cells were washed once with 100 µl PBS and fluorescence was quantified 
immediately in 40 µl PBS (Ex/Em 460/535 nm: green fluorescence and 485/600 nm: red 
fluorescence) using a multimode plate reader (Fluroskan Ascent FL, Thermo Scientific, VIC, 
Australia). The increase in the ratio of fluorescence intensity at 535 nm versus 600 nm, 
indicative of lipid peroxidation, was expressed as the percentage of control values. Lipid 
peroxidation was measured in at least three replicate wells/ sample These three replicates 
provided the average for each experiment. Three independent experiments were performed and 
one representative experiment was shown for all cells. 
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2. 3.5.5.2 Reactive Oxygen Species (ROS)  
 
ROS is a direct measurement of oxidative stress. It can be measured in cells using an indicator 
dye such as chloromethyl derivative of 2′, 7′-dichlorodihydrofluorescein diacetate (CM-
H2DCFDA) (Molecular Probes, Life Technologies, USA). CM-H2DCFDA passively diffuses 
into cells, and its acetate groups are cleaved by intracellular esterases while the chloromethyl 
groups react with intracellular glutathione and other thiols producing the relative water soluble, 
cell membrane-impermeable product H2DCF (2′, 7′-dichlorodihydrofluorescein). This non-
fluorescent compound upon oxidation by cytosolic ROS (hydrogen peroxide, peroxynitrite, 
hydroxy radicals) gives rise to a highly fluorescent product DCF (2′, 7′-dichlorofluorescein). 
Accumulation of DCF in cells is measured as an increase in fluorescence. This assay was 
carried out according to the manufacturer’s instruction. Briefly, RGC5 cells were seeded at a 
density of 4*104 cells per well in black 96 well culture plates. After 24 h, the wells were washed 
with 100 µl of PBS and incubated with 865.4 nM CM-H2DCFDA (50 µg was dissolved in 100 
µl DMSO: concentration 865.4 µM) in Hank’s Buffered Saline Solution (HBSS) (865.4 µM 
was diluted in HBSS at a 1:1000 dilution: the final concentration of dye was 865.4 nM) for 30 
min under normal culture conditions. The cells were washed with 100 µl PBS once to remove 
excess dye before being treated with CQ (0, 0.5, 1, 5, 10 µM) in HBSS for different time 
intervals (30, 60, 90 and 120 min). Finally, the cells were washed with 100 µl PBS once and 
fluorescence was quantified in 40 µl PBS (Ex/Em 485 nm and 535 nm) using a multimode 
plate reader (Fluroskan Ascent FL Thermo Scientific, VIC, Australia). The measurements were 
expressed as the percentage of control values. The measurement of ROS was carried out in 5 
replicate wells per sample (n=1). 
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2. 3.5.6 Western Blot 
Western blots are utilized for separation, identification and quantification of specific proteins 
from a protein mixture based on their molecular weight through gel electrophoresis. 
 
2. 3.5.6.1 Protein Extraction & Protein Quantification 
 
Cells (RGC5, HepG2 & HEK293) were cultured in T-75 flasks for 4 days. The cells were 
harvested by trypsinization after they reached 80 % confluency followed by pelleting them at 
200 x g for 5 min at RT. The supernatant was removed and cells were resuspended in 1 ml of 
ice-cold PBS before again being centrifuged at 100 x g for 2 min and the supernatant discarded. 
Total cell lysates were obtained after extraction with lysis buffer (50 mM Tris pH 7.4, 150 mM 
NaCl, 2 mM EDTA, 2 mM EGTA, 0.2 % Triton X-100, 25 mM β-glycerolphosphate, 0.3 % 
NP-40 and freshly added 25 mM NaF, 0.1 % saturated PMSF, 1 µM DTT and 0.1 mM Na3VO4) 
for 15 min on ice with a brief mixing every 5 min. The lysates were cleared by centrifugation 
(14,500 x g, 20 minutes at 4 °C) to remove insoluble components and the supernatant was 
transferred to fresh Eppendorf tubes. Protein quantification was carried out using the Bio-rad 
DC method [see section 2.3.5.3 for detail]. 
 
2. 3.5.6.2 Protein Samples for SDS-PAGE 
 
The protein lysates containing equal amounts of protein were used. The samples for SDS-
PAGE were prepared by adding 25 % (vol/vol) of SDS-containing loading buffer (1M Tris pH 
6.8, 8 % SDS, 5 % β-mercaptoethanol, 40 % glycerol, 0.01 % bromophenol blue) to each 
protein lysate. The samples were then stored at -20 °C until the day of analysis. 
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2. 3.5.6.3 Gel Electrophoresis 
 
For western blot analysis, 12 % gels were cast (1.5 M Tris pH 8.8, 30 % acrylamide, 10 % SDS 
and freshly added 0.1 % APS and 1 % TEMED) in a commercial gel apparatus (Bio-Rad 
Laboratories PTY Ltd, Gladesville NSW, Australia). Isopropanol was layered on the top of the 
separating gel to smooth the border and reduce exposure of the top of the gel to oxygen. 
Isopropanol was removed after the polymerisation of the gel residual and isopropanol was 
cleaned with milliQ water before the inside of the glass plates was dried with absorbent paper. 
The stacking gel (1M Tris pH 6.8, 30 % acrylamide, 10 % SDS and freshly added 0.1 % APS 
and 1 % TEMED) was poured on the top of the separating gel and the comb was positioned. 
After the stacking gel was set, the comb was slowly removed and the wells were rinsed 
thoroughly with water. The wells were then partially filled with running buffer (25 mM Tris 
base, 192 mM glycine, 10 % SDS) to ease loading of samples. Protein samples were denatured 
for 5 min at 95 °C and loaded into each well. The gel cassette was then placed into the 
electrophoresis chamber, which was filled with running buffer. For two gels, electrophoresis 
was typically performed at a constant current of 0.06 amps for approximately one and a half 
hours. Protein transfer from separating gel onto a nitrocellulose membrane (GE Healthcare Life 
Sciences, NSW, Australia) was carried out by assembling a sandwich of gel, membrane and 
Whatman filter paper cut to size. The sandwich was placed inside a holder and submerged in 
the apparatus in the transfer buffer (25 mM Tris base, 192 mM glycine, 10 % SDS, 20 % 
methanol) with the gel facing the anode. The transfer was performed at constant voltage (100 
V) for one hour at 4 °C. Subsequently, the membrane was briefly washed in milliQ water and 
subsequently non-specific binding sites were blocked using 5 % skimmed milk powder in Tris-
buffered saline + 0.1 % Tween-20 (TBS-T) for 1 h. Then the membrane was incubated with 
the primary antibody against NQO1 (ab34173, Abcam, 1:1000) or GAPDH (ABS16, EMD 
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Millipore, 1:10 000) in blocking buffer overnight at 4 °C. The next day, the membrane was 
washed three times for 10 min with TBST and then incubated with the species-specific 
horseradish peroxidase-conjugated secondary antibody (ab97051, Abcam, 1:20 000) in 
blocking buffer for 1 hour at RT. The membrane was washed three times for 10 min with TBS-
T. Antibody binding was visualized using an image analyser (Chem Smart 5000) with 
enhanced chemiluminescence western blotting reagent (ECL; Sigma-Aldrich, Castle Hill, 
NSW, Australia) according to the manufacturer’s instructions. For each membrane, multiple 
exposures with different exposure times were routinely collected to prevent over or under 
exposure. Western blots were independently repeated at least three times. 
 
2.3.5.7 NQO1-Drug Interaction and NQO1 Enzyme Activity  
2.3.5.7.1 Mass Spectrometry Analysis of NQO1 and CQ Interaction 
 
As NQO1 is known to detoxify a number of quinones, mass spectrometry analysis was 
performed to investigate if CQ is also converted to a potentially less toxic metabolite by NQO1. 
Four reactions were prepared. Reaction one contained potassium phosphate buffer pH 7.4, CQ 
100 µM; the second reaction contained potassium phosphate buffer pH 7.4, CQ 100 µM, 
NADPH 200 µM; the third reaction contained potassium phosphate buffer pH 7.4, CQ 100 µM, 
NADPH 200 µM, NQO1 (10 µg/ml); and finally the fourth reaction contained potassium 
phosphate buffer pH 7.4, CQ 100 µM, NQO1 (10 µg/ml). The reactions were kept at 37 °C 
overnight for the reaction to take place before the mixtures were evaporated under vacuum 
using a miVac DNA centrifugal concentrator (Genevac, Suffolk, UK) at 50 °C for 2-4 h. A 
potential conversion of CQ in the presence of NQO1 was measured using mass spectrometry. 
Briefly, samples were analyzed using a Waters Acquity H-series UPLC coupled to a Waters 
Xevo triple quadrupole mass spectrometer. A Waters Acquity UPLC BEH C18 column (2.1 x 
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100mm x 1.7 micron particles) was used, with mobile phases A= 0.1 % formic acid in water 
and B= acetonitrile. A linear solvent gradient from 40 % A: 60 % B to 5 % A: 95 % B at 8.75 
min was used followed by 3 min re-equilibration time. Flow rate was 0.4 ml/min and the 
column was held at 45 °C. The mass spectrometer was operated in negative ion electrospray 
mode and CQ was targeted by Multiple Reaction Monitoring (MRM) after the preliminary 
establishment of an appropriate channel. The ion source temperature was 150 °C, the 
desolvation gas was nitrogen at 1000 l/hr, desolvation temperature was 300 °C and the capillary 
voltage was 2.7 KV. The MRM channel for CQ was m/z 303.9 to 126.95. The cone voltage 
was 65 V and collision energy was 24 V. Dwell time was 92 ms. Simultaneous full scan data 
acquisition was carried out from m/z 250 to 500 over 0.3 s with a cone voltage of 60 V. 25 µl 
samples were injected and data were acquired and processed with Waters MassLynx software. 
 
2.3.5.7.2 Cell-free NQO1 Enzyme Activity  
 
The activity of human recombinant NQO1 enzyme in the presence of CQ or 8-HQ or a known-
NQO1 inhibitor dicoumarol (Dic) was determined as previously described [294]. Briefly, the 
reaction buffer was prepared in a volume of 100 µl containing 50 mM potassium phosphate 
buffer (pH 7.4), 0.1 % Tween-20, 80 µM DCPIP, 1.25 µg/ml human recombinant NQO1, 200 
µM NADPH. The initial reaction mixture was prepared without NADPH, which was added to 
the reaction buffer to initiate the reaction. Reactions were performed for 1 min at 21°C in the 
absence or presence of CQ, 8-HQ or Dic. Enzyme activity was determined by measuring the 
enzyme-dependent linear decrease in DCPIP absorbance at 600 nm every 1 second for 60 
seconds. The experiment was performed independently three times. 
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2.3.5.7.3 Cellular NQO1 Enzyme Activity 
 
Cellular quinone-mediated NQO1 activity in the presence of CQ was determined by conversion 
of water-soluble tetrazolium dye WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulphonyl)-2H-tetrazolium) (SANTSC-213165, Santa Cruz Biotechnology, USA) to its 
corresponding formazan-product upon reduction by a hydroquinone. The assay was performed 
as described previously [295].  
 
Briefly, HepG2 cells were seeded at 1.0*104 cells/well in 96 well culture plates in low glucose 
culture media. After 6 h the culture media was replaced by challenge media containing glucose-
free cell culture media, 2 % FBS, 0.3 g/l glucose for 18 h. The cells were then pre-incubated 
with menadione (10 µM), with or without the NQO1-inhibitor Dic (10 µM), CQ or 8HQ (10, 
50, 100 µM) in challenge media for 1 hr. After the pre-incubation, the challenge media was 
replaced by HBSS containing 450 µM WST-1, menadione and Dic or CQ or 8HQ before WST-
1 reduction was measured using a multimode plate reader (Thermo Scientific Multiskan GO 
UV/Vis microplate spectrophotometer, SkanIt Software, VIC, Australia) at 450 nm, 37 °C for 
120 min. Cellular NQO1 enzyme activity was repeated independently three times. 
 
2.4 Statistical Analysis 
 
All data are expressed as mean ± standard deviation (SD) as indicated in the figure legends. 
Statistical significance was performed using Student t-test, one-way or two-way analysis of 
variance (ANOVA) where appropriate, followed by Dunnett’s multiple comparison tests to 
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evaluate the differences between controls and treatment groups using GraphPad Prism (Version 
6, GraphPad Software Inc, CA, USA). Pearson’s correlation coefficient (r2) was determined 
for the relationship between two variables when necessary. In all assays p<0.05 was considered 
as statistically significant. 
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2.5 Results 
2.5.1 CQ and 8-HQ Induce Mitochondrial Dysfunction 
 
From a previous screen of selected marketed drugs and drug-like molecules using an assay to 
identify drug-induced mitochondrial dysfunction; 2 strong hits were obtained: CQ and the 
structurally very closely related parent compound 8-HQ (data not shown) (Figure 13). From 
this point, I took over this project and started exploring the toxicity of these two compounds in 
more detail. 
 
Figure 13: Structure of hits from compound 
screening. 
Two hits, (a) Clioquinol (CQ) and (b) 8-hydroxy-
quinoline (8-HQ) were identified as hits from in-
vitro screening of compounds. These compounds 
are members of the hydroxy-quinoline family. 
 
 
  
The effect of CQ and 8-HQ on cellular viability was investigated as the first experiment to 
determine if these compounds are cytotoxic in two different cell lines, rodent retinal (RGC5) 
and human hepatocarcinoma (HepG2) cells. Cellular viability was measured by incubating 
RGC5 and HepG2 cells with CQ (1, 2, 3, 4, 5 and 10) µM for 7 and 10 days respectively 
followed by counting surviving colonies against untreated control cells. In RGC5 cells CQ 
dose-dependently reduced viability from 3 µM (p = 0.0033) and at 10 µM no colonies were 
detected (Figure 14a). In contrast using the same cell line a very steep drop in viability was 
already observed at 2 µM (P = 0.0001) of 8-HQ (Figure 14a) and no single colony was detected 
from 3 µM. Compared to RGC5 cells, HepG2 cells were very sensitive to long-term exposure 
of CQ and a very significant drop in viability was observed from 1 µM (Figure 14b). Several 
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studies have suggested that the cytotoxicity associated with CQ can be attributed to its metal 
chelation property [161,182]. To test this hypothesis, different concentrations of ZnCl2 alone 
or in combination with CQ were added to RGC5 cells and incubated for 7 days to determine if 
metal ion supplementation would attenuate CQ-induced cytotoxicity by replenishing the 
chelated metal ions. Intriguingly, ZnCl2 instead of rescuing cells enhanced CQ toxicity in a 
dose-dependent manner (Figure 15). Moreover, ZnCl2 per se was toxic to the cells reducing 
the cellular viability significantly to 71.85 ± 7 % (p<0.0001) at 50 µM and to 48.84 % ± 8.4 % 
at 100 µM.  
 
  
 
Figure 14: Clioquinol (CQ) and 8-Hydroxyquinoline (8-HQ) reduce cellular viability. 
(a) RGC5 and (b) HepG2 cells were treated with the indicated concentrations of CQ or 8-HQ in 
glucose-containing culture media for (a) 7 days and 14 days (b). The cell viability was assessed by 
colony formation assay. Colonies were stained and colonies ≥ 50 cells/colony were counted and 
presented as the percentage of control. Data represent the average of at least three individual samples 
per concentration of one experiment out of three independent experiments. p* <0.05, p** <0.01 and 
p*** <0.001 versus control using one-way analysis variance (ANOVA) followed by Dunnett’s 
multiple comparison tests. Error bar=SD.  
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Figure 15: Effect of metal ion and clioquinol (CQ) on cellular viability. 
RGC5 cells were treated with the indicated concentrations of CQ or ZnCl2 or both in glucose-containing 
culture media for 7 days. The cell viability was assessed by colony formation assay. Colonies were 
stained and colonies ≥ 50 cells/colony were counted and presented as the percentage of control. Data 
represent the average of three individual samples per concentration of one experiment. p* <0.05, p** 
<0.01 and p*** <0.001 versus control using one-way analysis variance (ANOVA) followed by 
Dunnett’s multiple comparison tests. p# <0.05 and p### <0.001 versus CQ using Student’s t-test. Error 
bar=SD. 
 
 
When glucose is abundant, cells in-vitro mainly rely on glycolysis to generate energy thus 
reducing the involvement of the most efficient energy source, the mitochondria [296]. 
However, when glucose is substituted with galactose, a net zero ATP is produced from 
glycolysis as a consequence this forces the cells to utilize mitochondrial-OXPHOS pathway 
for energy generation [296]. Under such conditions, the compounds that interfere with 
mitochondrial OXPHOS reduce cellular ATP levels. Therefore, to further confirm the in-vitro 
screening results, the effect of CQ and its structural related compound 8-HQ on cellular ATP 
levels were assessed in RGC5 cells under conditions of glucose versus galactose-containing 
media. Drug-induced mitochondrial dysfunction can be assessed by measuring cellular 
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hypersensitivity (measured as a drug-induced reduction in cellular ATP levels) in the presence 
of drugs in galactose- compared to glucose-containing media. RGC5 cells were hypersensitive 
to CQ in galactose- compared to glucose-containing media, which is a hallmark of drug-
induced mitochondrial dysfunction (Figure 16a). In RGC5 cells, in glucose-containing culture 
media, a significant reduction in cellular ATP levels was observed from 5 µM of CQ and at 10 
µM  ATP levels were reduced to nearly 30 % of untreated cells (100 %) over 24 h (Figure 
16a). In contrast, in galactose-containing medium, this effect was significantly more 
pronounced and a reduction of ATP levels by more than 90 % (0.104 ± 0.0059, p<0.0001) of 
untreated cells was detected at 10 µM of CQ. Since this response could have been due to a 
toxic effect on cell growth, protein content for each cell-culture condition and treatment 
condition was quantified. When ATP levels were standardised to protein content, no significant 
difference in cellular ATP levels were observed at any concentrations of CQ in glucose-
containing media (Figure 16b). This result suggests that CQ causes toxicity and that protein 
degradation must have occurred simultaneously with a loss of ATP production. In galactose 
containing-culture media, however, the observed results resembled the data without protein 
standardisation (Figure 16b).  
 
Similar results were also obtained for the closely related 8-HQ (Figure 17a). In fact, 8-HQ was 
more toxic than CQ in galactose-containing media where it reduced cellular ATP levels to 32 
% of untreated cells (100 %) at already 0.5 µM (P < 0.0001) (Figures 17a and b). This 
confirmed the results derived from the initial compounds screen. This toxicity could be cell-
type dependent and hence might only apply to a selective few cell lines. Therefore, 
mitochondrial dysfunction of CQ was attempted to confirm in a different cell line. Unlike 
RGC5 cells, however, HepG2 cells, showed only minor CQ toxicity at doses ≥ 5 µM 
(p<0.0001) and no major differences were observed between glucose- or galactose-containing 
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media after treatment with either CQ or 8-HQ (Figures 16a and 17a). Unlike RGC5 cells, 
cellular ATP levels in HepG2 cells after CQ treatment also did not differ much with or without 
protein standardisation (Figures 16a and b). Consistent with the results with CQ, long-term 
exposure of HepG2 cells with 8-HQ in glucose-containing media was followed by higher 
toxicity compared to RGC5 cells (Figures 17a and b).  
 
Further experiments were carried out to measure cellular ATP levels under acute exposure (up 
to 2h) with either CQ or 8-HQ in galactose-containing media. In RGC5 CQ or 8-HQ dose- and 
time-dependently reduced cellular ATP levels after short-term exposure (Figures 16c and 17c). 
10 µM of CQ or 8-HQ significantly reduced cellular ATP levels to almost 45 % (p<0.0001) of 
untreated cells (100 %) at 2 h and a significant reduction was observed at 1h after CQ (10 µM) 
treatment (81.61 ± 2.02 %, p<0.0001) (Figures 16c and 17c). In agreement with the previous 
results, HepG2 cells only showed a marginal effect at the highest concentration of CQ after 2 
h (Figure 16c), whereas significant reductions in cellular ATP levels by 8-HQ were not 
detected at any concentrations (Figure 17c).  Further experiments were only performed with 
CQ. 
 
CQ toxicity has been associated with elevated levels of reactive oxygen species (ROS) [182] and 
ROS production and ROS-mediated lipid peroxidation are the hallmarks of mitochondrial 
dysfunction. Therefore, CQ-mediated ROS production and lipid peroxidation were assessed in 
both cell lines. In RGC5 cells, treatment with CQ (up to 10 µM) for up to 2 h did not significantly 
increase ROS levels compared to untreated control cells (Figure 18). Therefore, no attempt was 
made to measure ROS production in HepG2 cells, which were resistant to CQ toxicity in acute 
ATP measurements. Consistent with CQ-induced mitochondrial dysfunction, CQ induced lipid 
peroxidation in RGC5 cells in a dose- and time-dependent manner, with a 50 % increase already 
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evident after 1h at 10 µM CQ (143.56 ± 5.77 %, p<0.0001) compared to untreated cells (Figure 
16d). Consistent with the previous results, CQ failed to induce lipid peroxidation in HepG2 cells 
under all tested conditions (Figure 16d). 
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Figure 16: Clioquinol (CQ) induces mitochondrial dysfunction. 
 (a) Long-term effect of CQ on cellular ATP levels. ATP levels of RGC5 and HepG2 cells grown for 24 
h in glucose- or galactose- containing media in the presence of CQ were measured. Data represent the 
average of at least four or five individual samples per concentration of one experiment out of three 
independent experiments. (b) Long-term effect of CQ on cellular ATP levels/protein. ATP levels of 
RGC5 and HepG2 cells grown for 24 h in glucose- or galactose-containing media in the presence of 
CQ were measured and standardised to protein content. Data represent the average of at least four or 
five individual samples per concentration of one experiment out of three independent experiments. (c) 
Short-term effect of CQ on cellular ATP levels. RGC5 and HepG2 cells were incubated in galactose-
containing media in the presence of up to 10 µM CQ for 30, 60, 90 and 120 min before ATP levels 
were measured. Data represent the average of at least four or five individual samples per concentration 
of one experiment out of three independent experiments. (d) Lipid peroxidation induced by CQ. RGC5 
cells and HepG2 cells grown in glucose-containing media were incubated with CQ up to 10 µM for up 
to 2 h before lipid peroxidation was measured using BODIPY-C11. Data represent the average of at 
least four or five individual samples per concentration of one experiment out of three independent 
experiments. p* <0.05, p** <0.01, p*** <0.001 versus control using one- or two-way analysis variance 
(ANOVA) followed by Dunnett’s multiple comparison tests. Error bar=SD. 
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 Figure 17: 8-Hydroxyquinoline (8-HQ) induces mitochondrial dysfunction. 
 (a) Long-term effect of 8-HQ on cellular ATP levels. ATP levels of RGC5 and HepG2 cells grown 
for 24 h in glucose- or galactose-containing media in the presence of 8-HQ. Data represent the average 
of at least four or five individual samples per concentration of one experiment out of three independent 
experiments. (b) Long-term effect of 8-HQ on cellular ATP levels/protein. ATP levels of RGC5 and 
HepG2 cells grown for 24 h in glucose- or galactose- containing media in the presence of 8-HQ were 
measured and standardised to protein content. Data represent the average of at least four or five 
individual samples per concentration of one experiment out of three independent experiments. (c) 
Short-term effect of 8-HQ on cellular ATP levels. RGC5 and HepG2 cells were incubated in galactose-
containing media in the presence of up to 10 µM 8-HQ for 30, 60, 90 and 120 min before ATP levels 
were measured. Data represent the average of at least four or five individual samples per concentration 
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of one experiment out of three independent experiments. p* <0.05, p** <0.01 and p*** <0.001 versus 
control using one-way analysis variance (ANOVA) followed by Dunnett’s multiple comparison tests. 
Error bar=SD. 
 
 
 
 
 
Figure 18: Clioquinol (CQ) does not contribute to cytoplasmic ROS production. 
RGC5 cells grown in glucose-containing media were incubated with CQ up to 10 µM for up to 2 
h before ROS was measured using CM-H2DCFDA dye. Data represent the average of five 
individual samples per concentration of one experiment. p* <0.05, p** <0.01, p*** <0.001 versus 
control using two-way analysis variance (ANOVA) followed by Dunnett’s multiple comparison 
tests. Error bar=SD. 
 
 
 
Cellular toxicity was observed after long-term CQ exposure to HepG2 cells at the level of both 
cellular viabilities (Figure 14b) and ATP (Figures 16a and b). To further investigate the 
nature of this toxicity, another endpoint of mitochondrial dysfunction was measured (which is 
a measurement of lactate levels in HepG2 cells after CQ treatment). In a situation where 
mitochondrial function is impaired, cells maintain sufficient energy levels by increasing 
glycolysis and as a result, produce excess extracellular lactate [297]. Therefore, elevated 
extracellular lactate is one of the biomarkers of mitochondrial dysfunction. CQ at 10 µM only 
slightly increased lactate levels in HepG2 cells over 24 h (120 % ± 3.8 %) and 48 h (118.6 % 
± 3.3 %) compared to untreated control cells (100 %) (Figures 19a and b). At the same time, 
treatment with the known mitochondrial inhibitor rotenone (Rot) significantly increased lactate 
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levels at 0.1 and 1 µM (24 h: 168.5 % ± 2.37 %, 143.36 % ± 5 %; 48 h: 174.25 ± 11.9 %) 
(Figures 19a and b). No significant increase in lactate levels was observed after 24 h treatment 
with Rot (10 µM).  CQ even at a 100-fold higher concentration than Rot did not increase the 
lactate levels to the extent Rot did. Since the previous results indicated that CQ did not induce 
mitochondrial dysfunction in HepG2 cells, it was also expected that the lactate levels in the 
same cells would not change in response to CQ treatment. In contrast to our expectations, the 
lactate levels increased dramatically when the results were standardized on protein content.  
Lactate levels increased nearly 2-fold over 24 h (194.6 % ± 6 %) and 6 fold over 48 h (634.23 
% ± 41.3 %) with 10 µM of CQ compared to untreated control cells (Figures 19c and d). In 
contrast, Rot at 0.1 and 1 µM only slightly increased lactate levels (24 h: 195.7 % ± 15.6 %, 
223.5 % ± 18 %). Only at a higher Rot concentration (10 µM), a similar trend compared to CQ 
was observed, where lactate/protein increased by almost 2-fold (24 h: 199 ± 6 % 48 h: 306.4 
% ± 22.3 %) compared to lactate levels that were not standardized to protein content. To 
understand this substantial increase, the morphology of untreated control cells, as well as CQ-
treated cells, was examined. CQ-treated cells showed less number of cells compared to the 
untreated control cells (Figures 19e and f). Therefore, lower cell numbers in the CQ treated 
plates are responsible for the drastic increase in standardized lactate levels. 
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Figure 19: Lactate levels measurement in HepG2 cells. 
HepG2 cells grown in glucose-containing culture media were treated with different concentrations 
of CQ and rotenone (Rot) in media containing high glucose for 24 h (a, c) and 48 h (b, d) before 
lactate levels were measured and standardised to protein content per well (c, d). (e, f) 
Representative images of HepG2 cells after 48 h of incubation with CQ (0-e, 10-f) µM. Data 
represent the average of at least 9 individual samples per concentration of one typical experiment 
from three independent experiments. p* <0.05, p** <0.01, p*** <0.001 versus control using one-
way analysis variance (ANOVA) followed by Dunnett’s multiple comparison tests. Error bar=SD. 
Scale bar=200 µm for images. 
 
  
  In-vitro Studies 
 
91 
 
2.5.2 CQ-induced Toxicity Depends on NQO1 Levels  
 
To understand the different response of CQ and 8-HQ in both cell types tested, differences 
between them were considered.  Besides differing in species and tissue of origin, these two cell 
lines differ particularly in their ability to respond to drugs and drug-induced oxidative stress 
(unpublished data, N. Gueven). This ability is associated with significantly different expression 
levels of the antioxidant gene product NQO1 (NAD(P)H Quinone Oxidoreductase 1). NQO1 
is a cytoplasmic FAD-dependent flavoprotein that catalyses the two-electron reduction of a 
variety of compounds [298]. In addition, NQO1 has shown to play a major role in protecting 
cells against oxidative stress by reducing potentially reactive compounds to their less reactive 
metabolites [298].  In fact, inactivation of NQO1 has been linked to many pathological 
conditions including cardiovascular diseases, cancer, neurodegenerative diseases and 
metabolic disorders [299]. Therefore, it was hypothesized that NQO1 might render cells 
resistant to CQ-induced toxicity. Therefore, it was tested if the NQO1 inhibitor dicoumarol 
(Dic) could increase the sensitivity of HepG2 cells to CQ. HepG2 cells cultured in glucose-
containing media over 24 h were treated with CQ or Dic or both in galactose-containing media 
for 2 h. Consistent with the previous result, 10 µM CQ only mildly reduced ATP levels by less 
than 5 % in HepG2 cells in galactose-containing culture media (Figure 20a). However, the 
combination of CQ and Dic significantly reduced ATP levels (69 % ± 2.19, p<0.0001) 
compared to the untreated cells at 2 h. Under these conditions, Dic alone only had a marginal 
effect that was not statistically significant from untreated control cells (p=0.1663) (Figure 
20a).  
 
Purely based on their origin, a large number of genetic differences between the two cell lines 
can be postulated. Given the putative role of NQO1 to influence CQ toxicity and to rule out 
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cell type dependent differences, 3 isogenic cell lines based on the Human Embryonic Kidney 
(HEK293) cell line were used. These HEK293 cell lines have an identical background 
regarding their nuclear DNA and differ only in their levels of NQO1 expression that is achieved 
by stable transfection of a constitutively active NQO1 expression plasmid. These include, 
HEK293 that either overexpress human recombinant NQO1 (clones 6 and 12) or carry the 
empty plasmid (neo). HEK293 cells were used for this experiment as they express extremely 
low to undetectable levels of NQO1 and are thus well suited for this approach [291]. NQO1 
expression in the three HEK293 cell lines, as well as RGC5 and HepG2 cells, was measured 
by western blot (Figure 20b). The equal loading of total cell extract (3 µg) was ensured by 
using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control. As 
previously reported [291], HepG2 cells showed very high NQO1 protein expression. In 
contrast, RGC5 cells showed lower NQO1 protein expression, compared to HepG2, while 
NQO1 levels in HEK293-neo cells were undetectable. Both NQO1 overexpressing HEK293-
clones (6 and 12) showed intermediate expression levels compared to HepG2 (Figure 20b).  
 
To investigate the protective role of NQO1 in ameliorating CQ-induced cellular toxicity the 
three previously assessed end-points were measured in these HEK293 cell lines: cellular 
viability, lipid peroxidation and ATP levels. The effect of NQO1 on cellular viability was 
examined by incubating HEK293 cells with CQ for 10 days under glucose-containing media 
and viability was assessed by counting number of surviving colonies compared to untreated 
control cultures. In cells that do not express NQO1 (HEK293-neo), CQ (8 µM) significantly 
reduced cellular viability to 21.85 % ± 2.85 % (p<0.0001) compared to untreated control cells 
(100 %) (Figure 20c). Consistent with the hypothesis that NQO1 can attenuate CQ toxicity, 
NQO1 expression significantly increased cellular viability in the presence of CQ by nearly 120 
% in both clone 6 (47.16 ± 5.87, p= 0.0002) and clone 12 (47.67 ± 14.39, p=0.0125) compared 
  In-vitro Studies 
 
93 
 
to CQ-treated neo cells (Figure 20c). Furthermore, in HEK293-neo cells, CQ significantly 
induced lipid peroxidation (1.5 h: 115.2 % ± 5.4 %; 2 h: 139.1 % ± 12.2 %) compared to the 
untreated cells (100 %). Consistent with a protective effect, expression of NQO1 significantly 
prevented CQ-induced lipid peroxidation in both NQO1 expressing cell lines at 1.5 h (clone 6: 
98.5 % ± 10.6 %, p=0.0093; clone 12: 98.6 % ± 3.54 %, p=0.0173) and 2 h (clone 6: 117.5 % 
± 8.5 %, p=0.0040; clone 12: 116.1 % ± 8.6 %, p=0.0013) compared to CQ treated neo cells 
(Figure 20d).  
 
To investigate the mitochondrial dysfunction of CQ under a condition of undetectable NQO1, 
HEK293-neo cells cultured in glucose-containing media over 24 h, were treated with different 
concentrations of CQ (0.5, 1, 5, 10 µM) in galactose-containing media for up to 2 h followed 
by measurement of ATP levels. Acute incubation of HEK293-neo cells with CQ strikingly led 
to a pronounced reduction of ATP levels comparable to the effects seen in RGC5 cells. In a 
dose- and time-dependent manner, CQ reduced cellular ATP levels with a significant reduction 
already evident at 30 min with 10 µM CQ (80.12 ± 12.05 % P=0.0138) and at 2 h ATP levels 
were reduced to 36 % ± 14.3 % (P<0.0001) compared to untreated control cells (Figure 20e). 
After confirmation of CQ toxicity in HEK293-neo cells, HEK293 cells were incubated with 10 
µM of CQ in galactose-containing media for 2 h and ATP levels were quantified. In HEK293-
neo cells, CQ (10 µM) significantly reduced ATP levels (31.5 % ± 5.8 %, p<0.0001) compared 
to untreated control cells. On the other hand, under these conditions, NQO1 expression in 
HEK293-clone 6 and HEK293-clone 12 significantly protected against CQ-induced decrease 
of cellular ATP levels (clone 6: 82.8 % ± 5.87 %, p <0.0001) and (clone 12: 52.8 % ± 9.51 %, 
P=0.0010) (Figure 20f). The differences in the level of protection shown by NQO1 expressing 
cells led us to closely investigate this protective effect of NQO1.  
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 Figure 20: NQO1-dependent clioquinol (CQ) toxicity. 
 (a) CQ-induced reduction of cellular ATP levels in the presence of the NQO1 inhibitor dicoumarol 
(Dic). HepG2 cells were treated with 10 µM CQ and/or 10 µM Dic in galactose-containing media for 
2 h before ATP levels were measured. Data represent the average of at least four or five individual 
samples per concentration of one experiment out of three independent experiments. (b) Western blot 
analysis of NQO1 expression. Representative western blot image of NQO1 and GAPDH in HepG2, 
RGC5, HEK293-(neo, clone 6, clone 12). Data represent one typical experiment out of 5. (c) Cellular 
viability of HEK293 cells in the presence of CQ. HEK293 cells were grown in glucose-containing 
media in the presence of CQ for 10 days and numbers of colonies were counted against untreated 
control cells. Data represent the average of four individual samples per concentration of one 
experiment out of three independent experiments. (d) Effect of NQO1 on CQ-induced lipid 
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peroxidation. HEK293 cells were treated with 10 µM of CQ for up to 2 h and lipid peroxidation was 
measured using BODIPY-C11 dye. Data represent the average of at least four or five individual 
samples per concentration of one experiment out of three independent experiments. (e) Short-term 
effect of CQ on cellular ATP levels. HEK29-neo cells incubated in galactose-containing media in the 
presence of up to 10 µM CQ for 30, 60, 90 and 120 min before ATP levels were measured. Data 
represent the average of at least three individual samples per concentration of one typical experiment. 
(f) NQO1 dependent reduction of cellular ATP levels by CQ. HEK293 cells were treated for 2 h with 
10 µM CQ in galactose-containing media before ATP levels were measured. Data represent the 
average of at least four or five individual samples per concentration of one experiment out of at least 
three independent experiments. p* <0.05, p** <0.01 and p*** <0.001 versus control using Student’s 
t-test or one- or two-way analysis variance (ANOVA) followed by Dunnett’s multiple comparison 
tests where appropriate. Error bars = SD for all experiments. clone 6/clone 12 = NQO1 
overexpressing cells, neo = empty vector. 
 
 
 
 
Strikingly, when NQO1 expression of all cells used in this study was analysed against CQ-
induced toxicity, a direct correlation was observed with cellular levels of ATP and lipid 
peroxidation (Figures 21a r2= 0.9235 and b r2= 0.8772). When NQO1 expression is very low 
as in HEK293-neo cells, CQ efficiently induced cellular toxicity, measured as CQ-induced 
reduction of cellular ATP levels and increased lipid peroxidation (Figures 21a and b). On the 
other hand, increased NQO1 expression showed a clear NQO1-dependent reduction in CQ-
induced toxicity, which was evident by increased cellular ATP levels and decreased lipid 
peroxidation (Figures 21a and b). 
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Figure 21: Correlation of clioquinol (CQ)-induced toxicity versus NQO1 expression levels. 
Cellular toxicity was measured as changes to (a) ATP (% Control) and (b) lipid peroxidation (% 
Control) after treatment with CQ (10 µM) for 2 h in galactose-containing media and HBSS 
respectively. ATP levels (% Control) are defined as % of CQ-induced ATP reductions in all cell lines 
relative to that in HepG2 cells (= 100 %). Lipid peroxidation (% Control) is defined as the % increase 
in lipid peroxidation by CQ in all cell lines relative to that in HepG2 cells (= 100 %). NQO1/GAPDH 
(% Control) is defined as % NQO1/GAPDH expression in all cell lines relative to that of HepG2 
cells (= 100 %). Pearson’s correlation coefficient (r2) was determined for the correlation experiment. 
Error bars = standard deviation (SD) for ATP, lipid peroxidation and NQO1/GAPDH. 
 
2.5.3 CQ induces Toxicity through Generation of ROS 
 
Since cellular protection against CQ-induced toxicity correlated with the expression of the 
antioxidant enzyme NQO1, oxidative stress was a possible mechanism of CQ toxicity. In order 
to confirm this possibility, it was tested if exogenous antioxidants could rescue CQ-induced 
toxicity. In order to find suitable antioxidants at their right concentrations, several different 
antioxidants for their ability to rescue CQ-induced lipid peroxidation were examined along 
with CQ in RGC5 cells. RGC5 cells, grown in glucose-containing media, were pre-treated with 
antioxidants; N-acetyl cysteine (NAC; 1 mM), trolox (10 µM), vitamin C (30 µM) and vitamin 
E (10 µM) for 30 min and co-treated with CQ (10 µM) before lipid peroxidation was measured.  
Consistent with the previous result, CQ treatment of RGC5 cells for 2 h significantly increased 
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lipid peroxidation (146.2 % ± 14.5 %, p<0.0001) compared to untreated control cells. Out of 
the antioxidants tested, NAC (117.7 % ± 3.5 % p=<0.0001) and trolox (126.4 % ± 5.8 %, 
p=0.0017) significantly reduced CQ-induced lipid peroxidation, while only a slight reduction 
was observed with vitamin C (131.4 % ± 2.9 %, p=0.0381) compared to untreated control cells 
(Figure 22a). Therefore, further experiments only included NAC and trolox.  
 
The role of these antioxidants to ameliorate CQ toxicity was further explored in series of 
experiments where antioxidants were either used alone or in combination with CQ to determine 
if the CQ-mediated increase in lipid peroxidation, the decrease in cellular viability and the 
reduction in ATP levels could be rescued. This was tested only in HEK293-neo cells as they 
were highly vulnerable to CQ toxicity. Consistent with the previous lipid peroxidation results, 
CQ significantly increased lipid peroxidation compared to untreated control cells (126.9 % ± 
1.5 %, p<0.0001). The antioxidants NAC and trolox (Figure 22b) showed no effect on lipid 
peroxidation when used alone.  However, when they were used in combination with CQ (8 
µM), a significant reduction in CQ-induced lipid peroxidation was observed compared to 
untreated control cells (NAC: 112.5 % ± 3.3 % p<0.0001; trolox: 117.3 % ± 4.3 %, p=0.0027). 
Similar results were obtained with regards to cellular viability measurement. Consistent with 
the previous result, CQ reduced cellular viability in HEK293-neo cells to 22.5 % ± 3.9 % 
compared to untreated control cells. NAC (1mM) and trolox (10 µM) did not affect cellular 
viability on their own. However, when they were combined with CQ, a significant increase in 
cellular viability by 200 % (NAC: 66.5 ± 7.2 %, p<0.0001) and 115 % (trolox: 70 ± 2.67 %, 
p<0.0001) was observed compared to CQ-treated cells (Figures 22c and d). However, the 
antioxidants were unable to rescue the cellular viability to the level of the untreated cells 
(p<0.0001). Similarly, when trolox and NAC were used at the same concentration range, CQ-
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induced decreases in cellular ATP levels in HEK293-neo cells were also rescued by 112 % and 
125 % respectively  (p= 0.0207: trolox, p=0.0174: NAC) (Figure 22e). 
 
NQO1 protein levels are generally highly inducible and NQO1 expression is modulated by a 
protein complex, composed of the nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-
like ECH-associated protein (keap1) [300]. NQO1 protein expression is induced as an adaptive 
mechanism in response to pro-oxidative conditions. Therefore, it was tested if NQO1 
expression could be induced by CQ-mediated oxidative stress. This was initially examined in 
HepG2 cells under normal culture conditions (low glucose DMEM) using 10 µM CQ and 
hydrogen peroxide as a positive control (H2O2, 300 µM) at 24, 48 and 72 h [301]. CQ as well 
H2O2 treatment in HepG2 cells did not induce NQO1 expression at any time-points compared 
to untreated control cells. (Figure 23a). These results are in contrast to reports that pro-oxidants 
can induce Nrf2-regulated genes such as NQO1 in HepG2 cells [301]. However, it was shown 
that pro-oxidants induce NQO1 in HepG2 cells under high glucose condition [302]. Therefore, 
HepG2 cells were cultured in high glucose- (4.5 g/l) containing media for 6 passages before 
being treated with 10 µM CQ and H2O2 at 300 µM under high glucose conditions. Again, 
neither CQ nor H2O2 induced NQO1 expression in HepG2 cells at any time point (Figures 23b 
and c).  
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Figure 22: ROS-dependent clioquinol (CQ) toxicity. 
 (a, b) Antioxidants ameliorate CQ-induced increase of lipid peroxidation. (a) RGC5 cells grown in 
glucose-containing media were pre-treated with antioxidants N-acetyl cysteine (NAC; 1mM) and 
trolox (Tro; 10 µM), vitamin C (30 µM) and vitamin E (10 µM) for 30 min and co-treated with 10 
µM of CQ for 2 h before lipid peroxidation was measured using Bodipy-C11 dye. Data represent the 
average of at least five individual samples per concentration of one typical experiment. (b) HEK293-
neo cells grown in low glucose were co-treated with antioxidants NAC (1mM) or trolox (10 µM) 
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and/or 10 µM of CQ for 2 h before lipid peroxidation was measured using BODIPY-C11 dye. Data 
represent the average of at least four or five individual samples per concentration of one experiment 
out of three independent experiments. (c, d) Antioxidants ameliorate CQ-induced reduction of 
cellular viability. HEK293 cells grown in low glucose were treated with CQ and indicated 
concentrations of (c) NAC or (d) trolox before cellular viability was measured by colony formation. 
Data represent the average of at least four or five individual samples per concentration of one 
experiment out of three independent experiments.  (e) Antioxidants ameliorate CQ-induced reduction 
of cellular ATP levels. HEK293 cells grown in glucose were co-treated with antioxidants NAC 
(1mM) or trolox (10 µM) and/or 10 µM of CQ for 2 h before ATP levels were measured. Data 
represent the average of at least four or five individual samples per concentration of one experiment 
out of three independent experiments.  p* <0.05, p** <0.01 and p*** <0.001 versus control using 
one-way analysis variance (ANOVA) followed by Dunnett’s multiple comparison tests. Error 
bar=SD.  
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Figure 23: Effect of clioquinol (CQ) on NQO1 protein expression. 
HepG2 cells were incubated with CQ (10 µM) and H2O2 (300 µM) for different time intervals and 
harvested at the same time. (a) Western blot analysis of NQO1 expression in low glucose (1g/l). 1 µg 
of cellular protein was separated on a 12 % sodium dodecyl sulfate-polyacrylamide gel. 
Representative western blot images of NQO1 and GAPDH are shown. Data represent one 
experiment. (b) Western blot analysis of NQO1 expression in high glucose (4.5g/l). 0.5µg of cellular 
protein was separated on a 12 % sodium dodecyl sulfate-polyacrylamide gel. Representative western 
blot images of NQO1 and GAPDH are shown. Data represent one experiment out of three 
independent experiments. (c) Densitometry of NQO1/GAPDH relative to the untreated control at 24 
h and 48 h time intervals was quantified using ImageJ software. Equal loadings of western blots were 
ensured by GAPDH.  p* <0.05 versus control using one-way analysis variance (ANOVA) followed 
by Dunnett’s multiple comparison tests where appropriate. Error bars = SD. 
 
2.5.4 Interaction of NQO1 with CQ and 8-HQ   
  
The results described in the previous sections demonstrate that CQ-induced cellular toxicity is 
inversely correlated with NQO1 levels. NQO1 is known to be essential for cells to detoxify 
numerous compounds such as quinones, quinoneimines, nitroaromatic, glutathionyl-
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substituted napthoquinones, dicholorophenolindophenol (DCPIP) and azo dyes into less toxic 
products [298]. It was therefore speculated that the cytoprotective function of NQO1 against 
CQ-toxicity could be based on an NQO1-dependent metabolism of CQ into a less toxic 
metabolite. Human recombinant NQO1 is extremely active in cell-free assays [291] and can 
convert its substrate compounds in a few seconds at room temperature. CQ and NQO1 were 
nevertheless reacted under optimal conditions of temperature and substrate availability over 24 
h before a possible metabolic conversion of CQ was assessed using mass spectrometry. Under 
these conditions, unexpectedly no metabolic products of CQ were detected at all (Figure 24a). 
  
An inverse correlation observed between NQO1 levels and CQ toxicity supports the point that 
there is a possible biochemical interaction between NQO1 and CQ. In the absence of a direct 
conversion of CQ into a less toxic metabolite, it was therefore hypothesized that CQ might 
have a direct effect on NQO1 activity instead. Therefore, to explore this possibility, the activity 
of human recombinant NQO1 was monitored in a cell-free assay by measuring the enzyme-
dependent linear decrease in DCPIP absorbance at 600 nm for 60 seconds in the absence or 
presence of CQ or 8-HQ or dicoumarol (Dic; NQO1 inhibitor). It became evident that both CQ 
and 8-HQ efficiently inhibited NQO1 activity in a dose range between 10-100 µM (Figures 
24b and c). The addition of 10 µM of the NQO1 inhibitor, Dic completely inhibited NQO1-
induced reduction of DCPIP. Considering 100 % NQO1 inhibition by Dic, up to 70 % 
inhibition of NQO1activity was observed when using 100 µM of CQ or 8-HQ while 40-50 % 
inhibition was observed at already 10 µM of CQ and 8-HQ.  This inhibitory activity was further 
confirmed in HepG2 cells by measuring the change in absorption of WST-1 induced by NQO1-
dependent reduction of quinone (menadione). It was demonstrated that WST-1 is reduced to 
its formazan product only in the presence of functional NQO1, whereas NQO1 inhibitor, Dic 
can completely abolish the reduction of WST-1 [295]. Consistent with the results from the cell-
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free assay, co-incubation of HepG2 cells with menadione as NQO1 substrate and CQ, 
significantly inhibited WST-1 reduction in a dose- dependent manner with a maximum 
inhibition at 100 µM of CQ, although a significant inhibition by CQ was already evident at 10 
µM (p=0.0005).  Interestingly, the maximum inhibition by CQ was comparable to the inhibition 
by the known NQO1 inhibitor Dic at 10 µM (Figure 24d). The IC50 of CQ and 8-HQ to inhibit 
NQO1 activity derived from dose-response curves were 13.4 µM and 6µM respectively 
(Figures 25a and b). 
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Figure 24: Interaction of CQ and 8-HQ with NQO1. 
 (a) Mass spectrometric analysis of CQ. Potential metabolic conversion of CQ in the presence of 
NQO1 and NADPH was analysed by mass spectrometry. (b, c) Cell-free NQO1 activity 
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measurement using recombinant human NQO1. NQO1 enzyme activity in the presence of 12.5-
100 µM CQ (b) or (c) HQ was determined by measuring the NQO1-dependent linear decrease in 
DCPIP absorbance at 600 nm. (d) Cellular measurement of CQ-mediated NQO1 inhibition. 
Cellular NQO1 enzyme activity in the presence of CQ (10-100 µM) was measured using NQO1 
mediated WST-1 dye reduction in HepG2 cells. p* <0.05, p** <0.01 and p*** <0.001 versus 
control using two-way analysis variance (ANOVA) followed by Dunnett multiple comparison 
tests. Error bar=SD. Men: Menadione, CQ: Clioquinol, 8-HQ: 8-Hydroxyquinoline, Dic: 
Dicoumarol. 
 
 
 
 
 
 
 
 
Figure 25: IC50 of Clioquinol (CQ) and 8-Hydroxyquinoline (8-HQ) against recombinant human 
NQO1 activity. 
Inhibition of recombinant human NQO1 activity by CQ and 8-HQ was determined by measuring the 
enzyme-dependent linear decrease in DCPIP absorbance at 600 nm at 60 seconds in a cell-free assay 
system.  IC50 of CQ (a) = 13.36 µM; IC50 of HQ (b) =5.97 µM. Data represent values from a typical 
experiment. 
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2.6 Discussion  
2.6.1 General CQ Toxicity 
 
Many drugs are converted into different metabolites in the body to elicit drug effects. In most 
cases, drugs are converted to chemically inactive metabolites that react with the respective 
receptors to evoke therapeutic effects while in some cases, they may be converted to reactive 
metabolites that produce a toxic response. These drugs may induce toxicity by drug overdose, 
drug-drug interactions, rare idiosyncratic reactions or adverse effects at therapeutic doses 
[303]. Some of the examples of drugs being withdrawn from the market due to adverse effects 
at therapeutic doses include troglitazone, rofecoxib and CQ [208,303]. 
 
The mechanism of toxicity associated with CQ has been extensively studied in in-vitro. CQ is 
a lipophilic metal-chelator of iron (Fe), zinc (Zn) and copper (Cu) and is increasingly believed 
to cause cytotoxicity due to its metal chelation and ionophoric activities [161,176,304]. The 
ionophoric property of CQ effectively transports chelated metal ions into the cells. Although 
CQ toxicity has also been observed to be independent of metal ions, many studies have 
indicated metal-dependent CQ toxicity that is aggravated by the presence of enhanced cation 
levels [161,176,304,305]. In this context, malignant cells that are characterised by elevated 
levels of metal ions (Cu, Zn and Fe) are reported to be more sensitive to CQ treatment, hence 
CQ has been proposed as an effective anticancer agent [176,304].  
  
Treatment of human cancer cell lines with CQ inhibited cell growth and survival in a Zn-
dependent manner [304]. Furthermore, CQ-induced cell death was more pronounced in the 
presence of Zn and Cu [304]. CQ-Zn chelate acted as a mitochondrial toxin in human 
melanoma cells that altered mitochondrial membrane potential and ultimately caused cellular 
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toxicity [161]. Similarly, in rat liver mitochondria, CQ uncoupled oxidative phosphorylation 
thus impairing energy metabolism in the presence of magnesium [306]. The mitochondrial 
dysfunction due to elevated levels of intracellular metal ions has also been demonstrated in 
malignant cells [307]. Exposure of prostate cancer cell lines to physiological levels of Zn 
directly affect mitochondrial function leading to a reduction in mitochondrial transmembrane 
potential, cytochrome c release and degradation of the anti-apoptotic Bcl-2 protein. This 
process subsequently triggered caspase activation followed by apoptotic cell death [307,308]. 
The metal–dependent cytotoxicity of CQ is displayed in malignant cells by its effect on 
metalloprotein (XIAPs) X-linked inhibitor of apoptosis whose primary function is to inhibit 
caspase activity and prevent apoptotic cell death [309,310]. CQ was reported to translocate 
cytoplasmic XIAPs to the nucleus and at the same time caused cytoplasmic clearance of other 
IAP proteins, thus promoting apoptotic cell death [309]. In addition, it is thought that CQ 
induces apoptosis in malignant cells by two additional mechanisms, both of which were 
described to be potentiated by addition of Cu or Zn ions [181,311-313]. It was recently 
demonstrated that CQ targets Zn to the lysosomes in human malignant cells [181]. The 
examination of intracellular Zn distribution after CQ treatment in human prostate cancer cells 
using florescence-labelled probes revealed the co-localization of Zn with lysosomes. Elevated 
Zn levels in lysosomes are described to disrupt the lysosomal membrane, release proteases 
known as cathepsins and induce apoptosis in cancer cells [181,313]. The proteasome is 
responsible for enzymatic degradation of misfolded proteins. Consequently, proteasome 
inhibition leads to accumulation of excess and misfolded proteins thus impairing regulation of 
proteins responsible for cell-cycle progression, DNA repair and transcriptions [176]. In 
malignant cells, CQ inhibits the proteasome through a copper-dependent and independent 
mechanism. CQ-Cu chelates in human prostate cancer cells or CQ in Cu-enriched malignant 
cells inhibited proteasome activity, inhibited NFkB, and subsequently induced apoptosis 
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[312,314]. This is further supported by a significant reduction of NFκB target genes, such as 
cyclin D1, which is responsible for CQ-induced cell cycle arrest, in a CQ-concentration-
dependent manner [315]. In this context, it has to be noted that NFκB activity reduces ROS 
levels through increased expression of antioxidant proteins including MnSOD, NQO1, HO-1, 
GPx1 and thioredoxins [316]. Therefore, not surprising inhibition of NFκB activity may lead 
to excess ROS production and eventually oxidative stress.  
 
The mechanism of CQ-induced cell death has been suggested to be mediated by oxidative stress 
[179,317]. Exposure of cultured human lung carcinoma cells (A549) to Fe (III) citrate chelate 
of CQ reportedly induced cell death through increased intracellular levels of Fe. This, in turn, 
increased cellular lipid peroxidation and DNA strands break, most likely as a consequence of 
Fenton-reaction derived ROS [317]. However, cytotoxicity of CQ was also reproduced in non-
malignant cells although at twice the concentration necessary to induce toxicity in tumor cells 
[318]. Similar results were observed in the current study, where during long-term treatment, 
human hepatocarcinoma (HepG2) cells were more sensitive to low dose CQ (up to 5 µM) 
compared to rodent retinal ganglion cells (RGC5). Nevertheless, both cell lines were equally 
hypersensitive to high doses of CQ (10 µM), indicating that CQ-induced toxicity at higher 
concentrations can be cell type-independent. It is worth mentioning that this study addresses 
two different possible modes of CQ toxicity; one that is NQO1-dependent and the other that is 
NQO1-independent. The observed cell type-independent CQ toxicity is NQO1-independent 
toxicity. 
 
It is interesting to note that the concentrations of CQ (≤ 10 µM) used in this study are clinically 
relevant based on pharmacokinetic studies in animals and humans. In animal models of SMON, 
peak serum levels of CQ that produced neurotoxicity were approximately 17 µM in monkeys 
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and 46 µM in dogs [177,319]. In comparison, CQ was administered orally to SMON patients 
typically around 1.5g/day [175]. In healthy human volunteers that received 3 x 0.5 g CQ /day 
p.o. over three days, peak plasma concentrations of CQ reached 30 µg/ml (98 µM) [168,177]. 
This concentration range of CQ is further supported by a phase II clinical trial in Alzheimer’s 
disease (AD) patients. The steady state concentrations after oral administration of 250 mg, 500 
mg and 750 mg of CQ resulted in plasma concentrations of 13.19 ±6.87 µM, 22.06 ± 12.11 µM 
and 24.87 ± 7.037 µM respectively in these patients [188,320]. In the context of drug-induced 
toxicity, it is striking that the documented plasma concentrations even at the lowest oral CQ 
dose used in AD patients was higher than the concentration of CQ that completely inhibited 
cellular viability in RGC5 and HepG2 cells (10 µM) in the present study. It has to be noted 
however that in-vitro toxicity in immortalized cell lines does not necessarily correspond to the 
observed neuronal side effects of systemic CQ usage in patients. 
 
2.6.2 Is Metal Chelation a Mechanism of CQ-induced Neurotoxicity 
 
CQ has been used extensively for the treatment of diarrhoea and acrodermatitis enteropathica 
(zinc malabsorption syndrome) between 1950 and 1969. However, its oral form was banned in 
many countries after it was linked to an endemic outbreak of SMON (subacute mylo-optic 
neuropathy) that affected at least 10, 000 individuals in Japan [167]. At the time, SMON was 
characterised by the presence of abdominal pain, subacute ascending dysesthesia, paresthesia 
of lower extremities and bilateral visual impairment [162,166]. To establish a possible 
mechanistic connection between CQ and SMON, many toxicological studies were carried out 
in animals {reviewed by [165,177]}. In animal studies, neurotoxicity was the most prominent 
adverse effect of CQ [176]. CQ administration in animals (dogs, cats and monkeys) at doses of 
200 mg/kg/day for over a month or at doses of 400 mg/kg/day within a week successfully 
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recapitulated the common pathological features of SMON, including abdominal symptoms 
preceding to neurotoxicity [175-177]. These animal studies unequivocally demonstrated that 
CQ is neurotoxic.  
 
In light of recent efforts to develop disease-modifying treatment options for neurodegenerative 
diseases, CQ and its structural analogues have gained attention and have been re-investigated 
in preclinical and clinical studies. This apparent emerging neuroprotective effect of CQ and its 
analogues is in stark contrast to its neurotoxic history. Therefore, numerous studies have 
attempted to explain the mechanism of CQ-induced neurotoxicity [161,182,184]. CQ is 
reported to cause neurotoxicity by DNA damage or by disrupting the antioxidant defence 
system leading to oxidative stress [180,182,184]. In human neuroblastoma cells, CQ induced 
neurotoxicity at 10-20 µM through DNA double-strands break that lead to the subsequent 
induction of apoptosis [184]. Similarly, in PC12 cells, CQ (1µM) inhibited nerve growth factor 
(NGF) signalling, that is essential for neuronal survival, leading to neurite retraction and 
neuronal death [185]. In the same cell line, CQ treatment also reduced histone acetylation, a 
process essential for the transcriptional activation of genes that are responsible for cell 
proliferation [186]. Conversely, the use of a histone deacetylase inhibitor antagonized CQ-
induced histone deacetylation restored CQ-induced NGF signalling and prevented neuronal 
cell death [186].  
 
There is also good evidence that CQ induces neurotoxicity through oxidative stress [180]. CQ 
treatment (1-3 μM) of cortical cultures containing neurons and astrocytes obtained from 
B6/129 mice increased oxidative stress after 24 h [180]. As shown for other cell types, the 
addition of metal ions (Fe2+, and Cu2+) enhanced CQ toxicity and caused cell death even at a 
previously non-toxic concentration of CQ [180]. These results support the observation of the 
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present study, where an addition of ZnCl2 to the cell culture medium further enhanced the 
cytotoxicity of CQ in RGC5 cells. This result is in opposition to the recently proposed 
hypothesis that metal chelation, which means the removal of metal ions from the culture media, 
can be regarded as the mechanism of CQ toxicity [182]. CQ is demonstrated to cause 
neurotoxicity through its effect on the antioxidant defence mechanism which is suggested to 
be a consequence of its metal-chelation activity. Superoxide dismutases (SODs) are primarily 
cytoplasmic and mitochondrial ROS detoxifying enzymes that convert superoxide radicals into 
hydrogen peroxide and molecular oxygen [321]. Most cells express three distinct SOD 
enzymes. SOD1 (Cu/Zn SOD) is found mainly in the cytoplasm [322], although small fraction 
can be found in the intermembrane space of the mitochondria [23]. SOD2 (MnSOD) is 
exclusively present in the mitochondrial matrix [23]. SOD3 contains Cu and Zn in its active 
site and is mainly extracellular [321]. CQ was reported to inhibit SOD1 at a concentration 
between 10-50 µM by chelating the metal ions in human-derived neuroblastoma cell lines 
[182]. Inhibition of SOD1 caused excessive ROS generation and subsequent neuronal cell 
death through apoptosis [182]. If metal chelation is responsible for CQ toxicity, CQ induced 
toxicity should be attenuated by supplementing chelated metal ions. When this possibility was 
investigated in RGC5 cells, the addition of non-toxic concentration of ZnCl2 did not rescue 
CQ-induced cellular toxicity but rather enhanced it. This suggests that CQ induces 
neurotoxicity through a mechanism distinct from direct metal chelation. A second hypothesis 
was put forward where CQ was suggested to induce toxicity through zinc ionophore activity 
whereby CQ transports zinc across the plasma membrane to increase intracellular Zn levels 
[304,323]. It has been demonstrated that increased intracellular Zn exposure is associated with 
oxidative stress [324]. Therefore, the results of the current study could be explained by CQ-
induced increased intracellular Zn levels leading to oxidative stress and subsequent cell death 
of RGC5 cells. This hypothesis is directly supported by our experimental result where an 
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addition of premixed CQ and Zn to the human kidney cells enhanced cellular toxicity compared 
to CQ and Zn alone (Farooq M, unpublished data). Previous studies have shown that CQ targets 
Zn to specific cellular organelles such as mitochondria and lysosomes [161,181]. In the present 
study, intracellular Zn ions as well their localization were not explored. Based on the previous 
evidence of CQ-Zn targeting to mitochondria and the in-vitro screening results, where CQ and 
8-HQ inhibited mitochondrial function (Dilek J, unpublished data), the mitochondrial liability 
of these compounds were further explored in RGC5 and HepG2 cells. Although RGC5 cells 
were used for initial experiments to confirm mitochondrial dysfunction of CQ, these cells were 
not used for subsequent experiments due to the uncertainty regarding the origin of this cell line 
[325]. The RGC5 cell line was originally described as SV-40-immortalized retinal ganglion 
cells derived from rat tissue [325]. There is, however, some evidence to suggest that at least 
some sub-strains in some laboratories are not of RGC origin but are mislabelled 661W cells, a 
mouse SV-40 immortalized photoreceptor cell line that was generated in the same lab as the 
original RGC5 line [326,327]. 
 
2.6.3 Are CQ and 8-HQ Mitochondrial Toxins? 
 
Under normal culture conditions, cells use glycolysis to generate almost all of the ATP for their 
metabolic needs and are mostly resistant to the effects of xenobiotics that impair mitochondrial 
function [296]. However, replacing glucose with galactose yields no net ATP via glycolysis, 
thus forcing cells to rely entirely on mitochondrial OXPHOS to generate sufficient ATP for 
survival [296]. Under such conditions, the mitochondrial toxins will show pronounced effects 
on cellular ATP levels. Long- and short-term treatment of RGC5 cells with CQ and 8-HQ 
showed that these cells were very susceptible to CQ and 8-HQ toxicity in galactose-containing 
media compared to glucose-containing media. This selective hypersensitivity therefore 
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strongly suggests that drug-induced mitochondrial dysfunction as the likely mechanism of 
action. Since this mitochondrial dysfunction was observed both with CQ and its parent 
compound 8-HQ, it is likely that the toxicity is not restricted to CQ but applies to the entire 
class of hydroxyquinoline-compounds.  
 
It is important to note that besides generating ATP, mitochondria are also one of the main 
sources of cellular ROS (80-90 %) [15]. At the same time, the function of these organelles is 
highly susceptible to the detrimental effects of oxidative stress [15]. Superoxide radicals can 
attack iron-sulfur centers in the mitochondrial ETC enzymes, which causes the release of free 
ferric iron [321]. This free iron then catalyzes the generation of reactive hydroxyl radicals from 
H2O2 and superoxide radicals through the Haber-Weiss reaction [321]. Depending on their 
concentrations, ROS are known to transmit both beneficial as well as detrimental effects on 
different cellular processes [13]. At low concentration, ROS regulate cellular functions through 
redox-dependent signalling and redox-dependent transcription factors [13]. However, at high 
concentrations ROS impair vital cellular processes as a consequence of their damaging effects 
on cellular macromolecules such as protein, lipids and DNA [13]. In this study, this effect was 
examined by measuring lipid peroxidation in the presence of CQ in the hypersensitive RGC5 
cells. Consistent with mitochondrial impairment, CQ significantly increased lipid peroxidation 
in RGC5 cells. These findings support previous studies, where CQ induced cell death in in-
vitro through mitochondrial dysfunction and enhanced lipid peroxidation [161,179].  
 
One of the conundrums in this context is that elevated ROS levels may be causal for 
mitochondrial dysfunction or on the other hand, may be the result of mitochondrial dysfunction 
itself. In this study, there was a realistic possibility that CQ-mediated ROS could have been 
upstream of mitochondrial dysfunction. However, this possibility was practically ruled out by 
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showing that downstream events of ROS-mediated mitochondrial dysfunction, such as reduced 
cellular ATP levels, increased lipid peroxidation and cell death could be attenuated by several 
antioxidants that presumably reduced elevated ROS levels. It was surprising to observe that 
ROS was mainly detected at the level of lipid peroxidation whereas use of the predominantly 
water soluble ROS-indicator dye CM-H2DCFDA, did not provide any evidence of ROS. This 
illustrates that CQ does not lead to uniformly elevated ROS production across the cell but a 
rather restricted localisation to the membrane compartment. Another explanation is that the 
particular CQ-induced ROS-species is not detected with this particular dye since most dyes do 
not equally react with all ROS species. For example, CM-H2DCFDA does not react with 
superoxide, singlet oxygen or hypochlorous acid to produce the fluorescent product [328-330]. 
Based on the data of the current study, it is possible that CQ-induced ROS generation impairs 
mitochondrial function, and also lead to lipid peroxidation.  Although, mitochondrial ROS 
production, in particular was not directly confirmed in CQ-treated cells in this study, overall, 
the results strongly indicate that oxidative stress is at the core of CQ-induced mitochondrial 
dysfunction. 
 
Although HepG2 cells showed some CQ and 8-HQ cytotoxicity in long-term treatment in 
glucose-containing media, all attempts to confirm mitochondrial dysfunction in the form of 
ATP depletion or increased lipid peroxidation failed in these cells. This was further confirmed 
by measuring lactate levels, another characteristic metabolic signature of mitochondrial 
dysfunction. Using the well-known mitochondrial toxin, rotenone, mitochondrial dysfunction 
significantly increased lactate levels in HepG2 cells, while surprisingly a 100-fold higher CQ 
concentration increased lactate levels only slightly. CQ at this higher concentration was 
evidently cytotoxic, limiting cell proliferation and reducing clonal cell viability. This 
cytotoxicity explained the low lactate levels in response to CQ. When lactate levels were 
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standardized on residual protein levels in each reaction, lactate levels/protein showed a 
dramatic increase in CQ-treated cells, which suggests that cells died in response to CQ-
treatment before they were able to synthesize significant levels of lactate. These results suggest 
that in addition to mitochondrial dysfunction in the absence of NQO1, there is likely an 
additional NQO1-independent mechanism of CQ cytotoxicity in HepG2 cells. Several different 
additional mechanisms related to CQ-induced toxicity in cancer cell lines have been proposed, 
such as inhibition of the 20S proteasome, disruption of a lysosomal membrane through both 
metal-dependent and independent mechanisms, DNA damage [176,181,183,184,313,314].  
 
2.6.4 Is CQ-induced Mitochondrial Dysfunction Dependent on NQO1? 
 
A growing body of evidence suggests that NQO1 plays a crucial role in modulating 
mitochondrial function and cellular viability [331,332]. NQO1 is an FAD-containing cytosolic 
protein that catalyses the two-electron reduction of quinone compounds to prevent the 
formation of reactive semi-quinones, free radicals and ROS, which thus protects cells from 
oxidative stress [333]. In addition to the indirect prevention of superoxide formation, NQO1 
can directly scavenge superoxide as well. Furthermore, due to its redox activity, NQO1 can 
maintain the two essential endogenous antioxidants, Vitamin E and ubiquinol, in their anti-
oxidant state to regulate cellular ROS levels [333]. It has been shown that NQO1 
overexpression renders cells resistant against mitochondrial toxins of the electron transport 
chain such as rotenone and antimycin [331,332]. In contrast, cells with low or absent levels of 
NQO1 are characterized by increased oxidative stress, reduced ATP production as well 
enhanced cellular vulnerability to mitochondrial toxins [332]. This has also been demonstrated 
in-vivo where compared to the wild-type mice, NQO1 knock-out mice showed high sensitivity 
to drug-induced hepatotoxicity, increased ROS levels, reduced ATP synthesis and severe 
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mitochondrial dysfunction [331]. These findings strongly suggest that there is an association 
between NQO1 and mitochondrial function and a better understanding of this link would be 
warranted to gain insight if this process is associated with the pathology of the mitochondrial 
disease.  
 
The putative role of NQO1 as endogenous antioxidant was observed in the present study where 
expression of NQO1 was positively correlated with cellular protection against CQ-induced 
toxicity. In NQO1 deficient cells (HEK293-neo), significantly reduced ATP levels, increased 
lipid peroxidation and reduced cellular viability were observed in the presence of CQ. 
However, cells with higher NQO1 levels (HEK293-clone6/12) showed protection against CQ-
induced reduction in cellular ATP levels, increased lipid peroxidation and reduction in cellular 
viability. These results suggest a pivotal role of NQO1 in the protection against CQ-induced 
cellular mitochondrial-dysfunction. This protective role of NQO1 against CQ-induced toxicity 
observed in the present study is in good agreement with previous studies. Neuronal cell lines 
used as an in-vitro model for the study of CQ-induced neurotoxicity include the human 
neuroblastoma cell lines (SH-SY5Y, IMR-32) and primary neurons. These cells are 
characterised by low levels of endogenous antioxidant defence systems and in particular, low 
NQO1 expression [180,334,335]. It is likely that this reduced NQO1 expression, predisposed 
these cells to CQ-induced toxicity. Interestingly the neurotoxic concentrations previously 
reported for these cell lines are very consistent with the results of the present study 
[180,334,335]. 
  
Beside its antioxidant function, NQO1 is also essential to stabilize the tumor suppressor protein 
p53, which regulates the expression of genes that modulate cell-cycle checkpoints, apoptosis, 
DNA repair and the cellular stress response [298,321]. And it is important to note that p53 is 
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the most commonly inactivated gene in cancer cells [321]. Under normal conditions, cellular 
p53 levels are maintained at low levels due to a rapid degradation by the 20S proteasome [321]. 
However, in response to different forms of stress, NQO1 acts as a gatekeeper of the proteasome, 
binds to p53 and prevents its entry into the proteasome. This process causes a rapid 
accumulation of p53 protein levels that are then able to perform a multitude of functions [321]. 
In line with the p53 stabilizing role of NQO1, NQO1 knock-out mice showed lower p53 levels 
and consequently decreased rates of apoptosis [336]. This tight connection between NQO1 and 
p53 is also illustrated by the significant susceptibility of NQO1-deficient mice towards induced 
malignancies, which is undistinguishable from the phenotype of p53 knock-out animals [336-
338] 
 
The present study demonstrated a clear protective effect of NQO1 against CQ-induced 
mitochondrial-dysfunction. However, NQO1 is mainly described to be a cytoplasmic protein 
and has not yet been reported to translocate to the mitochondria. Therefore, it is unlikely that 
NQO1 exerts its mito-protective role by a direct interaction with the mitochondria but rather 
via some indirect activity involving additional signalling molecules or proteins. One possibility 
is that the NQO1-dependent protection against CQ-induced mitochondrial-dysfunction could 
be transmitted through an NQO1-mediated activation of p53-target genes. In addition to its 
regulatory function of cell death, p53 is increasingly reported to regulate the cellular 
antioxidant defence system and metabolic pathways that reduce glycolysis and increase 
oxidative phosphorylation [339,340]. The antioxidant properties of p53 are mediated to some 
extent through induction of the mitochondrial antioxidants ALDH4 (aldehyde dehydrogenase 
4), GLS-2 (glutaminase 2) and TIGAR (TP53-induced glycolysis and apoptosis regulator) that 
ultimately facilitates the production of the reduced form of glutathione and the rest through 
transcriptional induction of the antioxidant proteins peroxiredoxin reductase and glutathione 
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peroxidase 1 (GPx) [340]. It is possible that this NQO1/p53-mediated upregulation of 
mitochondrial antioxidants is able to rescue CQ-induced mitochondrial dysfunction seen in the 
present study. Although both HepG2 and HEK293 cells used in the current study express wild-
type p53, they differ significantly in their expression levels [341,342]. Expression of p53 in 
HepG2 cells is significantly higher than in HEK293 cells which correlate well with the 
NQO1expression in these cells. However, this study did not explore the p53 status of the cell 
lines used. Moreover, the HEK293 cells used in this study were stably transfected with NQO1 
expression plasmids and no attempts have been made to measure differences in NQO1-
mediated p53-induced gene expression. Therefore, the above hypothesis of NQO1 dependent 
protection against CQ-toxicity via p53-dependent gene expression needs to be further explored. 
In particular, the expression of p53-dependent mitochondrial antioxidant proteins such as 
peroxiredoxins and GPx need to be assessed.  
 
Another possibility for NQO1-dependent protection against CQ toxicity could be due to a direct 
effect of NQO1 on ROS. NQO1 is also known to directly scavenge superoxide and therefore 
may directly inhibit CQ-induced ROS-production as well as all subsequent events such as 
mitochondrial dysfunction, lipid peroxidation and cell death.  
 
2.6.5 Is NQO1 Expression Upregulated by CQ-induced Oxidative Stress? 
 
NQO1 is generally highly inducible and NQO1 expression is regulated by a protein complex 
consisting of the nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-
associated protein 1 (Keap1) [343]. Under normal physiological conditions cytoplasmic Nrf2 
binds to the ubiquitin ligase systems (Cullin 3-base-E3 ligase) via Keap1, which promotes 
continuous ubiquitination and proteasomal degradation of Nrf2 [343]. Under conditions of 
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oxidative stress, some of the highly reactive cysteine residues at positions 257, 273, 288 and 
297 in Keap1 are easily attacked by radicals, which destabilizes the complex with Nrf2 
[298,344,345]. As a result, Nrf2 is not ubiquitinated but rather accumulates in the nucleus, 
where it binds to the antioxidant-response elements (ARE) in the promoter regions of its target 
genes. This binding promotes increased transcription of a broad range of cytoprotective genes 
such as heme oxygenase (HO-1), γ-glutamyl-cysteine-ligase (GCL), glutathione S-transferase 
(GST), glutathione peroxidase (GPX) as well as NQO1 [344,346]. A significant part of this 
cellular response to pro-oxidative conditions can be attributed to NQO1 since induction or 
knockdown of NQO1 is directly associated with decreased or increased levels of oxidative 
stress [298]. Since it was observed that CQ-toxicity is mediated by oxidative stress, it was 
hypothesised that NQO1 protein expression might increase in response to oxidative stress. 
When this hypothesis was examined in HepG2 cells both under low and high glucose condition, 
CQ at 10 µM and even H2O2 (300 µM) did not increase NQO1 expression at any time point 
compared to untreated controls. These results, however, are in contrast to previous studies in 
HepG2 cells where increased NQO1 expression in response to oxidative stress was shown 
[301,302]. One explanation for this unexpected result in the present study could be the presence 
of extremely high basal NQO1 expression levels in HepG2 cells, as seen in this present study, 
which may not allow further increase by pro-oxidants. A second possibility could be the 
experimental condition including pro-oxidant concentrations and their incubation periods. It is 
possible that the constant exposure of the cells to high concentrations of CQ and H2O2 may fail 
to upregulate NQO1 expression. The shortest incubation period of the present study was 6 
hours, which might be already too long to observe oxidative stress-mediated NQO1 induction 
at high CQ concentrations. Therefore, it would be interesting to explore if NQO1 could be 
induced in HepG2 cells or other cell lines under different conditions such as lower CQ 
concentrations over longer exposure times or at higher CQ doses over shorter periods of time. 
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Additionally, it would also be of interest if NQO1 can be induced in cell lines that are 
characterised by a low basal NQO1 expression, such as human neuroblastoma cell lines or even 
primary cultures [334,347].  
 
2.6.6 How Does NQO1 interact with CQ/8-HQ? 
 
Generally, NQO1 is known as a detoxifying enzyme, as it detoxifies a number of compounds, 
such as quinones, into less-reactive and less-toxic metabolites [333]. This suggested that the 
cytoprotective effect of NQO1 against CQ-induced toxicity demonstrated in this study could 
also be the result of a direct NQO1-mediated detoxification of CQ to less reactive metabolites. 
However, no evidence could be found for this. First of all, CQ is chemically unrelated to all 
known NQO1 substrates and secondly, mass spectrometry analysis of CQ reaction products in 
the presence of NQO1 under optimal conditions failed to provide any evidence of metabolic 
conversion. 
 
Structural and functional studies of NQO1 have shown that NQO1 contains two active binding 
sites that work via a “ping-pong” mechanism {reviewed by [300]}. One site binds the electron 
donor NAD(P)H and another site is for substrate binding such as quinones. Once NAD(P)H 
binds to NQO1, it reduces the tightly bound cofactor flavin adenine dinucleotide (FAD) to 
FADH2, while NAD(P)+ is released from the active site. This allows the second substrate to 
bind and subsequently be reduced by FADH2. One of the best-studied inhibitors of NQO1 is 
dicoumarol [(Dic), 3,3′-methylenebis (4-hydroxycoumarin)], which is one of the most potent 
known competitive inhibitors of NQO1. Dic competes with NAD(P)H for binding to NQO1 
and thus prevents the reduction of FAD to FADH2. In the absence of a direct metabolic 
conversion of CQ by NQO1, it was speculated if CQ or 8-HQ may interact with the Dic-binding 
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site of NQO1. To explore this possibility, NQO1 enzyme activity was examined both in cell-
free and cell-based systems in the presence of CQ or 8-HQ or Dic. The extent of NQO1 
inhibition by CQ in cell-free and cellular system varied. At CQ (10 μM), inhibition of NQO1 
activity was around 40-50 % (when considering the Dic effect as 100 % inhibition) in the cell-
free system, whereas in the cellular system it was only around 25 %. It is important to note that 
in cells, NQO1 inhibition was measured by NADPH-dependent NQO1-mediated quinone 
reduction to hydroquinone, which in turn reduces WST-1. The observed differences in 
inhibition could, therefore, be attributed to the additional electron transfer steps inherent to the 
cell-based measurement system, which is absent in the cell-free system. Another point to note 
is the obvious difference of CQ and quinone uptake into the cells that is required to measure 
NQO1 activity in cells. Furthermore, varying NADPH levels and the presence of other 
redundant enzymes such as VKORC1 (vitamin K oxidoreductase C1) in the cells are all 
parameters that can influence the final results. Irrespective of these limitations, in both systems, 
lower CQ concentrations (10 μM) were not as potent as Dic while higher CQ concentrations 
(100 μM) showed comparable inhibitory activity towards NQO1. These results suggest that 
NQO1 inhibition by lower concentrations of CQ and its associated mitochondrial-dysfunction 
can become relevant in cell lines that already have a low NQO1 expression such as HEK293 
and RGC5 cells. This was not the case in high NQO1 expressing HepG2 cells where a slight 
inhibition of NQO1 by CQ may not be sufficient to induce mitochondrial-dysfunction. Most 
importantly, this NQO1 expression-dependent effect can be of great importance when looking 
at heterozygous carriers of the inactivating NQO1 polymorphism. These individuals should be 
at a relatively greater risk of losing more of their residual NQO1 activity by a direct inhibition 
by CQ exposure. This finding is quite relevant to the SMON cases reported in Japan where the 
majority of the population is carrying the inactivating NQO1 polymorphism.  Hence, it is 
possible that due to this deficiency, CQ more severely affected this population group compared 
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to the rest of the world. 
  
Overall the in-vitro results of the present study suggest that CQ can directly inhibit NQO1 
activity, especially under conditions of low NQO1 expression, which in addition to the direct 
CQ effects on ROS levels described above can further exacerbate toxicity. 
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Chapter 3:  In-Vivo Studies 
3.1 Overview/Rationale  
 
The in-vitro results described above strongly indicate that CQ-induced toxicity is negatively 
correlated with NQO1 expression. In order to translate the in-vitro results to an in-vivo system, 
a suitable animal model was required. To confirm our findings in in-vivo, the essential 
requirement of an animal model should include conditions of both high and low NQO1 
expression. Zebrafish are a suitable candidate for this purpose because only recently it was 
reported that they lack retinal NQO1 expression during their early larval stages (7 dpf), while 
subsequently NQO1 is highly expressed in the adult retina [348]. The other benefits of using 
zebrafish lie in the possibility to perform higher-throughput drug toxicity screening, a rapid 
eye development that allows to test visual function already at 5 dpf, a visual system that reflects 
the human situation in many respects including cone-dominant vision and finally a plethora of 
genetic information that is available from zebrafish mutants associated with defective visual 
development and function [220]. Therefore, visual function was examined in zebrafish in the 
presence of CQ. The visual function was measured using a visual behavioural test, known as 
the optokinetic response (OKR). There are other visual behavioural tests described for 
zebrafish such as optomotor response, startle response, phototactic behaviour and escape 
response [220]. However, the advantages of the OKR include the ability to use larvae from 
only 5 dpf, reliability and specificity (tests each and every individual animal) while these 
characteristics not all associated with any of the other assays. Hence, in the current study, OKR 
was employed to examine the visual function test in zebrafish. 
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3.2 Aim and Objectives  
 
The overall aim of the in-vivo study is to investigate the connection between NQO1 levels and 
CQ-induced toxicity. 
To achieve this aim, I: 
  investigated the effect of NQO1 expression on visual acuity of CQ-treated zebrafish  
  examined histological sections of zebrafish retina  
  examined NQO1 expression and activity in the adult zebrafish retina 
 
3.3 Materials and Methods 
3.3.1 Animal Husbandry 
 
All animal experiments were approved by the Animal Ethics Committee (AEC), University of 
Tasmania, Australia (Animal Ethics approval numbers: A12817 and A0015097) and were 
carried out according to ARRIVE guidelines ([349]. The husbandry of adult wild-type 
zebrafish (petstore-purchased; PET and AB strains) was carried as previously described [350]. 
Fish were raised under standard conditions (14:10 light: dark cycle, 26-28 ˚ C) in a recirculating 
system (Zebtec, Techniplast, USA for PET strain and Z-hab mini system, AquatiHabitats, 
Pentair, US for AB) that continuously aerates and filters the water in order to maintain a healthy 
aquatic environment. Water parameters were monitored daily and maintained to ensure a 
predefined target range (pH: 6.5-7.5, conductivity 690-750 µs, bicarbonates 30-35 (mg/l), 
nitrite: 0 mg/l, nitrate: 0-10 mg/l). Zebrafish were fed twice per day with flake food 
(Nutrafinmax) in the morning and in the evening and with brine shrimp (hatched in-house from 
artemia cysts: Inve group) in the morning (3 drops of concentrated brine shrimp per fish from 
a 5 ml syringe). Breeding of zebrafish was set up fortnightly. Zebrafish were allowed to spawn 
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and eggs were collected 4 h after the lights turned on at 8 a.m. Fertilized eggs were cultured in 
embryo media 0.5 x E2 (7.5 mM NaCl; 0.25 mM KCl, 0.5 mM MgSO4, 0.075 mM KH2PO4, 
0.025 mM Na2HPO4, 0.5 mM CaCl2, 0.35 mM NaHCO3) [351] in an incubator in the dark at 
28.5 ± 0.5 ˚C.  
 
3.3.2 Maximum Tolerated Concentration (MTC) in Zebrafish Larvae 
 
The assessment of a maximally tolerated drug concentration (MTC) in fish was performed 
according to a protocol described previously [281,286]. Briefly, in a 12 well culture plate, 3 
dpf PET or AB strains larvae (n=10) were placed in individual wells at 2 pm. Larvae were 
exposed to one compound concentration per well. Seven concentrations of the drug (CQ) 
ranging from 1 mM, 0.3 mM, 100 µM, 30 µM, 10 µM, 3 µM, 1 µM (PET) and four 
concentrations of NQO1 inhibitor, dicoumarol (Dic) ranging from 0.01, 0.1, 1, 3 µM (AB) 
were tested. The larvae were incubated with the compounds for 48 h at 28.5 ± 0.5 ˚C in the 
incubator. Toxicity was assessed after 24 h and 48 h of drug exposure based on the following 
criteria: absence of heart beat, loss of startle response (using dish tapping and sudden exposure 
to light), swim position (loss of dorsoventral balance), morphological aberration (pericardial 
oedema, bent body, failure to inflate swim bladder). Overall, the assays were not evaluated if 
more than 10 % of the untreated control larvae also showed signs of toxicity. 
 
3.3.3 Drug Treatment in Adult Zebrafish  
 
Unlike for larvae, MTC was not determined for the adult zebrafish. Instead PET strain adult 
zebrafish in the age range between 1.5-2 years were treated with the CQ concentration that 
produced visual toxicity in larvae. Adult zebrafish (n=4) were placed in a small tank containing 
In-vivo Studies 
 
126 
 
a litre of system water and were left overnight to settle. Subsequently, the fish were exposed to 
drugs including CQ or a known NQO1 inhibitor, Dic or a combination of CQ and Dic for 48 h 
under standard conditions (14:10 light: dark cycle, 26-28 ˚C). The control fish were exposed 
to 0.1 % DMSO (solvent control). During the treatment period, feeding was carried out 
according to a standard husbandry. Feeding was stopped 24 h before OKR measurement to 
avoid regurgitation during an anaesthetic procedure. Similar to the assessment of toxicity in 
larvae, the assessment of toxicity in adult fish was done after 24 h and 48 h of drug exposure 
and was based on the following criteria: absence of a heartbeat, eating behaviour, loss of 
dorsoventral balance. Overall the assays were not evaluated if the control fish also showed 
signs of toxicity. 
 
3.3.4 Optokinetic Response (OKR) 
3.3.4.1 OKR in Zebrafish Larvae 
 
The OKR in zebrafish larvae was measured using a commercial system (Visio Tracker TSE 
systems, Germany) according to a previously described protocol [352]. OKR was measured in 
zebrafish by a staircase approach whereby the stimulus parameter was increased from the 
lowest to the highest setting followed by a stepwise decrease back to the lowest setting. Each 
step in this staircase approach lasts for 9 secs with sinusoidal changes of direction (3 number 
of cycles, i.e from right to left, left to right and again from right to left, each cycle lasting for 3 
secs) [263]. At 5 dpf all larvae were transferred in fresh egg media from the treatment plate 
and OKR was performed from 2 pm to 5 pm. Briefly, larvae were immobilized in pre-warmed 
3 % methylcellulose solution in 35 mm petri-dishes. The larvae were well mixed into the 
methylcellulose mixture and were positioned dorsal side up. Any air bubbles generated during 
this process were removed using a small needle. The fish were left in methylcellulose for 5-10 
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min against a white background under flickering light allowing enough time for them to embed 
and to avoid any spontaneous body movement that could impair the experimental data during 
the stimulus exposure. The petri dish containing larva was placed on the Visio Tracker 
instrument before the camera was focused on the eyes. The fish were exposed to a computer-
generated stimulus pattern that consists of rotating black and white stripes. The stimulus was 
run at varying absolute velocities (5, 7, 10, 15, 20, 25, 30 deg/sec) and constant contrast (10 
%) and spatial frequency (0.11 cycles/ degree) for about 2 min. Before initiation of eye velocity 
measurements, the fish were pre-stimulated with contrast (10 %), spatial frequency (0.11 
cycle/deg) and angular velocity (7.5 deg/sec) for a total of 9 secs for experiments conducted at 
varying absolute velocities. The word contrast refers to the difference between black and white 
moving stripes, spatial frequency refers to the frequency of direction changes of stripes and 
angular velocity refers to the speed of rotation of stripes. The raw eye velocity measurements 
were filtered for saccades to extract slow-phase velocity. In order to smooth the saccade-
filtered eye velocity curves, averages were calculated using a sliding window of 7 frames. The 
average velocities of both right and left eyes at varying stimuli (angular velocities) were 
calculated in real time (deg/sec) and finally compared between the DMSO- and drug-treated 
groups.  
 
3.3.4.2 OKR in Adult Zebrafish  
 
The OKR in adult zebrafish was measured according to previously described protocols 
[262,263] (Figure 26). As for larvae, the OKR in adult zebrafish was also measured by 
staircase approach whereby the stimulus parameter was increased and then decreased stepwise 
with each step lasting for 6 secs in unidirectional changing direction [263]. Before initiation of 
eye velocity measurements, the fish was pre-stimulated for a total 9 secs at 99 % contrast, 0.2 
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cycle/deg spatial frequency and 12 deg/sec angular velocity. For the adult zebrafish, both eyes 
were stimulated with a unidirectional motion stimulus (from right to left) but the evaluation 
was done only in one eye (right) as this allows more precise positioning of the eye that was 
being examined. After 48 h of drug exposure, the fish were transferred to a tank containing 
system water. The fish were briefly anesthetized with 300 mg/l MS-222 dissolved in system 
water and clamped between two pieces of sponge and plastic to restrain the body movement 
while the head and gills were left free. A single fish was placed in a flow-through chamber 
where the gills were supplied with a constant flow of oxygenated water, which was designed 
to recirculate back to the supply tank through an outlet present in the flow chamber. The water 
in the supply tank was maintained at 28 °C ± 0.5 °C using an aquarium heater (Eheim aquatics, 
Germany) and oxygenated using an air pump. The flow through chamber was kept under the 
visual field of the camera and the fish were exposed to a computer-generated stimulus pattern 
consisting of black and white stripes at constant contrast of 99 %, 0.2 cycles/ degree spatial 
frequency and at varying absolute velocities of 5, 10, 12, 15, 20 deg/sec for nearly 2 min. The 
raw eye velocity measurements were filtered for saccades to extract slow-phase velocity. In 
order to smooth the saccade-filtered eye velocity curves, averages were calculated using a 
sliding window of 3 frames. The average eye velocities of only the right eyes at varying stimuli 
(angular velocities) were calculated in real time (deg/sec) and finally the DMSO- and drug-
treated groups were compared.  
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 Figure 26: Experimental set-up of optokinetic response (OKR) measurement in the adult 
zebrafish. 
 (a) Adult zebrafish, immobilized in a flow-through chamber to restrain the body movement, were 
exposed to the visual stimulus of rotating black and white stripes. (b) The right eye was evaluated 
by precisely controlling its position. 
 
 
3.3.5 Termination of Experiment and Tissue Harvesting 
 
The larvae and adult zebrafish were euthanized using a rapid cooling technique according to 
the protocol in the AVMA (American Veterinary Medical Association) guidelines on 
euthanasia (2013), whereby the fish irrespective of age are transferred to 2-4 °C water for at 
least 20 minutes. In the case of adult zebrafish, the eyes were removed using a scalpel and fine 
forceps, whereas for the larvae the whole fish were used. The harvested tissues were either 
fixed in 4 % PFA (in PBS) to carry out histological analysis on paraffin sections and 
cryosections or snap-frozen in liquid nitrogen and stored at -80 °C for subsequent western blot 
analysis. 
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3.3.6 Histology 
3.3.6.1 Mold Design 
 
To enable higher throughput histology of zebrafish larvae an embedding mold was designed 
according to a previously described protocol [353] (Figure 27a). Briefly, the mold measures 
35.5 mm by 17 mm, width 2 mm, surrounded by 4 mm walls along the length of the structure 
and was designed using AutoCAD 2015 Student version (Figure 27a). The mold consists of 
arrays of triangular teeth measuring 4 mm (base to apex), 0.8 mm base width and 1 mm in 
height (approximately equal to a dimension of 5-7 dpf larvae). Each tooth is separated by a 
distance of 1.2 mm. The mold-design was printed on two different 3D printers: Object 
Eden260VS Dental AdvantageTM (Stratasys) printer or Miicraft digital micromirror device 
(DMD)-based 3D printer (Miicraft, Hsinchu, Taiwan). The polymer called ink veroclear was 
used with Object Eden260VS Dental AdvantageTM and a colourless or blue coloured 
epoxy/acrylate resin was used with Miicraft. The Object Eden260VS Dental Advantage 
operates by spraying liquid polymer drops in tiny layers followed by a UV light curing 
procedure [354]. Although the proprietary clear polymer (Ink Veroclear RGD 810, Stratasys) 
produced a strong and durable mold, the mold lacked smooth edges, especially on the base of 
the triangular structures, due to insufficient resolution (Figure 27b). In contrast to the Dental 
advantage system, the Miicraft DMD printer operates by building each layer individually and 
adding up each successive layer on top of the previous layer and the process is repeated until 
the model is completed upside down, which is subsequently postcured [355]. The final products 
obtained from the Miicraft printer varied in resolution depending on the resin that was used. 
The photosensitive colourless polymer (acrylate/epoxy resins) provided strength as well as a 
better resolution of the finished product compared to a product obtained from Object 
Eden260VS Dental AdvantageTM printer (Figure 27c). However, an even higher-resolution 
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end product was obtained from the Miicraft printer when the proprietary blue resin was used 
(Figure 27d). The optical transparency was not critical to the function of the mold whereas the 
high resolution of the mold was essential to achieve the right size pockets that exactly fit the 
zebrafish larvae. Therefore, for experiments involving histology of zebrafish larvae, only the 
blue resin was used for printing the embedding mold.  
 
 
Figure 27: Mold-design for agarose embedding of zebrafish larvae. 
The mold-design was printed in different materials using two different 3D printers. (a) AutoCAD 
construction image used for 3D printing, (b) mold printed in Object Eden260VS Dental Advantage TM 
printer using Ink veroclear (polymer), (c) mold printed in Miicraft digital micromirror device using 
clear resin, (d) mold printed in Miicraft digital micromirror device using blue resin. 
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3.3.6.2 Tissue Fixation 
 
After euthanasia in ice-cold water, 5 dpf zebrafish larvae and adult zebrafish eyes were fixed 
in 4 % PFA (in PBS, pH 7.4) for overnight at 4 °C. 
 
3.3.6.3 Using the 3D-printed Embedding Mold 
 
To fill the mold described in 3.3.6.1 with embedding agarose solution, the open slides of the 
mold were closed using sticky tape. 1 % agarose in distilled water was heated in a microwave 
for 2 min to dissolve the agarose. The solution was allowed to cool down to around 55 °C and 
was subsequently used to fill the mold with warm agarose solution. The volume of the solution 
needed to cast a mold was calculated based on the following formula: 
[mold length x mold width x agarose depth (4 mm)] – [(volume of tooth) x number of teeth)] 
[35.5 x 17 x 4] – (0.5 x 4 x 1 x 0.8) x 30 mm3  
2366 mm3 = 2.366 cm3 = 2.366 ml 
 
After the agarose had solidified, the tape was removed and the agarose block peeled out of the 
mold. Fixed zebrafish larvae were then transferred to the wells (one in each well) using a 
stereomicroscope and a fine needle followed by filling the wells with 55 ˚C agarose solution to 
immobilize the embryos. The solidified agarose block was placed in a labelled cassette, 
immersed in 70 % ethanol and kept in the auto-processor until the tissues and agarose block 
were dehydrated, cleared and infiltrated. 
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3.3.6.4 Tissue Processing 
 
Tissue processing was carried out using a Leica ASP 200 auto-processor (Leica Biosystems, 
VIC, Australia). Before the tissue was infiltrated with paraffin wax, the water in the tissue was 
removed completely as water and wax are immiscible. Therefore, tissue processing involved 
series of steps including dehydration in increasing concentrations of ethanol, clearing in xylene 
before finally infiltrating in paraffin wax (Table 5). 
 
 
 
3.3.6.5 Embedding and Sectioning 
 
The agarose blocks containing larvae as well as processed adult zebrafish eyes were embedded 
into paraffin wax blocks using a metal mold. 
 
A microtome (Leica 2250 microtome, Leica Biosystems, VIC, Australia) was initially adjusted 
to 10 µm for coarse sections followed by 4 µm sections when the area of interest was reached. 
Table 5: Steps in zebrafish tissue processing 
Solution  Duration  
(Minutes) 
Temperature  
(˚C) 
Ethanol 70 % 15 37 
Ethanol 95 % 30 37 
Ethanol absolute  15 37 
Ethanol absolute 15 37 
Ethanol absolute 15 37 
Ethanol absolute 20 37 
Xylene  35 37 
Xylene  35 37 
Paraplast wax  60 60 
Paraplast wax 60 60 
Paraplast wax 60 60 
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Sections were mounted on IHC microscopy slides (Dako, NSW, Australia) and dried overnight 
at 37 ˚C. 
 
3.3.6.6 H & E Staining 
 
Paraffin sections were dewaxed in fresh xylene 1 and 2 for 5 min each, 100 % ethanol, 95 % 
ethanol, 70 % ethanol for 2 min each. Subsequently, the sections were incubated with Mayer’s 
haematoxylin (H) for 5 min before exposure to ammonia water for 30 sec to stain nuclei blue. 
The sections were counterstained with eosin (E) for 1 min and dehydrated with 95 % ethanol 
for 30 sec, 2 steps of 100 % ethanol for 1 min each and finally cleared in 2 steps of fresh xylene 
for 2 min each. Cover-slipping was done manually using a mounting agent (Dako, NSW, 
Australia) before the slides were dried. Finally, the mounted sections were examined using a 
light microscope (Leica DM 2500 microscope, Leica Biosystems, VIC, Australia). Leica 
Application Suite Version 3.4.1 was used to record the images. Digital images were mounted 
into panels and labelled using Adobe Photoshop Software (CS6). All H & E sections of larvae 
were evaluated for any drug-induced gross morphological changes by comparing the number 
of retinal ganglion cells (RGC) between DMSO-treated and drug-treated groups. The number 
of RGC on a 40 x image of each retina was counted and the final count was obtained by 
averaging n=3 retinas from each group.  
 
3.3.6.7 Immunohistochemistry 
 
Paraffin sections were placed in a heater maintained at 60 ˚C for 1 hour. (This step melted the 
paraffin and firmly attached the specimen to the slide). Dewaxing and tissue rehydration were 
performed as described [see section 3.3.6.6 for detail]. Antigen retrieval was achieved by heat 
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(pressure cooker method in 10 mM citrate buffer pH 6 for 10 min). The sections were washed 
with TBS (Tris base: 50 mM, NaCl: 150 mM pH 7.5) followed by incubation with 3 % 
hydrogen peroxide for 20 minutes at RT to block the activity of endogenous peroxidases. The 
sections were washed three times for 5 min each with TBS-T (TBS + 0.05 % Tween-20). To 
block non-specific background staining, the sections were incubated with 10 % goat serum, 1 
% BSA, 1 % Triton X-100 in TBST 2 h at RT before incubating with primary antibodies against 
nitrotyrosine (AB5411-Millipore, 1:400) or NQO1 (ab34173, Abcam) in blocking buffer (1 % 
goat serum, 1 % BSA, 1 % Triton X-100 in TBST) overnight at 4 ˚C (nitrotyrosine) or 30 min 
or 2 h (NQO1). After the sections were rinsed three times with TBST for 5 min each they were 
allowed to react with goat anti-rabbit IgG conjugated to horseradish peroxidase (1:200, 
ab97051-abcam) or its isotype control antibody (rabbit immunoglobulin fraction, Dako X0903, 
1:10 000) in blocking buffer (1 % goat serum, 1 % BSA, 1 % Triton X-100 in TBST) at RT for 
1 h. The sections were washed three times with TBST for 5 min each. The histological signal 
was detected by incubating the sections in 50 µl of 3, 3’-diaminobenzidine (Abcam, England, 
UK) in a chromogen solution (1:50) for 5 min followed by washing with TBST once and with 
water before counterstaining with haematoxylin. The sections were dehydrated and mounted 
using mounting medium (Dako, NSW, Australia) on IHC microscopic slides. Finally, the 
mounted sections were examined using light microscopy (Leica DM 2500 microscope, Leica 
Biosystems, VIC, Australia). Leica Application Suite Version 3.4.1 was used to record the 
images. Digital images were mounted into panels and labelled with Adobe Photoshop Software 
(CS6). 
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3.3.7 Western Blot Analysis Using Zebrafish Tissues 
3.3.7.1 Protein Lysates of Larvae 
 
Protein lysates from zebrafish were prepared according to a protocol described previously 
[356]. 5 dpf euthanized zebrafish larvae (n=10) were transferred in 1 ml ice-cold PBS in 
Eppendorf tubes before deyolking was performed by pipetting the fish up and down 20 times 
using 200 µl pippette tips followed by centrifugation (Eppendorf® Micro Centrifuge, 5417R, 
Eppendorf, NY, USA) at 2000 rcf for 2 min. The supernatant was removed without disturbing 
the layer of larvae at the bottom. In order to remove remaining yolk proteins, the PBS washing 
and centrifugation step were repeated twice.  
 
3.3.7.2 Protein Lysates of Adult Eyes 
  
Adult zebrafish were euthanized in ice-cold water for 20 min and the eyes removed using 
forceps. The eyes were frozen down in liquid nitrogen and stored at -80 ˚C until use. On the 
day of protein sample preparation, the lens of the eyes was removed using sharp forceps and 
the humour squeezed out of the eyeball to prevent dilution of the protein extracts. 
 
Proteins from both larvae and adult zebrafish were extracted using pre-cooled lysis buffer (50 
mM Tris pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM beta glycerol phosphate, 
0.3 % NP-40, 0.1 % SDS, 1 % Triton X-100, 25 mM NaF, 0.1 mM Na3VO4, 1 mM PMSF) at 
2 µl/embryo and 10 µl/adult eye followed by homogenization on ice using a Kontes Pellet 
Pestle (Fisher Scientific, VIC, Australia). The lysate was centrifuged (Eppendorf centrifuge, 
5417R, Eppendorf, NY, USA) at 20 000 rcf at 4 ˚C for 15 min before supernatants were 
transferred to pre-cooled Eppendorf tubes. Determination of protein content and gel 
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electrophoresis was performed as previously described [see sections 2.3.5.3 and 2.3.5.6 for 
detail]. HepG2 cell extracts were used as a positive control for NQO1. NQO1 protein 
expression in the adult zebrafish eyes and the whole larvae was then compared. 
 
3.3.8 Bioinformatics on Zebrafish NQO1 
3.3.8.1 Subcellular Localisation of NQO1 in zebrafish 
 
The nucleotide sequences of four different splice variants of zebrafish NQO1 were obtained 
from ENSEMBL (http://asia.ensembl.org/Danio_rerio/Transcript/Summary?g=ENSDAR 
G00000010250;r=7:56401846-56420909;t=ENSDART00000004964). The nucleotide 
sequences of all splice variants were manually edited to remove introns and only exons were 
translated to protein sequences using an online nucleotide-protein translator 
(http://www.fr33.net/translator.php). From the different reading frames, the protein sequence 
from frame 1 was selected as it generated the largest open ready frame. For all the splice 
variants subcellular localization of NQO1 protein was predicted using online software 
(http://ppopen.informatik.tu-muenchen.de/). 
 
3.3.8.2 Comparison of NQO1 Protein Sequences  
 
Protein sequence data of NADPH dehydrogenase quinone 1 (NQO1) was obtained for 
zebrafish (Danio rerio) from NCBI (http://www.ncbi.nlm.nih.gov/protein). To compare 
protein homology of zebrafish NQO1 against human NQO1, protein-protein BLAST was 
performed between the query sequence (zebrafish NQO1) against non-redundant protein 
sequence of human NQO1.  
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(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins&PROGRAM=blastp&BLAST_PRO
GRAMS=blastp&QUERY=AAH65622.1&LINK_LOC=protein&PAGE_TYPE=BlastSearch
). The search was performed without a sequence filter. Sequences with E values of less than 1 
x10-4 can be considered as homologous. 
 
3.3.9 NQO1 Enzyme Activity on Adult Eye Tissue 
 
The best sectioning method for zebrafish to preserve enzyme activity is to prepare cryosections. 
Cryosectioning was carried out according to a protocol described previously [357,358]. Eyes 
from adult fish were removed immediately after the fish were euthanized and fixed in 4 % PFA 
(in PBS) for 2 h at 4 ˚C. PFA was replaced by 25 % sucrose (in PBS) until the eyes sank and 
then replaced with 35 % sucrose (in PBS) and stored overnight at 4 ˚C. Subsequently, the eyes 
were embedded in cryomolds (10 mm x 10 mm x 5 mm; Tissue-Tek Cryomold, Sakura, USA) 
containing OCT (Tissue-Tek, Sakura, USA) before freezing down in a cryostat (Leica CM 
1850; Leica Biosystems, VIC, Australia) for 10 min. The frozen tissue block was sectioned 
into 25 µm thick sections with the cryotome maintained at -20 ˚C. Eye sections were placed on 
IHC microscope glass slides (Dako, NSW, Australia) and dried at RT for exactly 2 h before 
NQO1 enzyme activity was detected. Shorter drying periods resulted in the loss of tissue during 
the washing steps, while longer drying period resulted in failure to detect NQO1 enzyme 
activity. 
 
NQO1 enzyme activity was detected according to a modified protocol as previously described 
[359]. This assay is based on the reduction of nitro-blue tetrazolium dye (NBT) into its blue 
formazan product in the presence of active NQO1, NAD(P)H and an NQO1 substrate. Briefly, 
the cryosections were washed with Tris-buffer (pH 7.4) to remove excess OCT compound and 
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were preincubated in preincubation solution (25 mM Tris, 0.08 % Triton-x, 2mg/ml BSA) in 
the presence or absence of 100 µM dicoumarol for 30 min at RT. The preincubation solution 
was replaced with buffer containing 100 µM NBT (ab146262, Abcam), 1 mM NADPH (final), 
100 µM NQO1 substrate menadione ± 100 µM dicoumarol. The reaction was incubated at 37 
˚C for 30 min. The development of the characteristic blue stain was observed under a light 
microscope. Subsequently, the sections were dehydrated as described [see section 3.3.6.6 for 
detail] and finally cover-slipped using a mounting medium (Dako, NSW, Australia). Images 
were captured using a light microscope with a digital camera (Leica DM2500; Leica 
Biosystems, VIC, Australia) at a 40 x magnification. Leica Application Suite Version 3.4.1 
was used to record the images. Digital images were assembled into panels and labelled using 
Adobe Photoshop Software (CS6). 
 
3.4 Statistical Analysis  
 
All data are expressed as mean ± standard error of mean (SEM) as indicated in the figure 
legends. Statistical significance was assessed using either Student’s t-test or one-way analysis 
of variance (ANOVA) where appropriate, followed by Dunnett’s multiple comparison tests to 
evaluate the differences between controls and treatment groups using GraphPad Prism (Version 
6, GraphPad Software Inc, CA, USA). In all assays p<0.05 was considered statistically 
significant. 
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3.5 Results 
3.5.1 Determination of Maximum Tolerated Concentration of CQ 
 
In order to translate in-vitro findings of NQO1-dependent CQ toxicity to the in-vivo situation, 
a model system characterized by both high and low NQO1 expression was needed. Luckily, 
zebrafish were only recently reported to lack NQO1 expression in their retina during the early 
larval stages (7 dpf), while NQO1 is highly expressed in the adult retina [348]. Visual function 
was therefore measured in zebrafish to study CQ-induced toxicity under conditions of both 
high (adult) and absent retinal NQO1 (larvae). For initial dose-finding experiments the 
maximum tolerated concentration (MTC) was established by exposing zebrafish larvae (PET 
strain) at 3 days post fertilisation (dpf) to different concentrations of CQ (1 µM - 1 mM) and 
DMSO (0.1 %) for 48 h before startle response and morphological features were examined. No 
mortality was associated with the standard conditions used in this study. Larvae at 3 dpf were 
chosen for the experiment, as the eye development in zebrafish is very rapid [220]. By 3 dpf 
the retinal structure of zebrafish becomes fully functional with progressive advancement in 
image formation [220]. At the same time the extra-ocular muscles become functional, which is 
a prerequisite for the tracking of moving objects by eye movement. PET strain larvae exposed 
to CQ ≥ 30 µM showed absence of heartbeat, startle response and loss of dorso-ventral balance 
as well as morphological defect such as bent body (Table 6). For zebrafish larvae the MTC for 
CQ was determined to be 10 µM. Therefore, only CQ at concentrations up to 10 µM were used 
for visual function test, since at these concentrations the larvae were still alive, have no 
morphological defects and have comparable locomotory activity and dorso-ventral balance to 
DMSO-treated control animals. PET strain zebrafish are from an unknown source and probably 
have a mixed genetic background [360]. Therefore, to work with a genetically distinct 
laboratory strain, we also used the AB strain for the OKR experiments. When 3 dpf AB larvae 
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were exposed to concentrations of CQ that were tolerated in PET larvae, surprising lethality 
was observed at 10 μM after merely 24 h of drug exposure (Table 6). Due to the observed 
inter-strain variation in sensitivity to CQ in zebrafish larvae, the PET strain was selected over 
the AB strain for all further studies involving both larvae (histology) and adult zebrafish. For 
the adult zebrafish study, MTC was not determined, instead the concentration of CQ that 
severely impaired the visual function in PET strain zebrafish larvae was used (Table 7).  
 
Table 6: Effect of CQ on the overall morphology and behaviour of zebrafish larvae 
Strain CQ  
(µM) 
Heart- 
beat 
Morphological 
defects* 
Startle 
response* 
Dorso-
ventral 
balance* 
MTC
  
(µM) 
PET 
 
 
 
 
 
 
 
AB 
1 
3 
10 
30 
100 
300 
1000 
 
1 
3 
10 
Present 
Present 
Present 
Absent 
Absent 
Absent 
Absent 
 
Present 
Present 
Absent 
No 
No 
No 
- 
- 
- 
- 
 
No 
No 
- 
Yes 
Yes 
Yes 
 - 
 - 
 - 
- 
 
Yes 
Yes 
- 
Yes 
Yes 
Yes 
- 
- 
- 
- 
 
Yes 
Yes 
- 
10  
 
 
 
 
 
 
 
3 
*Due to the absence of heartbeat, morphological defects, startle response and dorso-ventral balance 
were not assessed at concentrations > 10 µM. 
 
Table 7: Effect of CQ on the behaviour of PET adult zebrafish 
 
*Combination treatment with CQ and Dic caused death of 4 out of 4 fish within 6 h of treatment. 
 
CQ 
(µM) 
DIC  
(µM) 
CQ+DIC* 
(µM) 
Swimming 
 
Dorso-ventral 
balance 
 
10  
0.5 
 
 
 
10 + 0.5 
Yes 
Yes 
No 
Yes 
Yes 
No 
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3.5.2 CQ Induces Visual Function Loss only in NQO1-deficient Zebrafish Larvae  
 
OKR, a reflexive behavioural response that is elicited by a slow moving object in the visual 
field was employed to assess the effect of different CQ concentrations on the visual function 
of larvae and adult zebrafish. This response combines two eye movements: a smooth pursuit 
which is a slow tracking of a moving object followed by a rapid saccade which is fast resetting 
eye movement in the opposite direction of a moving object [279]. OKR has been extensively 
studied in zebrafish and is routinely used as readouts for visual performance defects in visual 
mutants as well as in drug-induced cases [237,281]. Drug-induced visual toxicity of the drugs 
has been identified by inhibition of OKR. It has to be noted that visual impairment was one of 
the main clinical features of CQ-linked SMON [162]. Therefore, to investigate the effect of 
CQ on visual function, 3 dpf zebrafish larvae were exposed to different concentrations of CQ 
(DMSO, 1, 3, 10 µM) for 48 h followed by measurement of OKR. It was shown that exposing 
larval zebrafish to unidirectional motion stimuli decreased the ratio of eye velocity to the 
stimulus velocity. In contrast, altering the direction of the motion of stimulus reduced saccade 
frequency and as a consequence increased the ratio of eye velocity to stimulus velocity [361]. 
Therefore, in this study, both eyes were stimulated using sinusoidal changing direction. The 
eye velocity was averaged over both eyes. CQ dose-dependently impaired OKR (measured in 
terms of average eye velocity) in the PET strain larvae (Figures 28a and b). A very significant 
drop in eye velocity was observed in the animals treated with ≥ 3 µM of CQ (p=0.0236) 
compared to the DMSO-treated control larvae. Animals treated with 10 µM of CQ were clearly 
not able to follow the visual stimuli, as a result, no eye movements were recorded (p=0.0080). 
Negative eye velocities were observed at this concentration, which could be due to the fact that 
zebrafish exhibited spontaneous eye movements and as a consequence, the pursuit (slow phase) 
movements were faster than resetting movements (Figure 28a). Nevertheless, this dose 
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response is surprisingly consistent with the results from the in-vitro toxicity studies (Figure 
14a).  
 
Using the same parameter, OKR was measured in AB strain larvae exposed to CQ (DMSO, 1, 
3 μM) at 24 h and 48 h. Visual function was not altered at any concentrations of CQ at 24 h 
(Figure 28c), however at 48 h a significant reduction of visual function (Figure 28d) was 
observed compared to DMSO-treated control, which is consistent with the results from the PET 
larvae.  
 
Table 8: Effect of Dic and CQ on the overall morphology and behaviour of zebrafish larvae 
Strain Dic  
(µM) 
+CQ 
(µM) 
Heart-
beat 
Morphological 
defects* 
Startle 
response* 
Dorso-ventral 
balance* 
AB 
 
 
 
 
0.01 
0.1 
1 
3 
0.01 
 
 
 
 
1 
Present 
Present 
Present 
Present 
Present 
No 
No 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
 
In order to test if CQ also induced visual impairment under conditions where NQO1 is highly 
expressed, OKR was measured in adult zebrafish after CQ treatment. The parameters of OKR 
measurement in the adult fish slightly differed from larvae in terms of stimulus direction and 
evaluation of eyes. A directional asymmetry has been reported supporting the movements of 
eyes in a temporal-nasal direction in the adult zebrafish [263]. In this study, both eyes were 
stimulated in one direction (from right to left and left to right) and only the right eyes were 
evaluated. Eye velocities in the nasal-temporal direction were found to be lower than temporal-
to-nasal direction and were also less constant. Therefore, in this study, although both eyes were 
stimulated using a one direction motion stimulus (from right to left) only one eye (right eye) 
that was stimulated in temporal-nasal direction was evaluated. In contrast to the larval OKR 
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results, in the adult zebrafish, 10 µM CQ did not cause any significant reduction in eye velocity 
as compared to DMSO-treated control animals (Figures 28e and f). The obvious question was 
could CQ impair visual function in the adult zebrafish if NQO1 is pharmacologically inhibited? 
In order to address this, adult zebrafish were exposed to dicoumarol (Dic, a known NQO1 
inhibitor), CQ or a combination of both followed by an examination of visual function. The 
concentration of Dic that was used for this experiment was 0.5 µM, which was reported to be 
fairly non-toxic, even to zebrafish larvae [362]. In addition, our experimental data showed that 
zebrafish larvae did not show any sign of toxicity when incubated with 3 µM Dic for 48 h 
(Table 8). Treatment with Dic in the adult zebrafish also did not significantly reduce the eye 
velocity compared to the DMSO-treated control (Figures 28e and f). Strikingly, when NQO1 
was inhibited by Dic, 10 µM CQ was highly toxic to the fish and all fish died unexpectedly 
within 6 h of drugs exposure. This result drastically highlighted the significant toxicity of CQ 
in the absence of NQO1 activity. Due to the severe toxicity, this result was communicated to 
the animal ethics committee (AEC) as an unexpected adverse event. The AEC subsequently 
decided that it would not agree to further concentration finding experiments with the 
combination of Dic and CQ. 
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 Figure 28: Effect of clioquinol (CQ) on visual function of zebrafish. 
 (a, b) CQ impairs visual function of petshop-purchased (PET) zebrafish larvae. 3 dpf PET strain 
zebrafish were exposed to up to 10 µM CQ for 48 h followed by optokinetic response (OKR) 
measurement at 5 dpf at (a) varying angular velocity of stimulus (b) at one angular velocity of 
stimulus (15 deg/sec). The visual function was measured in terms of eye velocity under bidirectional 
motion stimulus. The average velocity of both right and left eye was considered to compare the effect 
of CQ and is represented as % control. The graph shows the average eye velocity of zebrafish larvae 
of a typical experiment. (c, d) CQ impairs visual function of AB strain zebrafish larvae. 3 dpf AB 
strain zebrafish were exposed to CQ at concentrations up to 3 µM for 24 h (c) 48 h (d) followed by 
optokinetic response (OKR) measurement at days 5 dpf at one angular velocity of stimulus (15 
deg/sec). The visual function was measured in terms of eye velocity under bidirectional motion 
stimulus. The average velocity of both right and left eye was considered to compare the effect of CQ. 
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The graph shows the average eye velocity of zebrafish larvae of a typical experiment. (e, f) CQ does 
not impair visual function in the adult zebrafish.  Adult zebrafish were exposed to CQ 10 µM, Dic 
0.5 µM and DMSO for 48 hours under 14:10 light: dark cycle before visual acuity was measured. 
The visual function was measured in terms of eye velocity at varying angular velocity (e) and at one 
angular velocity (15 deg/sec) (f) under unidirectional stimulus. Only the average velocity of right eye 
was considered to compare the effect of CQ. The graph shows the average eye velocity the adult 
zebrafish of a typical experiment.  p* <0.05, ** <0.01 and p*** <0.001 versus control using one-way 
analysis variance (ANOVA) followed by Dunnett comparison tests. Error bar=SEM, n=10. nm: not 
measured. 
 
 
To examine if CQ-induced loss of visual function in zebrafish larvae was the result of a CQ-
mediated morphological defect in the eyes, formalin-fixed paraffin sections of the PET strain 
larvae were used for histopathological examination. Overall the H & E-stained eyes sections 
of larvae were examined for gross morphological defects and numbers of retinal ganglion cells 
(RGC). Although a significant visual function loss was observed in larvae treated with CQ ≥ 3 
µM, no gross morphological changes were detected at any of the tested concentrations 
compared to the DMSO-treated control larvae (Figures 29a-d). However, compared to the 
DMSO-treated group, RGC counts were slightly but significantly (88.18 % ± 1.74 %, 
p=0.0095) reduced in the group treated with the highest concentration of CQ (10 µM) (Figure 
29e). 
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Figure 29: Examination of gross morphological abnormalities in the eyes of clioquinol (CQ)-
treated zebrafish larvae. 
 (a-d) Representative images of formalin-fixed paraffin-embedded eye tissues from PET strain 
zebrafish larvae treated with CQ. (a) DMSO-treated, (b) (1 µM) CQ-treated, (c) (3 µM) CQ -treated, 
(d) (10 µM) CQ -treated. (e) Quantification of the retinal ganglion cells (RGC), in 40 x magnification 
images. Scale bar=100 µm for 40 x magnification. p* <0.05 and p** <0.01 versus control using 
Student’s-t test. Error bar=SEM, n= at least 3.  
 
 
3.5.3 Inhibiting NQO1 Does Not Contribute to CQ-mediated Visual Function 
Loss in Zebrafish Larvae 
 
Although it was reported that NQO1 is not expressed in the larval retina of zebrafish, it was 
nevertheless of interest to confirm this by examining whether the NQO1 inhibitor, Dic could 
modulate CQ toxicity in larvae. Therefore, AB strain larvae were exposed to different 
concentrations of Dic up to 3 µM for 48 h followed by measurement of OKR to establish the 
concentration that does not negatively affect eye velocity. The concentration ranges of Dic used 
in this study were chosen based on previous studies [362,363]. In these studies, Dic was used 
at concentrations ranging from 50 nM – 5 M without reported systemic toxicity in zebrafish 
embryos. Assuming NQO1 is present in the retina of zebrafish larvae, Dic concentrations that 
only inhibit NQO1 without having any effect on visual function itself were required. A non-
significant trend o reduced eye velocity was nevertheless observed at all Dic concentrations 
between 0.1-3 M (p=0.1049, 0.0844 and 0.1117) (Figure 30a). Therefore, a 10-fold lower 
concentration of Dic (0.01 M) was chosen for the combination experiment with CQ to avoid 
direct effects of Dic on visual function. For this combination treatment 1 µM of CQ was chosen, 
as at this concentration a reduction in eye velocity was not observed in both strains of larvae 
(Figures 28a, b and d). Consistent with previous results, CQ at 1 µM had no effect on visual 
In-vivo Studies 
 
149 
 
function after 48 h of treatment (Figure 30b). Moreover, inhibition of NQO1 by Dic did not 
increase the toxicity of CQ in terms of both loss of visual function and lethality. In contrast, 
CQ appeared to counteract the negative trend induced by low-dose Dic. Overall, these results 
are consistent with previous reports that NQO1 is not expressed in the retina of zebrafish larvae 
[348]. 
 
 
 Figure 30: Inhibition of NQO1 has no effect on the visual function of zebrafish larvae. 
 (a) 3 dpf zebrafish (AB strain) were exposed to indicated concentrations of dicoumarol (Dic) for 48 
h under dark-adapted condition before eye velocity was measured by optokinetic response (OKR) at 
5 dpf under bidirectional motion stimulus at spatial frequency (0.11 cycles/deg), angular velocity (7.5 
deg/sec) and contrast (7 %). (b) 3 dpf zebrafish (AB strain) were exposed to indicated concentrations 
of Dic and CQ for 48 h under dark-adapted condition before eye velocity was measured by OKR at 
5 dpf under bidirectional motion stimulus at spatial frequency (0.11 cycles/deg), angular velocity (15 
deg/sec) and contrast (10 %). The average eye velocity of both right and left eye was considered to 
compare the effect of drugs with the DMSO-treated group. The graph shows the average eye velocity 
of one experiment. p* <0.05, ** <0.01 and p*** <0.001 versus control using one-way analysis 
variance (ANOVA) followed by Dunnett comparison tests. Error bar=SEM, n=at least 5. 
 
3.5.4 Immunohistochemical Analysis of NQO1 in Adult Zebrafish Eyes 
 
The experiments described above showed that CQ impaired visual function in NQO1 deficient 
zebrafish larvae and not in the adult zebrafish that presumably express NQO1 in the retinal 
tissue. To confirm NQO1 expression levels in the adult zebrafish retina, formalin-fixed, 
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paraffin-embedded sections of zebrafish eyes were immuno-stained for NQO1. Although 
immunohistochemical staining for NQO1 was positive, it was only observed as nuclear staining 
in the inner photoreceptor layer, inner nuclear layer, outer nuclear layer and retinal ganglion 
cells of the retina (Figures 31a-g). This result was in stark contrast to previous studies that 
showed a primarily cytoplasmic localization of NQO1 in rat liver and pig corpus luteum 
[364,365]. So far, only low levels of NQO1 have been detected in the nucleus under normal 
conditions [366]. This nuclear immunostaining of NQO1 was observed even in sections where 
antibody dilutions of up to 32 times lower than the recommended dilution were used. More 
importantly this pattern of staining was also observed in the retina of zebrafish larvae that 
reportedly lack retinal NQO1 expression (Figure 32). Since these results would indicate non-
specific staining of the primary antibody, the primary antibody was replaced with a non-
specific IgG isotype (negative control). Since this control showed a complete absence of 
immunostaining under identical conditions, it is unclear at present with which nuclear epitope 
the anti-NQO1 antibody cross reacts.  
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Figure 31: Anti-NQO1 antibody staining in the adult zebrafish retina. 
Representative images of NQO1 staining of adult zebrafish retina. Formalin-fixed paraffin-
embedded adult (PET strain) retinal-sections were incubated with anti-NQO1 antibody for 30 min 
at different antibody dilutions before NQO1 expression was examined. (a)1:200, (b)1:400, (c)1:800, 
(d)1:1600, (e)1:3200, (f)1:6400, (g) nonspecific-IgG (negative control). Scale bar indicates 100 µm 
for all images. Images were taken at 40 x magnification. 
In-vivo Studies 
 
152 
 
 
Figure 32: Anti-NQO1 antibody staining in the retina of zebrafish larvae. 
a) Representative image of NQO1 staining of zebrafish larvae retina. Formalin-fixed paraffin-
embedded larval (PET strain) retinal-sections were incubated with anti-NQO1 antibody for 2h at 
1:200 antibody dilution before NQO1 expression was examined. b) Nuclear staining in RGC layer is 
shown at high magnification.  Scale bar indicates 100 µm. Image was taken at 40 x magnification. 
 
. 
3.5.5 Western Blot Analysis of NQO1 in Adult and Larval Zebrafish 
 
Since confirmation of NQO1expression in the retina through immunostaining provided 
inconclusive results, quantification of NQO1 expression was attempted by western blotting in 
both larvae and adult zebrafish eyes. Due to the small size of larvae (3-4mm), eyes could not 
be harvested and instead whole larvae were used for the analysis whereas only the eyes were 
harvested from the adult fish. HepG2 cells were used as a positive control. Protein bands for 
NQO1 in both larvae and adult eyes were detected. However, the molecular weight of the 
detected proteins did not correspond to the predicted size based on the protein sequences or the 
band detected in HepG2 cells (band size of NQO1= 31 kDa). A protein band derived from 
extracts from adult eyes was detected around 10 kDa whereas extracts from larvae produced a 
band of 45 kDa (Figure 33). It is worth stating that the anti-NQO1 antibody used for western 
blot analysis cross reacts with mouse, rat, guinea pig, human due to the significant level of 
NQO1 sequence homology across species but had not been evaluated for zebrafish before.  
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Figure 33: Western blot analysis of NQO1 in zebrafish. 
Representative western blot of NQO1 in zebrafish (whole 5 dpf larvae vs. adult eyes). Protein lysate 
of HepG2 cells was used as a positive control. 
 
 
3.5.6 Prediction of Cytoplasmic Localization of NQO1 in Zebrafish 
 
Since the immunohistochemistry result appeared to show nuclear localization of NQO1 in 
zebrafish, which is contradictory to the published reports in humans and other organisms 
[366,367], it was of interest to explore the subcellular localisation of NQO1 in zebrafish 
employing bioinformatics. Five different NQO1 splice variants (one without corresponding 
protein) have been described in ENSEMBL. Protein sequences translated from the coding 
region of the reported nucleotide sequences of four NQO1 splice variants were analysed, which 
predicted that NQO1 in zebrafish should also be cytoplasmic as described for all other 
organisms (Figures 34a-c). 
 
 
 
µg 
Number 
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Figure 34: Subcellular localization of NQO1 in different splice variants of zebrafish. 
(a) (a) Five different NQO1 splice variants of zebrafish have been described in ENSEMBL [368]. (b, c) 
All four different NQO1 splice variants of zebrafish are predicted to localize exclusively to the 
cytoplasm with a predicted confidence of 41 %-50 %. [369]. 
 
 
3.5.7 Zebrafish and Human NQO1 Display Genetic Homology 
 
After confirmation that NQO1 zebrafish should also be localised to the cytoplasm, it was 
suspected that NQO1 in zebrafish may not be homologous enough compared to human NQO1 
for antibody detection. Consequently, it was likely that the anti-NQO1 antibody specific to 
human NQO1 might have resulted in false positive results. Therefore, the homology of human 
and zebrafish NQO1 was analysed by blasting zebrafish NQO1 protein sequence against the 
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non-redundant human protein sequence (Figures 35a and b). From the data, it was revealed 
that human and zebrafish NQO1 display a protein sequence homology of 47-50 % (Figure 
35c). To further confirm this, the manufacturer of the antibody was contacted for the exact 
immunogen sequence the anti-NQO1 was raised against, unfortunately, this information was 
not disclosed. Hence, it cannot be confirmed the NQO1 epitope the antibody was raised against 
is present in zebrafish NQO1 protein.  
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Figure 35: Comparison of NQO1 protein sequences. 
Percentage identity of NQO1 protein between zebrafish isoform 1 (a, c) or isoform 2 (b, c) against the 
human NQO1 consensus sequence. 
 
Protein 
(Zebrafish) 
Accession  
Number 
Expect 
(E) 
% Identity 
  Human 
NAD(P)H dehydrogenase [quinone] 1 
isoform 1 
(289 amino acid) 
NP_001191201.1 2e-92 47 
NAD(P)H dehydrogenase [quinone] 1 
isoform 2 
(275 amino acid) 
NP_991105.1 3e-92 50 
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Figure 36: Multiple sequence alignments of human NQO1 and zebrafish NQO1 splice variants. 
Protein query sequences of all zebrafish NQO1 splice variants and human NQO1 were aligned using 
clustalW2 software [370]. 
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Figure 37: Post-translational modification sites in human and zebrafish NQO1 protein.  
Post-translational protein modification sites of human NQO1 were obtained from PhosphoSitePlus 
[371]. Putative protein modification sites of zebrafish NQO1 slice variants were shown based on 
conserved amino acid between human and zebrafish NQO1. PMW: predicted molecular weight. 
 
 
It has to be remembered that beside detecting protein bands inconsistent with the predicted 
size, which should be similar to human NQO1, NQO1 in larvae and adult zebrafish was 
detected at two different molecular weights (Figure 33). The detection of NQO1 protein of the 
same species at two different molecular weights could possibly be attributed to the existence 
of different NQO1 splice variants with different size. To investigate this possibility, the protein 
query sequences of all zebrafish splice variants were aligned using clustalW2 [370]. Alignment 
of multiple NQO1 sequences from all splice variants demonstrated large regions of homology 
to each other except for a non-coding NQO1 splice variant (Figure 36). Furthermore, 
identification of the putative post-translational protein modification sites in zebrafish NQO1 
splice variants based on homologous amino acid of known protein modification sites on human 
NQO1, indicate that in general the NQO1 protein is very conserved between human and 
zebrafish (Figure 37). 
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3.5.8 NQO1 Protects Against CQ-induced Vision Loss in Adult Zebrafish 
 
With the unsatisfactory immunohistochemistry and western blot results and more importantly 
due to unavailability of an anti-NQO1 antibody specific for zebrafish, NQO1 enzyme activity 
was detected instead, to explore the difference in NQO1 in the retinal layers of adult zebrafish 
(Figure 38). NQO1 enzyme activity was visualized in cryosection of zebrafish retinas from 
DMSO- and drug-treated adult fish. A strong positive histochemical staining reaction was 
observed in the retina of DMSO-treated adult animals in the presence of the NQO1 substrate-
menadione, NBT and NADPH. The resulting staining pattern was more diffuse as previously 
reported for the rat brain [359,367]. Overall, the staining extended throughout the different 
retinal layers, particularly in the photoreceptor layer (PR-outer segment), inner nuclear layer 
and retinal ganglion layer (Figure 39a). Since DMSO has been reported to induce oxidative 
stress in yeast[372], it was of interest to confirm whether DMSO contributed to the observed 
NQO1 staining. However, NQO1 enzyme activity in the DMSO-treated animals did not differ 
from the untreated animals (data not shown), indicative of a lack of interference by DMSO.  In 
CQ-treated fish, however, the staining intensity was reduced (Figure 39b) and was mainly 
restricted to the PR-outer segment and the inner nuclear layer. In Dic-treated animals (Figure 
39c) the staining was only observed in the photoreceptor layer, while it could hardly be detected 
in CQ- and Dic-treated animals (Figure 39d).  
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Figure 38: Retinal layer in zebrafish. 
Formalin-fixed paraffin embedded H & E section of the adult zebrafish retina. The retinal layer 
comprises of retinal pigment epithelium layer (RPE), photoreceptor layer (PR), which consists of 
outer segment and inner segment, outer nuclear layer (ONL), outer plexiform layer (OPL), inner 
nuclear layer (ONL) and retinal ganglion cells (RGC). Scale bar indicates 100 µm. Image was taken 
at 40 x magnification. 
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Figure 39: Histochemical detection of NQO1 enzyme activity in the adult zebrafish retina. 
Representative images of NQO1 enzyme activity in the adult zebrafish retina. Retinal cryosections 
of adult zebrafish were exposed to 100 µM menadione, 1 mM NADPH, 100 µM NBT for 30 min 
at 37 ˚C. A blue staining reaction was observed. (a) DMSO-treated (b) CQ- treated (10 µM), (c) 
Dic- treated (0.5 µM), (d) CQ and Dic- treated (10 µM and 0.5 µM). All in-vivo treatments were 
carried out for 48 hours except for the combination treatment where 4 out of 4 fish died within 6 
hours of commencing the treatment. Scale bar indicates 100 µm for all images. Images were taken 
at 40 x magnification. 
 
 
 
3.5.9 CQ Induces Oxidative Stress in the NQO1-Inactivated Zebrafish Retina 
 
After observing the status of NQO1 enzyme activity in control and drug-treated animals, it was 
of interest to examine CQ-induced oxidative stress in the adult retina under conditions of 
inactivated NQO1. As a marker for oxidative stress, the presence of nitrotyrosine was detected 
in formalin-fixed, paraffin-embedded retinal sections of DMSO- and drug-treated adult 
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zebrafish. A weak immunoreactivity for nitrotyrosine was observed in Dic (0.5 µM)-treated 
and CQ (10 µM)-treated fish particularly around the photoreceptor and RGC layer (Figures 
40b and c) compared to DMSO-treated fish (Figure 40a). In contrast, in the CQ + Dic-treated 
animals, a very strong immunoreactivity for nitrotyrosine was widely detected in all retinal cell 
layers, indicative of significantly elevated levels of oxidative stress induced by CQ when 
NQO1 was inactivated (Figure 40d). These results are in agreement with CQ-induced ROS 
production that was observed in in-vitro.  
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Figure 40: CQ induces oxidative stress in the NQO1 inactivated zebrafish retina. 
Representative images of nitrotyrosine staining of the adult zebrafish retina. Formalin-fixed, 
paraffin-embedded sections of adult zebrafish retina were subjected to immunohistochemical 
staining for nitrotyrosine, (a) DMSO-treated, (b) CQ-treated (10 µM), (c) Dic-treated (0.5 µM), (d) 
CQ + Dic-treated (10 µM + 0.5 µM) (e) negative control (where primary antibody in (d) was 
replaced with non-specific IgG). All the treatments were carried out for 48 h except for the 
combination treatment (CQ + Dic; d) where 4 out of 4 fish died within 6 hours of treatment. Scale 
bar indicates 100 µm for all images. Images were taken at 40 x magnification. 
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3.6 Discussion 
3.6.1 Suitability of an Animal Model 
 
In order to translate the in-vitro results to the in-vivo situation, a suitable animal model was 
required. The described in-vitro results consistently indicate that CQ-induced toxicity is 
inversely correlated with NQO1 expression. To test this hypothesis in in-vivo, the essential 
requirement for a suitable animal model would include conditions of high and low/no NQO1 
expression. Zebrafish were only recently reported to lack retinal NQO1 expression during their 
early larval stages (7 dpf), while NQO1 is highly expressed in the adult retina [348]. Low 
NQO1 activity during the early developmental stage of zebrafish is supported by a different 
study where the NQO1 inhibitor dicoumarol (Dic) failed to regulate the toxicity of menadione 
(detoxified by NQO1) and the activity of β-lapachone (bioactivated by NQO1) in zebrafish 
embryos [362]. This suggested that in the larvae the lack of NQO1 prevents detoxification and 
bioactivation of drugs [362]. This concept is further supported by the present study, where Dic 
failed to modulate CQ toxicity in zebrafish larvae. Incubation of zebrafish larvae with up to 3 
µM Dic was non-toxic and showed no significant effect on visual performance compared to 
DMSO-treated controls. Furthermore, NQO1 inhibition by Dic at a non-toxic concentration of 
CQ (1 µM) neither affected visual function nor caused lethality in zebrafish larvae. This could 
be explained by the absence of retinal NQO1 but also by generally very low NQO1 enzyme 
activity in other tissues as previously reported (59, 60).  
 
It has to be noted that visual impairment was one of the major adverse effects in patients that 
used oral CQ. Since the larvae and adult zebrafish have been reported to differ with regards to 
NQO1 expression in their retina, visual function was measured to study CQ-induced toxicity 
under conditions of both high (adult) and absent retinal NQO1 (larvae).  
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3.6.2 Strain-dependent Sensitivity of CQ Toxicity 
 
In the present study CQ and Dic were added to the zebrafish media and maximum tolerated 
concentrations (MTC) were determined before visual acuity was assessed. Only around 3 dpf 
the zebrafish mouth opens, by 4-5 dpf coordinated peristalsis waves starts while the gills 
become functional around 14 dpf [373]. Therefore, until 3 dpf, drug absorption is only possible 
through the skin and until 14 dpf the drug is absorbed both through the skin and via the mouth 
[373]. Overall, the drug logP correlates with drug absorption in zebrafish larvae. In a study, out 
of 19 drugs tested with a logP >1, 18 showed pharmacological effects in zebrafish larvae, 
indicating that the drugs with logP >1 are successfully absorbed by zebrafish larvae [286]. In 
this context, CQ with log P value of 3.36 would likely be absorbed through the skin to result 
in significant tissue concentrations to show pharmacological effects. It can be argued that tissue 
drug concentrations are directly related to their pharmacological effects. Although HPLC 
methods have been developed to measure tissue drug exposures [374], the present study did 
not aim to predict drug effects quantitatively but focused instead on the qualitative examination 
of drug effects on visual function [286]. 
 
Although zebrafish have been increasingly used as a model organism for many years now, 
there is only limited information available on physiological differences underlying genetic 
differences among the most frequently used inbred strains of zebrafish including AB, PET, 
Tuebigen (TU) and Tuptel long fin (TL) [360]. Strain-dependent responses to ethanol 
exposure-induced disturbances in developmental processes have been reported in zebrafish 
[375]. With regards to embryonic lethality of ethanol exposure, zebrafish belonging to the EK 
(Ekkwill) strain were the most resistant strain, AB were moderately affected and TU were the 
most susceptible. These strain-specific differences have also been observed in the present study 
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with regards to CQ sensitivity of zebrafish larvae. PET strain zebrafish were more resistant to 
CQ-induced acute toxicity compared to the AB strain. As a consequence, the MIC for CQ in 
the PET strain was more than 3 times higher compared to the AB strain zebrafish larvae, which 
implies that genetic variation between these two strains likely contributes to the variable 
response to CQ exposure. Since a recent study reported a significant mtDNA diversity within 
different “wild-type” strains of zebrafish [376], it is likely that these differences contributed to 
the increased sensitivity of the AB strain to mitochondrial toxin such as CQ observed in this 
study. 
 
3.6.3 Mitochondrial Function and Vision  
 
In the present study, CQ was shown to impair mitochondrial function in in-vitro. There is a 
growing body of evidence that suggests a mitochondrial dysfunction is a primary event in many 
ocular diseases [31]. At the same time, typical clinical phenotypes of ocular diseases such as 
bilateral central vision loss, colour vision loss and loss of retinal ganglion cells are also 
dominant characteristics of many inherited mitochondrial diseases [31]. This connection is in 
agreement with the bilateral visual impairment, colour vision loss and RGC loss reported in 
humans after CQ administration [167]. Comparable to the responses to CQ exposure in SMON 
patients, CQ-treatment also significantly decreased visual function in zebrafish larvae. 
Intriguingly, the CQ concentration range that produced visual impairment in zebrafish larvae 
was surprisingly consistent with the toxic effects that were observed in this study for CQ in in-
vitro, which further supports the hypothesis that mitochondrial dysfunction could be the key 
event that leads to loss of vision. 
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To correlate drug-induced vision loss with potential morphological defects, retinas from 
zebrafish larvae that were treated with CQ or DMSO were analysed histologically. 
Surprisingly, overall eye morphology of CQ-treated larvae was largely unaffected and 
therefore did not account for the observed visual defects at lower CQ concentrations up to 3 
µM. Only the highest CQ concentration tested (10 µM) resulted in a small but significant 
decrease in RGC numbers. In addition, under these conditions, the lens appeared to be 
somewhat shrunk. However, since this feature was not described in SMON patients and could 
possibly be the result of histological artefacts, this effect was not explored any further.  
 
It is noteworthy to mention here that autopsy of patients with SMON revealed severe lesions 
at the distal end of the optic tract around the lateral geniculate body. The proximal optic nerve 
was less severely affected and the inner ganglion cells of the retina least severely affected 
[162].  This specific pathology could well explain the visual defects observed in CQ-treated 
fish and support our finding that RGC were only slightly affected. However, CQ-induced 
lesions were not examined beyond the RGC layer in this study. Overall, the observed CQ-
induced vision loss and RGC loss in zebrafish larvae within 48 h support the notion that low 
concentrations of CQ are strongly neurotoxic in in-vivo.   
  
3.6.4 NQO1-dependent Protection Against CQ-induced Vision Loss 
 
It has been suggested that NQO1 expression negatively regulates drug-induced mitochondrial 
dysfunction both in in-vitro and in-vivo models [377]. High NQO1 expression decreased the 
sensitivity of cells to mitochondrial toxin-induced oxidative stress, energy depletion and cell 
death [332]. Similarly, NQO1 knockout mice were highly susceptible to drug-induced 
hepatotoxicity resulting in elevated ROS levels, mitochondrial dysfunction-mediated energy 
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depletion compared to the wild-type controls [331]. Mitochondrial dysfunction has been 
implicated in the major ocular diseases such as age-related macular degeneration, diabetic 
retinopathy and glaucoma [31]. Since NQO1 is reported to be absent in zebrafish larvae, it 
appears not surprising that CQ induced vision loss in a dose-dependent manner in these 
animals. This effect is likely due to the mitochondrial-dysfunction of CQ in the absence of 
NQO1. The protective effect of NQO1 against CQ-induced vision loss was further examined 
in the adult zebrafish where NQO1 is reported to be highly expressed in the retina [348]. 
 
Consistent with the hypothesis of this study, and in contrast to the zebrafish larvae, CQ even at 
the highest concentration did not impair visual function compared to DMSO-treated controls 
in PET adult zebrafish. In an attempt to investigate the effect of CQ under conditions of 
inactivated NQO1, adult zebrafish were treated with CQ and/or Dic followed by assessing their 
visual acuity. Visual function was not impaired when NQO1 was inhibited. However, the 
combination of CQ and Dic led to the unexpected death of fish within only a few hours after 
the start of treatment. This acute toxicity can be attributed to the systemic inhibition of NQO1 
in the major tissues such as heart, liver and brain. Although this study did not investigate the 
reason for this dramatic acute toxicity in detail due to significant concerns by the local animal 
ethics committee, this result strongly supports the hypothesis that CQ is very toxic under 
conditions where NQO1 is inactivated or absent, which is surprisingly consistent with the in-
vitro data of this study. Overall, NQO1 expression seems to protect against CQ-induced vision 
loss in the adult zebrafish.  
 
Zebrafish are reported to possess Nrf2-keap1 system [378]. In fact, Nrf2 and Nrf2-target genes 
such as GSTπ, NQO1 and GCSH are reasonably conserved between zebrafish and mammals 
[378]. Exposure of zebrafish to pro-oxidants induced Nrf2 and Nrf2-target genes such as GCLC 
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and NQO1 [378-381]. However, these studies only assessed mRNA expression and so far, there 
are no reports regarding measurement of NQO1 protein expression in zebrafish. In the current 
study, we were unable to confirm the presence of NQO1 protein in the retina of adult zebrafish 
due to the unavailability of zebrafish-specific anti-NQO1 antibodies. NQO1 is reported to 
localise primarily to the cytoplasm [366], which is in stark contrast to the current study where 
exclusively nuclear NQO1 immunostaining was observed with an anti-NQO1 antibody that 
was predicted to cross-react with zebrafish NQO1. Furthermore, in western blots, NQO1 
protein from adult and larval zebrafish was detected at two different molecular weights and 
both of them did not correspond to the predicted size of human NQO1. The bioinformatics 
analysis predicted that all four zebrafish NQO1 splice variants to be cytoplasmic. These splice 
variants differ mainly in the presence or absence of a 14 amino acid region encoded by exons 
4 and 5. The variants (003 and 001) lack these amino acids, which is consistent with human 
NQO1. In contrast, NQO1 variants (201 and 004) contain this particular amino acid sequence. 
There was a possibility that the detection of zebrafish NQO1 at two different molecular weights 
in the western blot could possibly be due to the presence of these NQO1 splice variants. 
However, the predicted molecular weights of these splice variants range from 21-32 kDa and 
are therefore unlikely to correspond to the molecular weight of about 45 and 10 kDa observed 
for larvae and adult fish respectively. These observations further question the specificity of the 
available anti-NQO1 antibody. Although this problem could have been solved by raising 
Zebrafish-specific NQO1 antibodies, this was clearly beyond the scope of this study but should 
be considered for future studies. 
 
A linear relationship between NQO1 protein content and activity has been reported in 
transfected cell lines, indicating that the expressed protein is active [382]. In addition, no major 
posttranslational modification that would affect NQO1 activity has been described. However, 
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there is the possibility that despite normal NQO1 levels, the NQO1 activity can be 
compromised {reviewed by [300]}. Different factors are described that can affect NQO1 
activity such as drugs (dicoumarol and flavonoids), advancing age, and cigarette smoke 
{reviewed by [300]}. Therefore, measurement of NQO1 activity can be seen as a much more 
relevant assessment compared to protein expression alone. Hence, NQO1 enzyme activity was 
measured in the retina of adult zebrafish. A strong staining reaction for NQO1 was observed 
in DMSO-treated adult animals, indicating high NQO1 enzyme activity. The staining was 
diffuse and visible in all retinal layers from the photoreceptor layer to the retinal ganglion cell 
(RGC) layer. This is somewhat consistent with the previous result in mice where NQO1 was 
reported to be expressed in the inner segment of the photoreceptor layer and RGC cells [383]. 
The positive staining of NQO1 activity in the photoreceptor layer in zebrafish, however, is in 
contrast to another study, where NQO1 mRNA expression was reported to be absent in the 
entire photoreceptor layer [348]. In Dic-treated fish, NQO1 staining was observed only in the 
photoreceptor layer. The inhibition of NQO1 activity staining in the most part of the retina of 
Dic-treated animals is most likely due to the inhibition of NQO1 enzyme activity, while the 
Dic-insensitive staining in the photoreceptor layer may be attributed to other reductase activity 
or different enzymes altogether [359]. It is intriguing to note that the NQO1 staining was first 
reduced in the RGC layer. This could indicate that RGCs have greater sensitivity to CQ 
treatment or could be that CQ gets access to the RGC layer first. However, these possibilities 
were not further explored in this study. Since the combination of CQ and Dic completely 
abolished the staining reaction, and the current study showed that both compounds inhibit 
NQO1 activity, it is likely that either NQO1 activity is measured or that CQ also inhibits the 
postulated unknown reductase as well. These results strongly suggest that NQO1 is present in 
the retina of adult zebrafish as reported and can, therefore, explain the NQO1-dependent 
protection against CQ-induced vision loss in adult fish versus the toxicity observed in larvae. 
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3.6.5 Oxidative Stress and CQ-induced Vision Loss 
 
The retina is rich in polyunsaturated fatty acids that are highly vulnerable to ROS and thus are 
easily peroxidised [384]. Excess ROS are normally detoxified by antioxidants present in the 
retina. However, any imbalance between ROS production and detoxification, due to 
disturbances in the antioxidant systems or mitochondrial dysfunction-induced excessive ROS 
production, may result in oxidative stress in the retina [31,385]. The tight connection between 
excess ROS and retinal function is highlighted by several animal models of ocular diseases that 
are based on changing the balance between ROS production and antioxidant protection. 
Recently, an imbalance between pro-oxidant and Nrf2-dependent antioxidant genes (NQO1, 
heme oxygenase 1, glutathione S-reductase) have been shown to play an important role in the 
onset and progression of age-related macular degeneration [386]. Furthermore, involvement of 
NQO1 in retinal pathology was shown indirectly in a study where Nrf2 deficient mice 
developed age-related retinopathy [387]. This is in line with the result of the present study 
where inactivation of retinal NQO1, by itself already increased oxidative stress levels in the 
retina. It is likely that the level of ROS production was insufficient to alter visual function in a 
relatively short period of time. However, the combination of Dic and CQ in the adult zebrafish 
caused significant levels of oxidative damage in the retina. This result thus unequivocally 
supports the finding of the in-vitro study and suggests that oxidative stress is the mechanism 
of CQ–induced neurotoxicity. Therefore, our results directly support the possibility that the 
SMON cases in Japan could be a direct consequence of CQ exposure under conditions of absent 
or dysfunctional NQO1 protein.  
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Chapter 4:  General Conclusion 
4.1 Summary 
 
A number of widely used drugs are reported to cause mitochondrial dysfunction and many are 
implicated in mitochondrial dysfunction-induced optic neuropathy [31]. With the aim to 
identify potential mitochondrial toxins, an in-vitro screen of around 200 drugs and drug-like 
compounds was performed. Two compounds 5-chloro-7-iodo-8-hydroxyquinoline (CQ) and 8-
hydroxyquinoline (8-HQ) were returned as hits. The fact that these two compounds share a 
common 8-hydroxyquinoline ring structure strongly supported the finding of the screen. A 
literature search on these two compounds revealed that CQ, a quinoline derivative, was widely 
used (1950 to 1969) as a topical disinfectant and as an oral anti-microbial agent to treat 
diarrhoea. However, its oral form was banned in many countries after being linked to endemic 
outbreak of SMON (subacute mylo-optic neuropathy) affecting 10, 000 people in Japan [167]. 
SMON was characterised by abdominal pain, subacute ascending dysesthesia, paresthesia of 
lower extremities and bilateral visual impairment [162,166]. Although a clear mechanistic 
connection remained elusive up to now, a reduction in the incidence of SMON was witnessed 
following the withdrawal of CQ from the market. Furthermore, the common pathological 
features of SMON-associated neurotoxicity have been successfully recapitulated in CQ-treated 
animals, which support a direct connection [176,177]. Despite ample evidence for their 
neurotoxicity, CQ and 8-HQ analogues have re-emerged as a potential therapeutic agent for 
the treatment of neurodegenerative diseases such as Alzheimer’s (AD), Huntington’s (HD) 
with some promising pre-clinical and clinical results [188,200,202,209-211,214,215]. These 
therapeutic outcomes are thought to be based on the metal chelating properties of CQ and its 
structural analogue PBT-2 [187-189,203,214,215]. Metal-induced oxidative stress by Zn, Cu, 
and Fe has been implicated in neocortical amyloid formation and deposition in AD brains as 
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well as aggregation of mutant huntingtin protein in HD [203,215]. In line with the proposed 
pathology of these neurodegenerative diseases, it was reported that CQ chelates and 
redistributes metal ions. As a consequence CQ is thought to disaggregate the existing as well 
as reduce de novo amyloid deposition in AD and reduce mutant huntingtin protein aggregates 
in HD [203,215]. In light of the obvious contradictory activities of CQ, neurotoxicity on the 
one hand and neuroprotection on the other, a thorough understanding of CQ-induced toxicity 
is warranted to prevent potential CQ-treatment associated adverse effects.  
 
In this study, I investigated the mechanism of CQ-induced toxicity in in-vitro and in-vivo. 
Using a number of in-vitro based assays, it was observed that CQ and its parent compound 8-
HQ induced mitochondrial-dysfunction in RGC5 cells both as a result of short- and long-term 
treatment. However, attempts to confirm this toxicity in a different cell line (HepG2) were 
unsuccessful. Unrelated observations from a different project suggested that one major 
difference between the two cell lines used (RGC5, HepG2) is their ability to respond to drugs 
and drug-induced oxidative stress. This ability is associated with significantly different 
expression levels of the antioxidant gene product NQO1. Western blot analysis revealed that 
RGC5 cells that were sensitive to CQ-mito toxicity have much lower NQO1 expression 
compared to HepG2 cells, which were CQ-resistant. NQO1 dependent CQ mitochondrial-
dysfunction was then confirmed in several isogenic cell lines that differ only in their NQO1 
levels. In these cells, expression of NQO1 was positively correlated with protection against 
CQ-induced mitochondrial-dysfunction. Furthermore, the present study clearly demonstrated 
that CQ-induced mitochondrial dysfunction was mediated through increased levels of oxidative 
stress by the observation that exogenous antioxidants were able to rescue CQ-induced 
mitochondrial-dysfunction. The inverse correlation between NQO1 expression and CQ toxicity 
observed in this study suggested a biochemical interaction between these two molecules. 
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Through both cell free and cell-based methods, it was revealed that CQ inhibited NQO1 
enzyme activity in a dose dependent manner. 
 
Based on the in-vitro results, zebrafish were chosen as a model system for many reasons. 
Firstly, zebrafish are reported to lack retinal NQO1 expression during their larval stage, while 
NQO1 is highly expressed in the adult retina. As a consequence, this model allows us to test 
CQ-induced toxicity in a situation of both absent and high NQO1 levels in the retina. Secondly, 
zebrafish are increasingly used as a model organism for toxicity screening and are a validated 
model for visual safety assessment of drugs [281,284]. The other reasons include a rapid eye 
development that allows examining visual function only 5 dpf and the high resemblance of 
their visual system with the human eye when compared for example to rodent models. 
Comparable to the human situation, CQ induced visual impairment in zebrafish larvae deficient 
in retinal NQO1 in a dose dependent manner. In contrast, visual function was not at all affected 
by CQ in the adult zebrafish that express high levels of retinal NQO1. This protective role of 
NQO1 against CQ-induced loss of visual function was confirmed by the presence of NQO1 
enzyme activity in the retinal section of the adult zebrafish. Consistent with this activity, 
positive immunostaining for nitrotyrosine, a marker for oxidative damage, was observed in 
retinal section of CQ-treated adult zebrafish where NQO1 had been inactivated 
pharmacologically. Furthermore, under these conditions, CQ also caused acute systemic 
toxicity in the adult zebrafish. These in-vivo results are in line with the in-vitro findings 
suggesting CQ-induced toxicity that is mediated by increased levels of oxidative stress and is 
dependent on expression of functional NQO1. 
 
Overall, the in-vitro and in-vivo results of the present investigation reinforce the concept that 
CQ and its parent compound 8-HQ induce mitochondrial dysfunction through oxidative stress 
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(Figure 41). Importantly, comparable to CQ-induced pathology in human SMON patients, the 
in-vivo data suggests that CQ treatment can lead to a clear dose-dependent loss of visual 
function under conditions of low or absent NQO1 expression or in the presence of an inactive 
NQO1 protein. Expression of NQO1 protected against CQ-induced mitochondrial-dysfunction 
in-vitro and vision loss in-vivo. The exact mechanism on how CQ-induced mitochondrial 
dysfunction and vision loss is attenuated by NQO1 still needs further investigation.  
 
 
Figure 41: Possible mode of CQ-induced neurotoxicity. 
CQ-induces cellular neurotoxicity through DNA breaks, activation of ATM (markers for DNA damage) 
and subsequent activation of p53 and its target genes that finally leads to apoptosis [184]. CQ-treatment 
also reduced histone acetylation, a process essential for DNA-repair and the transcriptional activation 
of genes that are responsible for cell proliferation [186]. CQ was also reported to produce cellular 
toxicity through oxidative stress by inhibition of superoxide dismutase 1 [182]. CQ induced 
mitochondrial dysfunction through oxidative stress which was prevented by NQO1. One possibility is 
that NQO1 can prevent CQ-induced mitochondrial-dysfunction through p53-dependent upregulation of 
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mitochondrial antioxidants genes.  Blue lines indicate experimental results of the present study, red and 
black lines indicate published results from previous studies. SOD: Superoxide dismutase; ROS: 
Reactive oxygen species; ATM: Ataxia Telangiectasia mutated; Nrf2: Nuclear factor erythroid 2-related 
factor 2; GPx: Glutathione Peroxidase 1; OH-1: Heme oxygenase 1; AO: Antioxidant; LP: Lipid 
Peroxidation.   
 
4.2 Implication of the Study 
  
In this study, the mechanism of CQ-induced toxicity was investigated both in in-vitro and in-
vivo and CQ-induced oxidative stress was identified as a key component of CQ toxicity. 
Moreover, in line with this underlying source of toxicity, a tight connection between NQO1 
and CQ toxicity was identified, which for the first time could potentially explain the restriction 
of CQ-induced SMON to the Japanese population.  
 
NQO1 is an FAD-containing cytosolic protein that catalyses the two-electron reduction of 
quinones and other compounds and prevents the production of semi-quinones, free radicals and 
ROS, thus protecting cells and tissues against oxidative stress. Since NQO1 expression/ activity 
is inversely correlated to CQ toxicity, it is essential to consider factors affecting NQO1 enzyme 
activity. There are several different factors that can inhibit NQO1 activity such as age, drugs 
(flavonoids, dicoumarol) but also a genetic predisposition. The most prominent reason for 
reduced NQO1 activity is NQO1 polymorphisms [300]. The most frequent and best-studied 
human NQO1 polymorphism is NQO1*2. NQO1*2 (C609T or Pro187Ser) is a single 
nucleotide polymorphism, a C to T change at position 609, which results in a proline to serine 
substitution at amino acid 187 of the protein. This polymorphism affects NQO1 protein 
stability and therefore the available NQO1 activity [388]. Heterozygote carriers (C/T) only 
show about 50 % NQO1 protein and activity compared to carriers of the C/C genotype. 
Homozygote carriers (T/T) only show very low to undetectable residual NQO1 activity 
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[389,390]. The striking connection of this to the Japanese SMON cases is a much higher 
prevalence (nearly 3-4 fold higher) of this inactivating C609T NQO1 polymorphism in 
Japanese and Asian populations compared to the African or European population [391,392] 
(Table 9). In the Europeans nearly 80 % of individuals harbour the normal C/C NQO1 
genotype. In contrast, nearly 70 % of the Japanese population (overall Asian) carries the 
inactivating C/T or T/T NQO1 genotype. Given this higher prevalence of NQO1 polymorphism 
in Japanese patients, these individuals should be much more susceptible to the toxicity of CQ. 
This hypothesis exactly aligns with the in-vitro data of this study where CQ-induced toxicity 
was mainly observed in the cell lines that already have low NQO1 expression or activity. 
Further inhibition of NQO1 activity by CQ (10 µM), although not that strong, could further 
enhance CQ toxicity in those who already have 50 % or lesser NQO1 activity. In contrast, CQ-
induced NQO1 inhibition might not affect those individuals with 100 % NQO1 activity. Hence 
the results of the present study could for the first time explain the geographic restriction of CQ-
induced neurotoxicity to Japan.  
 
Table 9: Prevalence of C609T genotypes in different ethnic groups 
 [391,392] 
 
 
 
 
 
 
C/C: wild type NQO1; C/T: heterozygote NQO1; T/T: homozygote NQO1. 
 
Genotype 
Ethnic group C/C (%) C/T (%) T/T (%) 
Asia (overall) 
     Chinese 
31.4 
28.6 
48.3 
50.0 
20.3 
22.4 
Caucasians 82 16 2 
Africans 61 33.8 5.2 
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It is worth noting that there are clinical trials being conducted to examine the potential role of 
CQ and its analogues as a disease-modifying treatment in neurodegenerative diseases. In fact, 
these clinical trials were undertaken in Europe and Australia, where the majority of participants 
would be likely to harbour the active NQO1 genotype. Based on the results of this study, this 
population group may not show CQ toxicity. Consequently, the clinical phenotypes of CQ-
induced SMON such as motor disorder and visual impairment may not have occurred in these 
trial participants. Nevertheless, a few cases of neurotoxicity have been reported. In a 
randomised placebo-controlled clinical trial in AD patients, 3 out of 16 patients that received 
CQ and Vitamin B 12 for 36 weeks developed impaired nerve conduction, 2 out of 16 patients 
complained of leg numbness and one patient developed visual impairment including loss of 
visual acuity and colour vision loss [188]. It is also important to note that neurotoxicity is 
typically a rather slow process and may take several weeks to develop, which is likely why 
these patients may not have developed the full neurotoxicity symptoms associated with SMON. 
Furthermore, due to the overlapping clinical symptoms of CQ-induced neurotoxicity and 
neurodegenerative diseases, drug-induced neurotoxicity (motor disorder, visual impairment) 
would have been difficult to distinguish from the natural progression of the disease itself.  
 
Therefore, in light of the recent emerging interest in CQ and its analogues for the treatment of 
neurodegenerative disorders such as Alzheimer’s and Huntington’s disease the results of this 
study are of direct importance. This study strongly suggests that the use of CQ or its derivatives 
for the treatment of neurodegenerative diseases should require a prior determination of the 
NQO1 activity status of patients. Consequently, the results of this study represent a significant 
step towards personalized medicine to minimize the risks associated with CQ and its analogues. 
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4.3 Limitations of the Study 
 
This study contemplated the molecular mechanism involved in CQ-induced toxicity and 
provides a possible explanation for the higher prevalence of this toxicity seen in the Japanese 
population. Although this study addresses all the aims and objectives, there were some 
limitations that have to be considered. The in-vitro results indicate that CQ is responsible for 
inducing ROS-mediated mitochondrial dysfunction. However, this study did not run any 
positive controls such as known mitochondrial inhibitors to confirm ROS production from 
mitochondrial dysfunction in cells. Hence, the origins of excess ROS are still unclear. 
Although, from the results of the study, it is possible that the ROS is generated as a consequence 
of the CQ-mediated increase in intracellular zinc levels or due to the inhibition of the ROS-
detoxifying enzyme, NQO1, further research is warranted to confirm any of those possibilities. 
In addition, the in-vitro results also indicate that CQ can directly inhibit NQO1 activity and 
consequently NQO1 expression protected against CQ-induced mitochondrial dysfunction. 
Given the cytoplasmic localization of NQO1, it is still unclear what biochemical pathways are 
involved in protecting mitochondrial impairment induced by CQ. One of the possibilities would 
be to use dyes that can detect mitochondrial superoxide such as MitoSOX or dihydroethidium 
(DHE) to examine if NQO1 directly scavenges ROS and protects against CQ-toxicity.  
 
The in-vivo results demonstrated that CQ-induced vision loss was negatively correlated with 
NQO1 expression. In this context, CQ showed a clear dose-dependent reduction of visual 
function in retinal-NQO1 deficient zebrafish larvae, whereas visual function was not affected 
in the adult zebrafish that presumably highly expressed NQO1 in the retina. However, 
expression of NQO1 could not be quantified due to the unavailability of antibodies that are 
specific to zebrafish.  
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The protecting role of NQO1 was confirmed in the retinal section of adult zebrafish. However, 
the NQO1 status in the retina of zebrafish larvae was not examined due to breeding difficulties 
of the PET strain in our facility. Hence, the reported absence of retinal NQO1 in zebrafish 
larvae was only confirmed through the indirect measurement of NQO1 activity in AB strain 
animals where inhibition of NQO1 failed to modulate CQ toxicity.  Furthermore, CQ-induced 
ROS production and its effect on mitochondrial function was not explored due to a temporary 
unavailability of larvae for the experiments.  
 
4.4 Future Directions 
 
The results of this study for the first time demonstrate that oxidative stress-mediated 
mitochondrial dysfunction is central to CQ-induced toxicity and highlight the importance of 
NQO1 in determining CQ toxicity. Furthermore, previously published genomic data revealed 
that the known inactivating NQO1 polymorphism (C609T) is highly prevalent among the 
Japanese population. Based on this, the results of the present study could for the first time 
explain geographic restriction of SMON cases to Japan. In light of re-emergence of CQ and its 
structural analogues for new indications, it has become crucial to understand the mechanistic 
association between SMON and CQ in order to avoid any potential adverse effects of CQ 
administration to patients. In this context, it becomes essential to strengthen the connection of 
NQO1 expression and CQ toxicity by investigating this hypothesis in patients that developed 
SMON. Therefore, we have started the collaboration with the former Head of the Japanese 
Government Commission that was tasked to identify the origins of SMON. We are currently 
in the process of collecting DNA samples from surviving SMON patients to confirm the 
presence of the inactivating NQO1 polymorphism. If we can show that these patients indeed 
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carry the polymorphism, our research would solve the 50-year-old mystery why, despite the 
global use of CQ, SMON cases were largely restricted to Japan. Another possibility would be 
to generate immortalized cell lines from C609T carriers to directly test CQ toxicity against cell 
lines from non-carriers (C/C). This study could be extended to identify the drugs that have the 
potential to interfere with NQO1 activity. This would be beneficial in the long run to minimize 
the risk associated with the administration of CQ and its analogues.   
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